0001493152-20-008620.txt : 20200514 0001493152-20-008620.hdr.sgml : 20200514 20200514090137 ACCESSION NUMBER: 0001493152-20-008620 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200514 DATE AS OF CHANGE: 20200514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Agape ATP Corp CENTRAL INDEX KEY: 0001713210 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] IRS NUMBER: 364838886 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-220144 FILM NUMBER: 20875498 BUSINESS ADDRESS: STREET 1: 1705-1708 LEVEL 17, TOWER 2, FABER TOWER STREET 2: JALAN DESA BAHAGIA, TAMAN DESA CITY: KUALA LUMPUR STATE: N8 ZIP: 58100 BUSINESS PHONE: (603) 27325716 MAIL ADDRESS: STREET 1: 1705-1708 LEVEL 17, TOWER 2, FABER TOWER STREET 2: JALAN DESA BAHAGIA, TAMAN DESA CITY: KUALA LUMPUR STATE: N8 ZIP: 58100 10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

For The Quarterly Period Ended March 31, 2020

 

or

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______________ to _______________

 

Commission File Number 333-220144

 

AGAPE ATP CORPORATION

(Exact name of registrant issuer as specified in its charter)

 

Nevada   36-4838886

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

1705 - 1708, Level 17, Tower 2, Faber Tower, Jalan Desa Bahagia,
Taman Desa, 58100 Kuala Lumpur, Malaysia.

(Address of principal executive offices, including zip code)

 

Registrant’s phone number, including area code (60) 192230099

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

YES [X] NO [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding twelve months (or shorter period that the registrant was required to submit and post such files).

 

YES [X] NO [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer [  ] Accelerated Filer [X] Non-accelerated Filer [  ] Smaller reporting company [X]

Emerging growth company [X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes [  ] No [X]

 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

 

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

 

Yes [  ] No [  ]

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class   Outstanding at May 11, 2020
Common Stock, $0.0001 par value   376,275,500

 

 

 

   
   

 

TABLE OF CONTENTS

 

    Page
PART I FINANCIAL INFORMATION  
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: F-1
  Unaudited Condensed Consolidated Balance Sheets F-2
  Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) F-3
  Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity F-4
  Unaudited Condensed Consolidated Statements of Cash Flows F-5
  Notes to Unaudited Condensed Consolidated Financial Statements F-6 - F-24
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 3
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 10
ITEM 4. CONTROLS AND PROCEDURES 11
PART II OTHER INFORMATION  
ITEM 1 LEGAL PROCEEDINGS 12
ITEM 1A RISKS FACTORS 12
ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 18
ITEM 3 DEFAULTS UPON SENIOR SECURITIES 18
ITEM 4 MINE SAFETY DISCLOSURES 18
ITEM 5 OTHER INFORMATION 18
ITEM 6 EXHIBITS 19
  SIGNATURES 20

 

 2 
   

 

PART I FINANCIAL INFORMATION

 

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

  Page
Unaudited Condensed Consolidated Financial Statements  
   
Unaudited Condensed Consolidated Balance Sheets at March 31, 2020 and December 31, 2019 F-2
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three Months Ended March 31, 2020 and 2019 F-3
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three Months Ended March 31, 2020 and 2019 F-4
Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019 F-5
Notes to Unaudited Condensed Consolidated Financial Statements F-6 - F-24

 

 F-1 
   

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

   March 31,   December 31, 
   2020   2019 
   (Unaudited)     
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $2,588,207   $2,744,457 
Accounts receivable – related party   523,141    520,786 
Amount due from a related party   2,227    2,217 
Prepayments and deposits   304,993    269,193 
Amount due from a director   656,495    - 
Total Current Assets   4,075,063    3,536,653 
           
OTHER ASSETS          
Investment in marketable securities   48,202    66,484 
Investment in non-marketable securities   1,500    732,137 
Total other assets   49,702    798,621 
           
TOTAL ASSETS  $4,124,765   $4,335,274 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Accounts payable  $-   $2,790 
Other payables and accrued liabilities   97,459    77,246 
Amount due to a director   -    3,952 
Total Current Liabilities   97,459    83,988 
           
TOTAL LIABILITIES   97,459    83,988 
           
STOCKHOLDERS’ EQUITY          
Preferred stock, $0.0001 par value; 200,000,000 shares authorized;
None issued and outstanding
   -    - 
Common stock, par value $0.0001; 1,000,000,000 shares authorized, 376,275,500 issued and outstanding as of March 31, 2020 and December 31, 2019   37,628    37,628 
Additional paid in capital   5,293,082    5,293,082 
Accumulated deficit   (1,320,959)   (1,089,209)
Accumulated other comprehensive income   17,555    9,785 
TOTAL STOCKHOLDERS’ EQUITY   4,027,306    4,251,286 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $4,124,765   $4,335,274 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 F-2 
   

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

   For the three months ended 
   March 31, 2020   March 31, 2019 
   (Unaudited)   (Unaudited) 
REVENUE – RELATED PARTY  $-   $464,297 
           
COST OF REVENUE   -    (420,178)
           
GROSS PROFIT   -    44,119 
           
SELLING, GENERAL AND ADMINISTRATIVE
EXPENSES
   (159,516)   (28,226)
           
INCOME (LOSS) FROM OPERATIONS   (159,516)   15,893 
           
OTHER INCOME (EXPENSES)          
Other Income (Expenses), Net   (53,696)   57,933 
Loss from equity investment   -    (26,085)
Unrealized holding loss on marketable securities   (18,538)   - 
Gain on deemed disposal of shares in Investee Company   -    16,509 
TOTAL OTHER INCOME (EXPENSES), NET   (72,234)   48,357 
           
INCOME (LOSS) BEFORE INCOME TAXES   (231,750)   64,250 
           
BENEFIT FOR INCOME TAXES   -    6,965 
           
NET INCOME (LOSS)   (231,750)   71,215 
           
OTHER COMPREHENSIVE INCOME (LOSS)          
Foreign currency translation adjustment   7,770    (3,197)
           
COMPREHENSIVE INCOME (LOSS)  $(223,980)  $68,018 
           
EARNINGS (LOSS) PER SHARE          
Basic and diluted  $0.00   $0.00 
           
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Basic and diluted   376,275,500    376,275,500 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 F-3 
   

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF

CHANGES IN STOCKHOLDERS’ EQUITY

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

   COMMON STOCK   ADDITIONAL       ACCUMULATED OTHER   TOTAL 
   Number of shares   Par value  

PAID IN

CAPITAL

   ACCUMULATED DEFICIT  

COMPREHENSIVE

INCOME (LOSS)

   STOCKHOLDERS’ EQUITY 
Balance as of December 31, 2018   376,275,500   $37,628   $5,293,082   $(373,082)  $(1,294)  $4,956,334 
Net income   -    -    -    71,215    -    71,215 
Foreign currency translation adjustment   -    -    -    -    (3,197)   (3,197)
Balance as of March 31, 2019   376,275,500   $37,628   $5,293,082   $(301,867)  $(4,491)  $5,024,352 

 

   COMMON STOCK   ADDITIONAL       ACCUMULATED OTHER   TOTAL 
   Number of shares   Par value  

PAID IN

CAPITAL

   ACCUMULATED DEFICIT  

COMPREHENSIVE

INCOME

   STOCKHOLDERS’ EQUITY 
Balance as of December 31, 2019   376,275,500   $37,628   $5,293,082   $(1,089,209)  $9,785   $4,251,286 
Net loss   -    -    -    (231,750)   -    (231,750)
Foreign currency translation adjustment   -    -    -    -    7,770    7,770 
Balance as of March 31, 2020   376,275,500   $37,628   $5,293,082   $(1,320,959)  $17,555   $4,027,306 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 F-4 
   

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”)

 

  

For the three months ended

March 31,

 
   2020   2019 
   (Unaudited)   (Unaudited) 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net income (loss)  $(231,750)  $71,215 
Adjustments to reconcile net income (loss) to net cash used in operating activities:          
Unrealized holding loss on marketable securities   18,538    - 
Loss from equity investment   -    26,085 
Gain on deemed disposal of shares in Investee Company   -    (16,509)
Changes in operating assets and liabilities:          
Accounts receivable – related party   285    (186,536)
Amount due from a related party   -    (2,200)
Prepayments and deposits   (34,593)   (100,029)
Accounts payable   (2,803)   1,323 
Customer deposits   -    (140,322)
Income taxes payable   -    (12,299)
Other payables and accrued liabilities   19,892    952 
Net cash used in operating activities   (230,431)   (358,320)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Proceeds from sale of non-marketable securities to a related party   70,173    - 
Net cash provided by investing activities   70,173    - 
           
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS   4,008    (3,197)
           
DECREASE IN CASH AND CASH EQUIVALENTS   (156,250)   (361,517)
           
CASH AND CASH EQUIVALENTS, beginning of period   2,744,457    3,452,917 
           
CASH AND CASH EQUIVALENTS, end of period  $2,588,207   $3,091,400 
           
SUPPLEMENTAL CASH FLOWS INFORMATION          
Income taxes paid  $-   $- 
Interest paid  $-   $- 
           
SUPPLEMENTAL NON-CASH FLOWS INFORMATION          
Amount transferred from investment in investee company to investment in non-marketable securities  $-   $724,619 
Sale of the non-marketable securities to a director in exchange for a loan receivable  $730,637   $- 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 F-5 
   

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

1. ORGANIZATION AND BUSINESS BACKGROUND

 

Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.

 

Agape ATP Corporation operates through its wholly owned subsidiary, Agape ATP Corporation, a Company organized in Labuan, Malaysia.

 

Agape ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International Holding Limited, a company incorporated in Hong Kong.

 

The Company and its subsidiaries provide health and wellness products and advisory services to the public. The principal activity of the Company and its subsidiaries is to supply high-quality health and wellness products, including supplement to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system in our body.

 

Details of the Company’s subsidiaries:

 

   

Subsidiary company

name

 

Place and

date of

incorporation

  Particulars of issued capital   Principal activities  

Proportional of ownership

interest and

voting power

held

 
                       
1.   Agape ATP Corporation   Labuan,
March 6, 2017
  100 shares of ordinary share of US$1 each   Investment holding     100 %
                         
2.   Agape ATP International Holding Limited   Hong Kong,
June 1, 2017
  1,000,000 shares of ordinary share of HK$1 each   Health and wellness products and health solution advisory services     100 %

 

Business Overview

 

Agape ATP Corporation is a company that provides health solution advisory services to our clients. We primarily focus our efforts on attracting customers in Malaysia. Our advisory services center on the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.

 

 F-6 
   

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

At its core, the ATP Zeta Super Health Program is focused upon biological energy, Adenosine Triphosphate (ATP), at the cellular level. The stimulation of ATP production at the cellular level can increase the metabolism and service to promote and maintain normal and healthy functioning of the body’s systems. As a strong advocator of “beauty from within”, our program shall emphasize nutrient absorption through the membrane ion channel to provide complete and balanced nutrients to improve cell health. Thus, ATP Zeta Super Health Program provides ionized and high zeta potential (high bioavailability) nutrients to enhance the absorption at the cellular level.

 

The ATP Zeta Super Health Program consists of eight products. None of these products are owned or produced by Agape ATP Corporation. In the event that any of these products are no longer produced, or are otherwise unavailable, we may have to devote significant effort to identifying and obtaining comparable replacement products. The eight products that comprise the ATP Zeta Super Health Program are ATP1s Survivor Select, ATP2 Energized Mineral Concentrate, ATP3 Ionized Cal-Mag, ATP4 Omega Blend, ATP5 BetaMaxx, AGN-Vege Fruit Fiber, AGP1-Iron and YFA-Young Formula.

 

At present, our products are mainly sold in Malaysia, and due to the contents and combination of the main ingredients in the products they are categorized as health food rather than medicines or drugs. As such, all products require authorization from the Food and Quality Division of Ministry of Health according to the Food Act of 1983 and Food Regulation 1985 in order to be sold in the country. All of the products in the ATP Zeta Super Health Program have obtained the appropriate authorizations.

 

As part of a continuous effort to increase market share of the health and wellness industry that is growing at an exponential rate, we will also evaluate adding additional products to the ATP Zeta Super Health Program; and considering the potential of the synergies between the health and beauty sectors, we will further involve ourselves in the topical approach of skin and hair regime. Other than organic growth, the Company will also consider mergers and acquisitions where synergistic. As detailed in Note 15, Subsequent Events, to improve its sales channel, the Company is in the process of acquiring a Malaysia incorporated entity whose principal activity is in the trading of health and wellness products.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.

 

Basis of presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for information pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”).

 

Basis of consolidation

 

The consolidated financial statements include the financial statements of the Company and its subsidiaries. All transactions and balances among the Company and its subsidiaries have been eliminated upon consolidation.

 

Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.

 

 F-7 
   

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Use of estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s consolidated financial statements include allowance for doubtful accounts, allowance for deferred tax assets and uncertain tax position, and impairment of investment in non-marketable securities. Actual results could differ from these estimates.

 

Cash and cash equivalents

 

Cash and cash equivalents are carried at cost and represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less.

 

Accounts receivable – related party

 

Accounts receivable – related party are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due on demand. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of March 31, 2020, and December 31, 2019, no valuation allowance was recorded.

 

Prepayments and deposits

 

Prepayments and deposits are cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after management has determined that the likelihood of collection is not probable. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary.

 

 F-8 
   

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Investment in marketable equity securities

 

Prior to July 1, 2019, marketable securities included in investment in marketable equity securities (non-current) are stated at the lower of cost or market in the aggregate. Other marketable securities (non-current) are stated at the lower of cost or market in the aggregate and investments other than marketable equity securities in other investments (non-current) are stated at cost less any significant decline in fair value assessed to be other than temporary. Realized gains and losses on the sale of securities are based on the average cost of all the units of a particular security held at the time of sale.

 

On July 1, 2019, the Company adopted ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Investments in marketable equity securities (non-current) are reported at fair value with changes in fair value recognized in the Company’s consolidated statements of operations and comprehensive loss in the caption of “unrealized holding losses on marketable securities” in each reporting period.

 

Investment in non-marketable equity securities

 

Prior to July 1, 2019, investments in non-marketable equity securities (non-current) are stated at cost less any significant decline in fair value assessed to be other than temporary. Realized gains and losses on the sale of securities are based on the average cost of all the units of a particular security held at the time of sale.

 

On July 1, 2019, the Company adopted ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Due to the Company’s non-marketable equity securities (non-current) does not qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issue.

 

At each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment loss equal to the difference between the fair value of the investment and its carrying amount.

 

 F-9 
   

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Revenue recognition

 

On July 1, 2019, the Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606) using the modified retrospective method for contracts that were not completed as of June 30, 2019. This did not result in an adjustment to retained earnings upon adoption of this new guidance as the Company’s revenue was recognized based on the amount of consideration expected to receive in exchange for satisfying the performance obligations.

 

The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

 

The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

 

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

 

Prior to July 1, 2019, the Company recognizes revenue from sales of goods when the following four revenue criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) selling price is fixed or determinable; and (4) collectability is reasonably assured. Revenue from supplies of health and wellness products is recognized when title and risk of loss are transferred and there are no continuing obligations to the customer. Title and the risks and rewards of ownership transfer to and accepted by the customer when the products are collected by the customer at the Company’s office. Revenue is recorded net of sales discounts, returns, allowances, and other adjustments that are based upon management’s best estimates and historical experience and are provided for in the same period as the related revenues are recorded.

 

The application of the five-step model to the revenue streams compared to the prior guidance did not result in significant changes in the way the Company records its revenue. Upon adoption on July 1, 2019, the Company evaluated its revenue recognition policy for all revenue streams within the scope of the ASU under previous standards and using the five-step model under the new guidance and confirmed that there were no differences in the pattern of revenue recognition.

 

 F-10 
   

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Sales of Health and Wellness products

 

- Performance obligations satisfied at a point in time

 

On July 1, 2019, the Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods, which is generally similar to when its delivery has occurred prior to July 1, 2019. Such revenues are recognized at a point in time after all performance obligations are satisfied. The revenue is recorded net of estimated discounts and return allowances. Historically, there were no sales return as the Company’s products sold are not refundable, returnable or exchangeable.

 

Disaggregated information of revenues by products are as follows:

 

   For the three months ended 
   March 31, 2020   March 31, 2019 
   (Unaudited)   (Unaudited) 
         
Ionized Cal-Mag  $-   $55,493 
Omega Blend   -    68,689 
Young Formula   -    116,979 
Organic Youth Care Cleansing Bar   -    17,675 
Trim+   -    65,295 
Lipomask   -    140,166 
Total revenues  $-   $464,297 

 

Cost of revenue

 

Cost of revenue includes freight-in and the purchase cost of manufactured goods for sale to customers

 

Selling, general and administrative expenses

 

Selling, general and administrative expenses are primarily comprised of rental of office premises, travelling, licensing and professional fees.

 

Income taxes

 

The Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

 

 F-11 
   

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Deferred taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.

 

An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. No penalties and interest incurred related to underpayment of income tax.

 

The Company conducts much of its businesses activities in Hong Kong and is subject to tax in this jurisdiction. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

 

Comprehensive income (loss)

 

Comprehensive income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders’ equity but are excluded from net income. Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.

 

Earnings (loss) per share

 

The Company computes earnings (loss) per share (“EPS”) in accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common share outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

 

 F-12 
   

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Foreign currencies translation and transaction

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the Condensed Consolidated Statements of Operations and Comprehensive Income.

 

The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. The Company’s subsidiary in Labuan maintains its books and record in United States Dollars (“US$”) albeit its functional currency being the primary currency of the economic environment in which the entity operates is the Malaysian Ringgit (“MYR”). The Company’s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars (“HK$”), similar to its functional currency.

 

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.

 

Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:

 

   As of and for the three months ended   As of 
   March 31, 2020   March 31, 2019   December 31, 2019 
   (Unaudited)   (Unaudited)     
             
Period-end MYR : US$1 exchange rate   4.34    4.10    4.09 
Period-average MYR : US$1 exchange rate   4.21    4.08    4.16 
Period-end HKD : US$1 exchange rate   7.75    7.85    7.79 
Period-average HKD : US$1 exchange rate   7.77    7.85    7.83 
Period-end AUD : US$1 exchange rate   1.63    1.41    1.43 
Period-average AUD : US$1 exchange rate   1.55    1.40    1.46 

 

Related parties

 

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

 

 F-13 
   

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Fair value of financial instruments

 

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

 

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

 

Operating leases

 

A lease for which substantially all the benefits and risks incidental to ownership remain with the lessor is classified by the lessee as an operating lease. All leases of the Company are currently classified as operating leases. The Company records the total expenses on a straight-line basis over the lease term.

 

The Company had on July 1, 2019, adopted ASU 2016-02, “Leases” (Topic 842), and elected the practical expedients that do not require us to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. The Company adopted the practical expedient that allows lessees to treat the lease and non-lease components of a lease as a single lease component. There is no impact from the adoption of ASC 842 as of January 1, 2020, as the Company did not have any existing leases with a lease term in excess of twelve months on January 1, 2020.

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of such any pronouncements may be expected to cause a material impact on its financial condition or the results of its operations, as follow:

 

In July 2017, the FASB Issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815). The amendments in Part I of the Update change the reclassification analysis of certain equity-lined financial instruments (or embedded features) with down round features. The amendments in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020.

 

 F-14 
   

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part II of this Update do not require any transition guidance because those amendments do not have an accounting effect. The adoption of this ASU did not have a material effect on the Company’s consolidated financial statements.

 

In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The amendments in this Update affect any entity that is required to apply the provisions of Topic 220, Income Statement – Reporting Comprehensive Income, and has items of other comprehensive income for which the related tax effects are presented in other comprehensive income as required by GAAP. The amendments in this Update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this Update should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. The adoption of this ASU did not have a material effect on the Company’s consolidated financial statements.

 

In August 2018, the FASB has issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements of Fair Value Measurement. This amendment modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits, with the primary purpose to improve the effectiveness of disclosures in the notes to financial statements by facilitating clear communication of the information required by US GAAP. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company is currently evaluating the impact of ASU 2018-13 will have on its consolidated financial statements.

 

In May 2019, the FASB issued ASU 2019-05, which is an update to ASU Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments— Credit Losses—Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders’ concerns by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful information. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 due the Company is qualified as an emerging growth company. The Company is currently evaluating the impact of ASU 2019-05 will have on its consolidated financial statements.

 

 F-15 
   

 

AGAPE ATP CORPORATION

NOTES TO CONDESNED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

In January 2020, the FASB issued ASU 2020-01 to clarify the interaction of the accounting for equity securities under ASC 321 and investments accounted for under the equity method of accounting in ASC 323 and the accounting for certain forward contracts and purchased options accounted for under ASC 815. With respect to the interactions between ASC 321 and ASC 323, the amendments clarify that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting when applying the measurement alternative in ASC 321, immediately before applying or upon discontinuing the equity method of accounting. With respect to forward contracts or purchased options to purchase securities, the amendments clarify that when applying the guidance in ASC 815-10-15-141(a), an entity should not consider whether upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in ASC 323 or the fair value option in accordance with ASC 825. The ASU is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.

 

Reclassification

 

Certain prior period amounts have been reclassified to conform to the current period presentation for the three months ended March 31, 2019. These reclassifications have no effect on the condensed consolidated statements of operations and comprehensive income.

 

3. CASH AND CASH EQUIVALENTS

 

As of March 31, 2020 and December 31, 2019 the Company recorded $2,588,207 and $2,744,457, respectively, of cash and cash equivalents, which consists $135,436 and $238,937, respectively, of cash in bank and $2,452,771 and $2,505,520, respectively, of time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less. The effective interest rate for the time deposits ranges between 2.95% to 3.25% per annum.

 

4. ACCOUNTS RECEIVABLE – RELATED PARTY

 

   As of
March 31, 2020
   As of
December 31, 2019
 
Accounts receivable – related party  $523,141   $520,786 
Allowance for doubtful accounts   -    - 
Total accounts receivable – related party  $523,141   $520,786 

 

 F-16 
   

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

5. INVESTMENT IN MARKETABLE SECURITIES

 

  (i) On May 17, 2018, the Company purchased 83,333 shares of common stock in Greenpro Capital Corp. for $500,000 at a purchase price of $6 per share.
     
  (ii) On October 16, 2018, the Company purchased 33,333 shares of common stock in Greenpro Capital Corp. for $1,000 at a purchase price of $0.03 per share.

 

   As of
March 31, 2020
   As of
December 31, 2019
 
Cost of investment  $66,484   $134,166 
Less: Unrealized holding loss   (18,538)   (68,391)
Exchange rate effect   256    709 
Investment in marketable securities  $48,202   $66,484 

 

6. INVESTMENT IN NON-MARKETABLE SECURITIES

 

The Company invested in Unreserved Sdn Bhd with the investment amount of $863,592 (MYR3,500,000), which approximated 20% of the equity interest of Unreserved Sdn Bhd and is accounted for under the equity method of accounting. On March 10, 2019 Unreserved Sdn Bhd issued additional common stock for working capital. As the Company did not subscribe for the additional common stock, the Company’s equity interest in investee company was diluted from approximately 20.0% to approximately 17.86%. Effective from March 10, 2019, the Company discontinued equity accounting on the investee company. The Company also ceased control over the operations of the investee company on the same date. Accordingly, the investment in investee company was reclassified to investment in non-marketable securities.

 

Unreserved Sdn Bhd was incorporated in Malaysia with 2,500,000 ordinary shares authorized, issued and outstanding. Mr. Lim Hun Soon @ David Lim and Ms. Aniza Helina Akmi Karim are the directors of Unreserved Sdn Bhd. Mr. How Kok Choong was a director of the company from April 30, 2018 to March 27, 2019.

 

On March 2, 2020, the Company agreed to sell the 17.86% ownership interest in Unreserved Sdn Bhd at the December 31, 2019 carrying value of $730,637 to Mr. How Kok Choong, the CEO and director of the Company. The Company received proceeds of $70,173, and had an amount due from director balance of $660,464 as at March 31, 2020.

 

In May 2020, the entire outstanding balance was settled as part of the consideration in a transaction which the Company had acquired the CEO’s ownership interest of Agape Superior Living Sdn. Bhd.

 

On April 3, 2019, the Company purchased a 5% of stock or 15,000,000 shares of common stock in Phoenix Plus Corp. for $1,500 at purchase price of $0.0001 per share.

 

 F-17 
   

 

AGAPE ATP CORPORATION

NOTES TO CONDESED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

6. INVESTMENT IN NON-MARKETABLE SECURITIES (Continued)

 

Unreserved Sdn Bhd  As of
March 31, 2020
   As of
December 31, 2019
 
Investment in non-marketable securities  $730,637   $730,637 
Less: Sale of investment in non-marketable securities   (730,637)   - 
Investment in non-marketable securities  $-   $730,637 
           
Phoenix Plus Corporation          
Cost of investment  $1,500   $1,500 
           
Total investment in non-marketable securities  $1,500   $732,137 

 

7. PREPAYMENTS AND DEPOSITS

 

   As of
March 31, 2020
   As of
December 31, 2019
 
Prepaid expenses  $5,458   $2,641 
Deposits to supplier   299,310    266,552 
Total prepaid expenses and deposits  $304,768   $269,193 

 

8. AMOUNT DUE FROM A DIRECTOR

 

On March 2, 2020, the Company agreed to sell the 17.86% ownership interest in Unreserved Sdn Bhd at December 31, 2019 carrying value of $730,637 to Mr. How Kok Choong, the CEO and director of the Company. On March 19, 2020, Mr. How made a payment of 10% of the amount due from him arising from the sale of the non-marketable securities. As of March 31, 2020, balance due from Mr. How was $656,495.

 

In May 2020, the entire outstanding balance was settled as part of the consideration in a merger transaction in which the Company had acquired the CEO’s ownership interest of Agape Superior Living Sdn. Bhd.

 

 F-18 
   

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

9. RELATED PARTY TRANSACTIONS

 

The Company’s related party list and relationship are as follows:

 

Related parties   Relationships
     
Agape S.E.A. Sdn Bhd   Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape S.E.A. Sdn Bhd
     
Agape Superior Living Pty Ltd   Mr. How Kok Choong, the CEO and director of the Company is a 51% shareholder and a director of Agape Superior Living Pty Ltd
     
Agape Superior Living Sdn Bhd   Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape Superior Living Sdn Bhd
     
Agape ATP (Asia) Limited   Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape ATP (Asia) Limited.

 

Related party transactions for the three months ended March 31, 2020 and 2019; and as of March 31, 2020, and December 31, 2019 are as per table below:

 

   For the three months ended   As of 
   March 31, 2020   March 31, 2019   March 31, 2020   December 31, 2019 
   (Unaudited)   (Unaudited)   (Unaudited)     
   Revenue   Accounts Receivable, Trade 
                 
Agape S.E.A. Sdn Bhd  $              -   $464,297   $523,141   $520,786 

 

 

   Expenses paid on behalf   Amount due from a related party 
                 
Agape ATP (Asia) Limited  $-   $2,200   $2,227   $2,217 

 

 

   Sundry Purchases   Prepayments and Deposits 
                 
Agape Superior Living Pty Ltd  $-   $-   $2,783   $- 

 

F-19
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

10. STOCKHOLDERS’ EQUITY

 

Preferred stock

 

As of March 31, 2020, and December 31, 2019, there were 200,000,000 preferred stocks authorized but none were issued and outstanding.

 

Common stock

 

As of March 31, 2020, and December 31, 2019, there were 1,000,000,000 common stocks authorized, 376,275,500 were issued and outstanding.

 

There were no stock options, warrants or other potentially dilutive securities outstanding as of March 31, 2020 and December 31, 2019.

 

11. OTHER PAYABLES AND ACCRUED LIABILITIES

 

   As of
March 31, 2020
   As of
December 31, 2019
 
Accrued professional fees  $68,474   $58,594 
Others   28,985    18,652 
Total payables and accrued liabilities  $97,459   $77,246 

 

12. INCOME TAXES

 

The United States and foreign components of income (loss) before income taxes were comprised of the following:

 

   For the three months ended 
   March 31, 2020   March 31, 2019 
   (Unaudited)   (Unaudited) 
Tax jurisdictions from:          
- Local  $(142,419)  $(14,724)
- Foreign - Labuan   (55,587)   59,674 
- Foreign - Hong Kong   (33,744)   19,300 
Income (Loss) before income tax  $(231,750)  $64,250 

 

F-20
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

12. INCOME TAXES (Continued)

 

The benefit for income taxes consisted of the following:

 

   For the three months ended 
   March 31, 2020   March 31, 2019 
   (Unaudited)   (Unaudited) 
Current:          
- Local  $-   $- 
- Foreign   -    (6,965)
           
Deferred:          
- Local   -    - 
- Foreign   -    - 
           
Benefit for income taxes  $-   $(6,965)

 

The effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rates. The Company and its subsidiary that operate in various countries: United States, Labuan and Hong Kong that are subject to taxes in the jurisdictions in which they operate, as follows:

 

United States of America

 

Agape ATP Corporation was incorporated in the State of Nevada and is subject to the tax laws of the United States of America. As of March 31, 2020, the operations in the United States of America incurred approximately $349,000 of cumulative net operating losses which can be carried forward to offset future taxable income. Approximately $10,000 and $24,000 of the net operating loss carry forwards will expire in 2027and 2028, respectively, if unutilized. The remaining balance can be carried forward indefinitely. The deferred tax valuation allowance as of March 31, 2020 and December 31, 2019 were approximately $73,000 and $43,000, respectively.

 

Labuan

 

Under the current laws of the Labuan, Agape ATP Corporation is governed under the Labuan Business Activity Act, 1990. The tax charge for such company is based on 3% of net audited profit. Due to Agape ATP Corporation is a holding company, it did not generate any income nor incurred any income tax. In addition, its related expenses incurred cannot be carried forward to offset any future operation income.

 

Hong Kong

 

Agape ATP International Holding (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income rate of 16.5% on its assessable income derived from Hong Kong. Business income derived or business expenses incurred outside the Special Administrative Region is not subject to Hong Kong Profits Tax or deduction.

 

F-21
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

12. INCOME TAXES (Continued)

 

The following table reconciles the local (United States) statutory rates to the Company’s effective tax rate for the periods indicated below:

 

   For the three months ended 
   March 31, 2020   March 31, 2019 
   (Unaudited)   (Unaudited) 
U.S. statutory rate   21.0%   21.0%
Valuation allowance   (21.0)%   (21.0)%
Permanent difference (1)   0.0%   (10.8)%
Effective tax rate   0.0%   (10.8)%

 

(1) This was related to disallowed expenditure incurred in the ordinary course of business.

 

The following table sets forth the significant components of the aggregate deferred tax assets of the Company as of:

 

   As of
March 31, 2020
  

As of

December 31, 2019

 
   (Unaudited)     
Deferred tax assets:          
Net operating loss carry forwards in U.S.  $73,318   $43,410 
Less: valuation allowance   (73,318)   (43,410)
Deferred tax assets  $-   $- 

 

13. CONCENTRATIONS OF RISKS

 

(a) Major customers

 

There were no sales for the three months ended March 31, 2020. For the three months ended March 31, 2019, one related party customer accounted for 100% of the Company’s total revenues.

 

As of March 31, 2020, and December 31, 2019, one related party customer accounted for 100% of the total balance of accounts receivable.

 

F-22
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

13. CONCENTRATIONS OF RISKS (Continued)

 

(b) Major vendors

 

There were no purchases for the three months ended March 31, 2020. For the three months ended March 31, 2019, two vendors accounted for approximately 54% and 46% of the Company’s total purchases, respectively.

 

Accounts payable as of March 31, 2020 was nil. As of December 31, 2019, one vendor accounted for 100% of the total balance of accounts payable.

 

(c) Credit risk

 

Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its account receivable is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Historically, the Company did not have any bad debt on its account receivable.

 

(d) Exchange rate risk

 

The Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower profit depending on exchange rate of RM$ and HK$ converted to US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.

 

14. COMMITMENTS AND CONTINGENCIES

 

Lease commitments

 

In view of the recent economic development in Hong Kong, the Company has decided not to extend the tenancy for the office in Hong Kong when the tenancy expires on April 30, 2020. Accordingly, the Company had on April 23, 2020 served a termination notice to the landlord, The Company’s commitment for minimum lease payments under the operating lease as of March 31, 2020 for the remaining lease period ending May 31, 2020 is $7,862.

 

Rent expense for the three months ended March 31, 2020 and 2019 was $13,508 and $13,375, respectively.

 

F-23
 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

14. COMMITMENTS AND CONTINGENCIES (Continued)

 

Purchase commitments

 

The total future minimum purchase commitment under a non-cancellable purchase contract as of March 31, 2020 for the next five years and thereafter is as follows:

 

Twelve months ending March 31,  Minimum purchase 
2021  $693,900 
2022   693,900 
2023   693,900 
2024   693,900 
2025   693,900 
Thereafter   1,908,225 
Total minimum purchase commitments required  $5,377,725 

 

As of the date of this report, the Company’s vendor is not able to meet the Company’s minimum purchase commitment of the health and wellness products due to the manufacturing process was being delayed by its vendor.

 

Contingencies

 

From time to time, the Company is party to certain legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued, as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the consolidated financial statements.

 

15. SUBSEQUENT EVENT

 

In December 2019, a novel strain of coronavirus (COVID-19) surfaced. The spread of COVID-19 around the world in the first quarter of 2020 has caused significant volatility in Malaysia. There is significant uncertainty around the duration of business disruptions related to COVID-19, as well as its impact on the Malaysia economies and, as such, the Company is unable to determine if it will have a material impact to its operations.

 

On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn Bhd, an entity incorporated in Malaysia for $1,714,003. The purchase consideration represented the net asset carrying value of the acquiree as of March 31, 2020. The payment, net of the amount due from Mr. How Kok Choong of $656,495 as of March 31, 2020 arising from the purchase of the Company’s non-marketable security, will be satisfied together with the issuance of 162,694 shares of the Company’s common stock. Upon completion, the number of shares of common stock of the Company will be increased from 376,275,500 to 376,438,194, equivalent to approximately 0.0432% increase of the total issued and outstanding common stock of the Company after the issuance of the additional shares, which was valued at $1,057,508 based on the closing price of $6.50 of the Company at March 31, 2020.

 

F-24
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The information contained in this quarter report on Form 10-Q is intended to update the information contained in our Form 10-K, dated March 27, 2020, for the three months ended march 31, 2020 and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information contained in such Form 10-K. The following discussion and analysis also should be read together with our consolidated financial statements and the notes to the consolidated financial statements included elsewhere in this Form 10-Q.

 

The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this transition report on Form 10-Q. The following should also be read in conjunction with the unaudited condensed Consolidated Financial Statements and notes thereto that appear elsewhere in this report.

 

Company Overview

 

Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.

 

Agape ATP Corporation operates through its wholly owned subsidiary, Agape ATP Corporation, a Company organized in Labuan, Malaysia.

 

Agape ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International Holding Limited, a company incorporated in Hong Kong.

 

The Company and its subsidiaries provide health and wellness products and advisory services to the public. The principal activity of the Company and its subsidiaries is to supply high-quality health and wellness products, including supplement to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system in our body.

 

Agape ATP Corporation is a company that provides health solution advisory services to our clients. We primarily focus our efforts on attracting customers in Malaysia. Our advisory services center on the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.

 

At its core, the ATP Zeta Super Health Program is focused upon biological energy, Adenosine Triphosphate (ATP), at the cellular level. The stimulation of ATP production at the cellular level can increase the metabolism and service to promote and maintain normal and healthy functioning of the body’s systems. As a strong advocator of “beauty from within”, our program shall emphasize nutrient absorption through the membrane ion channel to provide complete and balanced nutrients to improve cell health. Thus, ATP Zeta Super Health Program provides ionized and high zeta potential (high bioavailability) nutrients to enhance the absorption at the cellular level.

 

3
 

 

The ATP Zeta Super Health Program consists of eight products. None of these products are owned or produced by Agape ATP Corporation. In the event that any of these products are no longer produced, or are otherwise unavailable, we may have to devote significant effort to identifying and obtaining comparable replacement products. The eight products that comprise the ATP Zeta Super Health Program are ATP1s Survivor Select, ATP2 Energized Mineral Concentrate, ATP3 Ionized Cal-Mag, ATP4 Omega Blend, ATP5 BetaMaxx, AGN-Vege Fruit Fiber, AGP1-Iron and YFA-Young Formula.

 

At present, our products are mainly sold in Malaysia, and due to the contents and combination of the main ingredients in the products they are categorized as health food rather than medicines or drugs. As such, all products require authorization from the Food and Quality Division of Ministry of Health according to the Food Act of 1983 and Food Regulation 1985 in order to be sold in the country. All of the products in the ATP Zeta Super Health Program have obtained the appropriate authorizations.

 

As part of a continuous effort to increase market share of the health and wellness industry that is growing at an exponential rate, we will also evaluate adding additional products to the ATP Zeta Super Health Program; and considering the potential of the synergies between the health and beauty sectors, we will further involve ourselves in the topical approach of skin and hair regime.

 

Results of Operation

 

For the three months ended March 31, 2020 and 2019

 

Revenue

 

The COVID-19 outbreak in the first quarter of 2020 has caused much disruptions in the economic landscape all around the world with different countries imposing sporadic lockdowns, some of which became nationwide at different points in time. Products of the Company originate from the United States, Germany, Australia and Taiwan. The Company was unable to obtain deliveries of its purchases as a result of the lockdowns. The Company, therefore did not generate any revenue for the three months ended March 31, 2020.

 

For the three months ended March 31, 2019, the Company generated revenue of $464,297. The revenues were mainly derived from the sale of health and wellness products.

 

Cost of Revenue

 

As explained in revenue above, cost of revenue for the three months ended March 31, 2020 was nil. Cost of revenue for the three months ended March 31, 2019 was $420,178. The costs were predominantly cost of goods purchased and packing materials.

 

Gross Profit

 

The Company, therefore did not generate any gross profit for the three months ended March 31, 2020. Gross profit for the three months ended March 31, 2019 amounted to $44,119, equivalent to gross margin of approximately 9.5%.

 

4
 

 

Operating Expenses

 

Selling, general and administrative (“SG&A”) expenses for the three months ended March 31, 2020 amounted to $159,516 as compared to $28,226 for the three months ended March 31, 2019. The amount mainly comprised of rental of office premises, travelling, licensing and professional fees which includes legal, audit, accounting and consulting services. The increase of SG&A expenses of $131,290 or approximately 465.1% are mainly due to the increase of professional fees of $102,043 as we have recently hired new professional firms located in the U.S. and Hong Kong, including legal counsel, auditor, and financial reporting consultant, to strengthen our current Securities and Exchange Commission (“SEC”) listing reporting documents and continue to stay compliant as compared to the three months ended March 31, 2019, we were using local professional firms in Malaysia. Professional fee incurred by the U.S. and Hong Kong firms are generally higher than the professional fees incurred by the Malaysia firms. The increase of SG&A was also due to the increase of $27,396 of travelling expenses for our CEO for potential business developments.

 

Other Income (Expenses)

 

For the three months ended March 31, 2020, we recorded an amount of $72,234 as other expenses, net as compared to $48,357 other income, net for the three months ended March 31, 2019. The net other expenses of $72,234 incurred during the three months ended March 31, 2020 comprised interest income of $18,129 and net foreign currency translation loss of $74,618, unrealized holding loss on marketable securities of $18,538 and rebate from sundry purchases of $2,793.

 

The net other income of $48,357 incurred during the three months ended March 31, 2019 comprised interest income of $23,921 and net foreign currency translation gain of $34,012, $26,085 on share of loss in Investee Company from our equity investment and $16,509 on gain on deemed disposal of shares in Investee Company.

 

Net Profit (Loss)

 

The Company sustained net loss of $231,750 for the three months ended March 31, 2020. The loss sustained was predominantly due to reasons as discussed above.

 

The Company generated net profit of $71,215 for the three months ended March 31, 2019.

 

The net profit reported for the three months ended March 31, 2019 was due to revenue generated while in the same period of fiscal year 2020 there was zero revenue. Selling, administrative and general expenses of the Company in the three months ended March 31, 2019 was also relatively lower as explained in operating expenses above. In addition, there were contribution from other income, net as compared to other expenses, net in the same period in fiscal year 2020. For the three months ended March 31, 2019, there was also a write-back of tax provision of $6,965. The tax provision for the Company’s subsidiary in Hong Kong was not required as the tax regime in Hong Kong exempts taxation on business profits derived outside the Special Administrative Region.

 

Liquidity and Capital Resources

 

The World Health Organization or WHO, had on March 11, 2020 declared the corona virus or COVID-19 a pandemic. Malaysia, where our products are mainly sold at present, reported 553 cases of the COVID-19 on March 16, 2020; and the number is still rising. In view of the seriousness of the matter, the local government of Malaysia had, on the same day, imposed a nationwide lockdown effective March 18, 2020. As at the date of reporting, COVID_19 cases in Malaysia were over 5,780; and the nationwide lockdown has yet to be fully lifted.

 

5
 

 

As the intermediary between our suppliers and our sole customer in Malaysia, the COVID-19 pandemic poses challenges to us at both sourcing and supplying our products. Our sole customer has confirmed that onward delivery of our products is via multi-level marketing or MLM to end users who are also members of the MLM group that make up consistent demand of our products. In an effort to embrace globalization, the MLM group has also embarked on e-commerce. The MLM group has synched up with a Malaysian e-commerce trading platform, which will make its debut in the next three months to commence e-marketing and e-trading of its products to members, as well as online e-recruitment of new members. The MLM group is positive that its online e-recruitment service which capitalizes on a large number of followers of well-known key products influencers will dramatically increase the number of members most expediently with minimal cost, thereby increasing demand of our products. Considering our products are health supplements, we also expect impressive demand growth at a time when everyone’s health is at risk. This should translate into sustainable growth once awareness of the importance of health is created. In term of collectability of our accounts receivable from our sole customer, an entity in which our President and CEO has significant influence and is financially healthy, we believe the financial effect of our collection from our sole customer will not be impacted.

 

Although some of the countries from which our products are sourced are experiencing lockdowns, industries involve in the provision of food especially health products and pharmaceuticals are normally exempted. We may experience slight delay in products delivery lead time but barring unforeseen circumstances, the setback should be temporary.

 

We anticipate operating primarily in Malaysia and expanding into the Asian markets in the future, with a particular focus, at least initially, on expanding into Thailand, Indonesia and Taiwan. We will explore expansion via e-commerce. When the pandemic has subsided or is over and restrictions on travelling between nations are uplifted, we will set up offices in the countries in which we operate to better service our customers.

 

Because of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the coronavirus cannot be reasonably estimated at this time. There is no guarantee that our total revenues will grow or remain at the similar level year over year in the next three quarters of 2020. In addition, we may have to record downward adjustments or impairment in the fair value of investments in the second quarter of 2020, if conditions have not been significantly improved and global stock markets have not recovered from recent declines.

 

As of March 31, 2020, we had working capital of $3,977,604 consisting of cash in bank of $135,436 and time deposit of $2,452,771 as compared to working capital of $3,452,665 consisting of cash in bank of $238,937 and time deposit of $2,505,520 as of December 31, 2019. In assessing our liquidity, we monitor and analyze our cash on-hand and our operating expenditure commitments. Our liquidity needs are to meet our working capital requirements and operating expenses obligations. We believe we will have sufficient liquidity to fund our working capital needs for the next 12 months from the date of issuance of the Form 10-Q.

 

The following summarizes the key components of our cash flows for the three months ended March 31, 2020, and 2019:

 

   For the three months ended 
   March 31, 2020   March 31, 2019 
   (Unaudited)   (Unaudited) 
Net cash used in operating activities  $(230,431)  $(358,320)
Net cash provided by investing activities   70,173    - 
Effect of exchange rate on cash and cash equivalents   4,008    (3,197)
Net change in cash and cash equivalents  $(156,250)  $(361,517)

 

6
 

 

Operating activities

 

Net cash used in operating activities for the three months ended March 31, 2020 was $230,431and mainly comprised of net loss of $231,750, the increase in prepayments and deposits of $34,593, the decrease of accounts payable of $2,803, offset by the increase in other payables and accrued liabilities of $19,892, the non-cash expense on unrealized holding loss on marketable securities of $18,538.

 

Net cash used in operating activities for the three months ended March 31, 2019 was $358,320 and mainly comprised of net profit of $71,215, the increase in accounts receivable (including related party) of $188,736, the increase in prepayments and deposits of $100,029 and the decrease in customer deposits of $138,999, decrease in income taxes payable of $12,299, offset by the non-cash expense of loss from equity investment of $26,085 net with gain on deemed disposal of shares in Investee Company of $16,509.

 

Investing activities

 

Net cash provided by investing activities for the three months ended March 31, 2020, was in respect of partial proceeds collected from the sale of our non-marketable securities. There were no investing activities for the three months ended March 31, 2019.

 

Financing activities

 

There were no financing activities for the three months ended March 31, 2020 and 2019.

 

Credit Facilities

 

We do not have any credit facilities or other access to bank credit.

 

Off-Balance Sheet Arrangements

 

As of March 31, 2020, we have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

 

Critical accounting polices

 

Use of estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s consolidated financial statements include allowance for doubtful accounts, allowance for deferred tax assets and uncertain tax position, and impairment of investment in non-marketable securities. Actual results could differ from these estimates.

 

7
 

 

Critical accounting polices (Continued)

 

Revenue recognition

 

On July 1, 2019, the Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606) using the modified retrospective method for contracts that were not completed as of June 30, 2019. This did not result in an adjustment to the retained earnings upon adoption of this new guidance as the Company’s revenue was recognized based on the amount of consideration expected to receive in exchange for satisfying the performance obligations.

 

The core principle underlying the revenue recognition of this ASU allows the Company to recognize- revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

 

The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

 

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

 

Prior to July 1, 2019, the Company recognizes revenue from sales of goods when the following four revenue criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) selling price is fixed or determinable; and (4) collectability is reasonably assured. Revenue from supplies of health and wellness products is recognized when title and risk of loss are transferred and there are no continuing obligations to the customer. Title and the risks and rewards of ownership transfer to and accepted by the customer when the products are collected by the customer at the Company’s office. Revenue is recorded net of sales discounts, returns, allowances, and other adjustments that are based upon management’s best estimates and historical experience and are provided for in the same period as the related revenues are recorded.

 

The application of the five-step model to the revenue streams compared to the prior guidance did not result in significant changes in the way the Company records its revenue. Upon adoption on July 1, 2019, the Company evaluated its revenue recognition policy for all revenue streams within the scope of the ASU under previous standards and using the five-step model under the new guidance and confirmed that there were no differences in the pattern of revenue recognition.

 

Sales of Health and Wellness products

 

- Performance obligations satisfied at a point in time

 

On July 1, 2019, the Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods, which is generally similar to when its delivery has occurred prior to July 1, 2019. Such revenues are recognized at a point in time after all performance obligations are satisfied. The revenue is recorded net of estimated discounts and return allowances. Historically, there were no sales return as the Company’s products sold are not refundable, returnable or exchangeable.

 

8
 

 

Critical accounting polices (Continued)

 

Fair value of financial instruments

 

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

 

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of such any pronouncements may be expected to cause a material impact on its financial condition or the results of its operations, as follow:

 

In July 2017, the FASB Issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815). The amendments in Part I of the Update change the reclassification analysis of certain equity-lined financial instruments (or embedded features) with down round features. The amendments in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part II of this Update do not require any transition guidance because those amendments do not have an accounting effect. The adoption of this ASU did not have a material effect on the Company’s consolidated financial statements.

 

In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The amendments in this Update affect any entity that is required to apply the provisions of Topic 220, Income Statement – Reporting Comprehensive Income, and has items of other comprehensive income for which the related tax effects are presented in other comprehensive income as required by GAAP. The amendments in this Update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this Update should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. The adoption of this ASU did not have a material effect on the Company’s consolidated financial statements.

 

9
 

 

Critical accounting polices (Continued)

 

In August 2018, the FASB has issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements of Fair Value Measurement. This amendment modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits, with the primary purpose to improve the effectiveness of disclosures in the notes to financial statements by facilitating clear communication of the information required by US GAAP. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company is currently evaluating the impact of ASU 2018-13 will have on its consolidated financial statements.

 

In May 2019, the FASB issued ASU 2019-05, which is an update to ASU Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments— Credit Losses—Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders’ concerns by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis.

 

In January 2020, the FASB issued ASU 2020-01 to clarify the interaction of the accounting for equity securities under ASC 321 and investments accounted for under the equity method of accounting in ASC 323 and the accounting for certain forward contracts and purchased options accounted for under ASC 815. With respect to the interactions between ASC 321 and ASC 323, the amendments clarify that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting when applying the measurement alternative in ASC 321, immediately before applying or upon discontinuing the equity method of accounting. With respect to forward contracts or purchased options to purchase securities, the amendments clarify that when applying the guidance in ASC 815-10-15-141(a), an entity should not consider whether upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in ASC 323 or the fair value option in accordance with ASC 825. The ASU is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.

 

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Foreign exchange risk. Substantially most of our revenues are denominated in the U.S. dollar while most of our expenses are denominated in Malaysian Ringgit and Hong Kong Dollar. We do not believe that we currently have any significant direct foreign exchange risk and have not hedged exposures denominated in foreign currencies or any other derivative financial instruments. Although in general, our exposure to foreign exchange risks should be limited, the value of an investment in our Common Stock may be affected by the foreign exchange rate between U.S. dollar and Malaysian Ringgit; and U.S. dollar and Hong Kong Dollar because the value of our business is effectively denominated in Malaysian Ringgit and Hong Kong Dollar, while the Common Stock is traded in U.S. dollars.

 

Credit risk. Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its trade receivables is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information.

 

10
 

 

ITEM 4 CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures:

 

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2020. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2020, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of March 31, 2020, our disclosure controls and procedures were not effective:

 

(1)The Company did not have sufficient full-time personnel with appropriate levels of accounting knowledge and experience to monitor the daily recording of transactions, address complex U.S. GAAP accounting issues and to prepare and review financial statements and related disclosures under U.S. GAAP.
(2)Lack of a functional internal audit department or personnel that monitors the consistencies of the preventive internal control procedures; lack of adequate policies and procedures in internal audit function to ensure that the Company’s policies and procedures have been carried out as planned.
(3)We do not have adequate segregation of duties and effective risk assessment. Lack of segregation of duties and effective risk assessment may cause the Company to face the likelihood of fraud or theft, due to poor oversight, governance and review to detect errors.

 

Management’s Remediation Initiatives

 

In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we will prepare written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines, to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity and debt transactions.

 

We plan to initiate the following series of measures to further strengthen the Company’s internal controls going forward:

 

1. We intend to engage an external consulting firm to supplement our efforts to the implementation of the 2013 Committee of Sponsoring Organizations of the Treadway Commission, or COSO, framework for internal controls.
   
2. We intend to establish an internal audit function with assessment of Sarbanes-Oxley compliance requirements and improvement of overall internal control.
   
3. Once we hire additional employees, we intend to initiate a comprehensive program and development plan to provide ongoing company-wide trainings regarding internal control, with particular emphasis on our accounting staff.

 

We anticipate that these initiatives will be at least partially, if not fully, implemented by the end of fiscal year 2020.

 

11
 

 

Changes in Internal Control over Financial Reporting:

 

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II — OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We know of no materials, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any beneficial shareholder are an adverse party or has a material interest averse to us.

 

Item 1A. Risk Factors.

 

Risks Related to our Business

 

We are exposed to concentration risk of heavy reliance on our major customer. A loss of our major customer may significantly impact on our business and results of operation.

 

Due to the business disruptions caused by the COVID-19 outbreak, we did not earn any revenue from our major customer for the three months ended March 31, 2020. Our major customer may terminate its business relationships with us at any time. We cannot assure you that our major customer will maintain current business relationship with us. If it chooses not to do so, our business, financial condition and operating results may suffer from a material adverse impact.

 

We are exposed to concentration risk of heavy reliance on our major supplier for the supply of our products, and any shortage of, or delay in, the supply may significantly impact on our business and results of operation.

 

The business disruptions caused by the COVID-19 outbreak also resulted in delay in the delivery of goods purchased from our supplier. As there were no goods delivered by our supplier during the three months ended March 31, 2020, we in turn were unable to deliver goods to our customer. The Company, therefore did not record any purchases for the period under review. Our business, financial condition and operating results depend on the continuous supply of products from our major supplier and our continuous supplier-customer relationship with it. Our heavy reliance on our major supplier for the supply of our products will have significant impact on our business and results of operation in the event of any shortage of, or delay in the supply.

 

Our major supplier may terminate the distribution agreement by giving notice to us, in which case our business, financial condition and operating results may suffer from a material adverse impact.

 

As is customary in distribution arrangements of this type, the distribution agreement with our major supplier is terminable by either party by giving notice. There is no assurance that our major supplier will not terminate the distribution agreement. In the event that it terminates the distribution agreement, we will have to source products from other suppliers and we may not be able to secure supply of products with quantity and quality required to support our business or at all. Such termination may therefore have a material adverse impact on our business, financial condition and operating results if we fail to engage any other suppliers before the termination.

 

12
 

 

We are exposed to unforeseeable events of labor disputes, strike action, natural disasters or other accidents, epidemic or pandemic, which may affect the supply of our products from our major supplier.

 

There is no assurance that our major supplier will continue to supply its products in the quantities and timeframes required by us to meet the needs of our customers or comply with its supply agreement with us. Our product supply may also be disrupted by potential labor disputes, strike action, natural disasters or other accidents, epidemic and pandemic affecting the supplier. If our supplier does not supply products to us in a timely manner or in sufficient quantities, our business, financial condition and operating results may be materially and adversely affected. Furthermore, in the event of any delay in delivery of the products to us, our cash flow or working capital may be materially and adversely affected as a result of the corresponding delay in delivery of our products to our customers, and hence the delay in our receipt of payment from our customers.

 

Our major supplier may change its existing sales or marketing strategy by changing its export strategy, reducing its sales or production volume, changing its selling prices or appointing other distributors which may compete with us in the market where we currently operate or which we plan to expand into.

 

Our major supplier may change its existing sales or marketing strategy in respect of the products supplied to us by changing its export strategy, reducing its sales or production volume or changing its selling prices. Consequently, there is no assurance that our major supplier will not appoint other dealers or distributors which may compete with us in the market where we operate. Furthermore, any significant increase in the selling prices of the products which we source from our supplier will increase our costs and may adversely affect our profit margin if we are not able to pass the increased costs on to our customers.

 

There is no assurance that there will be no deterioration in our relationship with our major supplier which could affect our ability to secure sufficient supply of products for our business. In the event that our major supplier changes its sales or marketing strategy or otherwise appoint other dealers or distributors who may compete with us, our business, financial condition and operating results may be materially and adversely affected.

 

We could be adversely affected by a change in consumer preferences, perception and spending habits and failure to develop or enrich our product offering or gain market acceptance of our new products could have a negative effect on our business.

 

The market we operate is subject to changes in consumer preference, perception and spending habits. Our performance depends significantly on factors which may affect the level and pattern of consumer spending in the market we operate. Such factors include consumer preference, consumer confidence, consumer income and consumer perception of the safety and quality of our products. Media coverage regarding the safety or quality of, or diet or health issues relating to, our products or the raw materials, ingredients or processes involved in their manufacturing, may damage consumer confidence in our products. A general decline in the consumption of our products could occur as a result of change in consumer preference, perception and spending habits at any time.

 

Any failure to adapt our product offering to respond to such changes may result in a decrease in our sales if such changes are related to certain of our products. Any changes in consumer preference could result in lower sales of our products, put pressure on pricing or lead to increased levels of selling and promotional expenses. In any event a decrease in customer demand on our products may also result in lower sales and slow down the consumption of our inventory to a low inventory turnover level. Any of these changes could result in a material adverse effect on our business, financial conditions or results of operations.

 

The success of our products depends on a number of factors including our ability to accurately anticipate changes in market demand and consumer preferences, our ability to differentiate the quality of our products from those of our competitors, and the effectiveness of our marketing and advertising campaigns for our products. We may not be successful in identifying trends in consumer preferences and developing products that respond to such trends in a timely manner. We also may not be able to effectively promote our products by our marketing and advertising

 

13
 

 

campaigns and gain market acceptance. If our products fail to gain market acceptance, are restricted by regulatory requirements, or have quality problems, we may not be able to fully recover our costs and expenses incurred in our operation, and our business prospects, financial condition or results of operations may be materially and adversely affected.

 

We may incur losses resulting from product liability claims or product recalls.

 

We may incur losses resulting from product liability claims with respect to our products supplied by our supplier. We may face claims or liabilities which may arise if there exist any defects in quality of these products or any of these products are deemed or proven to be unsafe, defective or contaminated. In the event that the use or misuse of any product distributed by us results in personal injury or death, product liability and/or indemnity claims may be brought against us, in addition to our product recalls, and the relevant regulatory authorities in the market we operate may close down some of our related operations and take administrative actions against us. If we experience any business disruption and litigation, we may incur additional costs and have to divert our management’s attention and resources on such matters, which may adversely affect our business, financial condition and results of operations.

 

We operate in a heavily regulated industry.

 

Our business is principally regulated by various laws and regulations in the market we operate, such as in Malaysia the Food Act of 1983 and Food Regulation 1985 mandate authorization from the Food and Quality Division of the Ministry of Health for our Company’s products to be sold in the country.

 

Various registrations, certificates and/or licenses for the conduct of our business are required under the above laws, which also contain provisions for requirements on the storage, labelling, advertising and importation of some of our products.

 

Based on our experience, some of the laws and regulations of the place where we operate our business are subject to amendments, uncertainty in interpretation and administrative actions from time to time. Therefore, we cannot assure you that, for the implementation of our business plans and the introduction of any new product, we will be able to obtain all the necessary registrations, certificates and/or licenses. Any failure to comply with the above laws and regulations may give rise to fines, administrative penalties and/or prosecution against us, which may adversely affect our reputation, financial condition or results of operation.

 

Legal disputes or proceedings could expose us to liability, divert our management’s attention and negatively impact our reputation.

 

We may at times be involved in potential legal disputes or proceedings during the ordinary course of business operations relating to product or other types of liability, employees’ claims, labor disputes or contract disputes that could have a material and adverse effect on our reputation, operation and financial condition. If we become involved in material or protracted legal proceedings or other legal disputes in the future, the outcome of such proceedings could be uncertain and could result in settlements or outcomes which adversely affect our financial condition. In addition, any litigation or legal proceedings could incur substantial legal expenses as well as significant time and attention of our management, diverting their attention from our business and operations.

 

If we are not successful in our innovation activities, our results may be negatively affected.

 

Achieving our business growth objectives depends in part on our ability to successfully develop, introduce and market new products. The success of our innovation activities in turn depends on our ability to correctly anticipate customer and consumer acceptance and trends, obtain, maintain and enforce necessary intellectual property protections and avoid infringing on the intellectual property rights of others. If we are not successful in our innovation activities, we may not be able to achieve our growth objectives, which may have a negative impact on our financial results.

 

14
 

 

Fluctuations in foreign currency exchange rates could have a material adverse effect on our financial results.

 

We earn revenues, pay expenses, own assets and incur liabilities in countries using currencies other than the U.S. dollar, including Australian Dollar, Malaysian Ringgit and the Hong Kong Dollar. Because our consolidated financial statements are presented in U.S. dollars, we must translate revenues, income and expenses, as well as assets and liabilities, into U.S. dollars at exchange rates in effect during or at the end of each reporting period. Therefore, increases or decreases in the value of the U.S. dollar against other currencies affect our net operating revenues, operating income and the value of balance sheet items denominated in foreign currencies. We cannot assure you that fluctuations in foreign currency exchange rates, particularly the strengthening of the U.S. dollar against major currencies would not materially affect our financial results.

 

Our business depends on the continued contributions made by Mr. How Kok Choong, as our key executive officer, the loss of who may result in a severe impediment to our business.

 

Our success is dependent upon the continued contributions made by our CEO and President, Mr. How Kok Choong. We rely on his expertise in business operations when we are developing our business. We have no “Key Man” insurance to cover the resulting losses in the event that any of our officer or directors should die or resign.

 

If Mr. How Kok Choong cannot serve the Company or is no longer willing to do so, the Company may not be able to find alternatives in a timely manner or at all. This would likely result in a severe damage to our business operations and would have an adverse material impact on our financial position and operating results. To continue as a viable operation, the Company may have to recruit and train replacement personnel at a higher cost.

 

Additionally, if Mr. How Kok Choong joins our competitors or develops similar businesses that are in competition with our Company, our business may also be negatively impacted.

 

Our future success depends on our ability to attract and retain qualified long-term staff to fill management, technology, sales, marketing, and customer services positions. We have a great need for qualified talent, but we may not be successful in attracting, hiring, developing, and retaining the talent required for our success.

 

If we are not able to achieve our overall long-term growth objectives, the value of an investment in our Company could be negatively affected.

 

We have established and publicly announced certain long-term growth objectives. These objectives were based on, among other things, our evaluation of our growth prospects, which are generally driven by the sales potential of many product types, some of which are more profitable than others, and on an assessment of the potential price and product mix. There can be no assurance that we will realize the sales potential and the price and product mix necessary to achieve our long-term growth objectives.

 

We face risks related to health epidemics, severe weather conditions and other outbreaks.

 

In recent years, there have been outbreaks of epidemics in various countries, including Malaysia. Recently, there was an outbreak of a novel strain of coronavirus (COVID-19), which has spread rapidly to many parts of the world, including Malaysia. In March 2020, the World Health Organization declared the COVID-19 a pandemic. The epidemic has resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in Malaysia for the past few weeks.

 

Substantially all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially, affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact, almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:

 

15
 

 

temporary closure of offices, travel restrictions, financial impact of our customers or suspension supplies may negatively affected, and could continue to negatively affect, the demand for our products;
our sole customer may require additional time to pay us or fail to pay us at all, which could significantly increase the amount of accounts receivable and require us to record additional allowances for doubtful accounts. We may have to provide significant sales incentives to our sole customer during the outbreak, which may in turn materially adversely affect our financial condition and operating results;
any disruption of our supply chain, logistics providers or customers could adversely impact our business and results of operations, including causing us or our suppliers to cease manufacturing for a period of time or materially delay delivery to our sole customer, which may also lead to loss of our sole customer; and
the global stock markets have experienced, and may continue to experience, significant decline from the COVID-19 outbreak and the marketable securities that we have invested in could be materially adversely affected, which may lead to significant impairment in the fair values of our investments and in turn materially adversely affect our financial condition and operating results.

 

Because of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the coronavirus cannot be reasonably estimated at this time. There is no guarantee that our total revenues will grow or remain at the similar level year over year in the next three quarters of 2020. We may have to record downward adjustments or impairment in the fair value of investments in the second quarter of 2020, if conditions have not been significantly improved and global stock markets have not recovered from recent declines.

 

In general, our business could be adversely affected by the effects of epidemics, including, but not limited to, the COVID-19, avian influenza, severe acute respiratory syndrome (SARS), the influenza A virus, Ebola virus, severe weather conditions such as flood or hazardous air pollution, or other outbreaks. In response to an epidemic, severe weather conditions, or other outbreaks, government and other organizations may adopt regulations and policies that could lead to severe disruption to our daily operations, including temporary closure of our offices and other facilities. These severe conditions may cause us and/or our partners to make internal adjustments, including but not limited to, temporarily closing down business, limiting business hours, and setting restrictions on travel and/or visits with clients and partners for a prolonged period of time. Various impact arising from a severe condition may cause business disruption, resulting in material, adverse impact to our financial condition and results of operations.

 

Risks Related to our Industry

 

Our business and reputation may be affected by product liability claims, litigation, customer complaints, product tampering, food safety issues, food-borne illnesses, health threats, quality control concerns or adverse publicity relating to our products. Product liability insurance of our supplier may not cover our liability sufficiently or at all.

 

Like other consumer product manufacturers, sale of our products involves an inherent risk of our products being found to be unfit for consumption or cause illness. Products may be rendered unfit for consumption due to raw materials or product contamination or degeneration, presence of microbials, illegal tampering of products by unauthorized third parties or other problems arising during the various stages of the procurement, production, transportation and storage processes. The occurrence of such problems may result in customer complaints, fines, penalties or adverse publicity causing serious damage to our reputation and brand, as well as product liability claims, other legal disputes and loss of revenues. Under certain circumstances, we may be required to recall our products. Even if a situation does not necessitate a product recall, we cannot assure you that product liability claims or other legal disputes will not be asserted against us as a result. Product liability insurance of our supplier may not cover our liability sufficiently or at all and will not cover liability that arises out of our default such as mishandling, poor storage condition and/or contamination of the products by us. As a result, a product liability or other judgment against us, or a product recall, could have a material adverse effect on our business, financial condition or results of operations.

 

16
 

 

Our business is susceptible to food-borne illnesses. We cannot assure you that we are able to effectively prevent all diseases or illnesses caused by our products or contamination of our products. Furthermore, our reliance on third-party product suppliers means that food-borne illness incidents could be caused by our suppliers outside of our control. New illnesses may develop in the future, or diseases with long incubation periods could arise that could give rise to claims or allegations on a retroactive basis. Reports in the media of instances of food-borne illnesses or health threats of our products or any of their major ingredients could adversely and significantly affect our sales, and have significant negative impact on our results of operations. This risk exists even if it were later determined that the illness or health threat in fact was not caused by our products.

 

In addition, adverse publicity about health and safety concerns, whether unfounded or not, may discourage consumers from buying our products. Even if a product liability claim is unsuccessful or is not fully pursued, the negative publicity surrounding any assertion that our products caused personal injury or illness could adversely affect our reputation and our corporate and brand image. If consumers were to lose confidence in our brand and reputation, we could suffer long-term or even permanent declines in our sales and results of operation. The amount of negative news, customers complaints and claims against us may also be very costly and may divert our management’s attention from our business operation.

 

Increased competition and capabilities in the marketplace could hurt our business.

 

The market where we operate is highly competitive. We compete with other companies that operate in multiple geographic areas, as well as numerous companies that are primarily regional or local in operation. Our ability to gain or maintain share of sales in the market where we operate or in various local markets may be limited as a result of actions by competitors. If we do not continue to strengthen our capabilities in marketing and innovation to maintain our brand loyalty and market share while we selectively expand into other product categories, our business could be negatively affected.

 

Risks Related to our Common Stock

 

The market price of our shares is likely to be highly volatile and subject to wide fluctuations in response to factors such as:

 

  variations in our actual and perceived operating results, especially during this time when the COVID-19 pandemic poses a threat;
     
  news regarding gains or losses of customers or suppliers by us or our competitors;
     
  news regarding gains or losses of key personnel by us or our competitors;
     
  announcements of competitive developments, acquisitions or strategic alliances in our industry by us or our competitors;
     
  changes in earnings estimates or buy/sell recommendations by financial analysts;
     
  potential litigation;
     
  the imposition of fines or penalties related to our activities in the market where we operate and failure to comply with applicable rules and regulations;
     
  general market conditions or other developments affecting us or our industry; and
     
 

the operating and stock price performance of other companies, other industries and other events or factors beyond our control.

 

17
 

 

In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are not related to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of the shares.

 

We may never be able to pay dividends and are unlikely to do so.

 

To date, we have not paid, nor do we intend to pay in the foreseeable future, dividends on our common stock, even if we become profitable. Earnings, if any, are expected to be used to advance our activities and for working capital and general corporate purposes, rather than to make distributions to stockholders. Since we are not in a financial position to pay dividends on our common stock and future dividends are not presently being contemplated, investors are advised that return on investment in our common stock is restricted to an appreciation in the share price. The potential or likelihood of an increase in share price is uncertain.

 

In addition, under Nevada law, we may only pay dividends subject to our ability to service our debts as they become due and provided that our assets will exceed our liabilities after the dividend. Our ability to pay dividends will therefore depend on our ability to generate sufficient profits.

 

Shareholders may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of securities.

 

Wherever possible, our board of directors will attempt to use non-cash consideration to satisfy obligations. In many instances, we believe that the non-cash consideration will consist of shares of our common stock, warrants to purchase shares of our common stock or other securities. Our board of directors has authority, without action or vote of the shareholders, to issue all or part of the authorized but unissued shares of common stock or warrants to purchase such shares of common stock. In addition, we may attempt to raise capital by selling shares of our common stock, possibly at a discount to market in the future. These actions will result in dilution of the ownership interests of existing shareholders and may further dilute common stock book value, and that dilution may be material. Such issuances may also serve to enhance existing management’s ability to maintain control of us, because the shares may be issued to parties or entities committed to supporting existing management.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

18
 

 

ITEM 6. Exhibits

 

Exhibit No.   Description
     
31.1   Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer*
     
32.1   Section 1350 Certification of principal executive officer *
     
101.INS   XBRL Instance Document*
     
101.SCH   XBRL Schema Document*
     
101.CAL   XBRL Calculation Linkbase Document*
     
101.DEF   XBRL Definition Linkbase Document*
     
101.LAB   XBRL Label Linkbase Document*
     
101.PRE   XBRL Presentation Linkbase Document*

 

* Filed herewith.

 

19
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AGAPE ATP CORPORATION
  (Name of Registrant)
     
Date: May 14, 2020    
  By: /s/ How Kok Choong
  Title:

Chief Executive Officer,

President, Director, Secretary and Treasurer

    (Principal Executive Officer)

 

20

 

EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION

 

I, HOW KOK CHOONG, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Agape ATP Corporation (the “Company”) for the quarter ended March 31, 2020;

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 14, 2020 By: /s/ How Kok Choong
    HOW KOK CHOONG
   

Chief Executive Officer,

President, Director, Secretary, Treasurer

    (Principal Executive Officer)

 

 

 

EX-32.1 3 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Agape ATP Corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), The undersigned hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: May 14, 2020 By: /s/ How Kok Choong
    HOW KOK CHOONG
    Chief Executive Officer, President, Director
    (Principal Executive Officer)

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

EX-101.INS 4 aatp-20200331.xml XBRL INSTANCE FILE 0001713210 AATP:GreenproCapitalCorpMember 2018-05-17 0001713210 2020-01-01 2020-03-31 0001713210 AATP:GreenproCapitalCorpMember 2018-10-16 0001713210 AATP:PhoenixPlusCorpMember 2019-04-03 0001713210 AATP:PhoenixPlusCorpMember us-gaap:CommonStockMember 2019-04-03 0001713210 2018-12-31 0001713210 2019-12-31 0001713210 us-gaap:CommonStockMember 2018-12-31 0001713210 us-gaap:CommonStockMember 2019-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001713210 us-gaap:RetainedEarningsMember 2018-12-31 0001713210 us-gaap:RetainedEarningsMember 2019-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001713210 AATP:SubsidiaryCompanyMember 2020-01-01 2020-03-31 0001713210 AATP:SubsidiaryCompanyMember 2020-03-31 0001713210 AATP:SubsidiaryCompanyOneMember 2020-01-01 2020-03-31 0001713210 AATP:SubsidiaryCompanyOneMember 2020-03-31 0001713210 AATP:IonizedCalMagMember 2020-01-01 2020-03-31 0001713210 AATP:OmegaBlendMember 2020-01-01 2020-03-31 0001713210 AATP:YoungFormulaMember 2020-01-01 2020-03-31 0001713210 AATP:OrganicYouthCareCleansingBarMember 2020-01-01 2020-03-31 0001713210 AATP:TrimPlusMember 2020-01-01 2020-03-31 0001713210 AATP:LipomaskMember 2020-01-01 2020-03-31 0001713210 AATP:PeriodEndMYRMember 2019-12-31 0001713210 AATP:PeriodAverageMYRMember 2019-12-31 0001713210 AATP:PeriodEndHKDMember 2019-12-31 0001713210 AATP:PeriodAverageHKDMember 2019-12-31 0001713210 AATP:PeriodendAUDMember 2019-12-31 0001713210 AATP:PeriodAverageAUDMember 2019-12-31 0001713210 AATP:MYRCurrencyMember 2019-07-01 2019-12-31 0001713210 AATP:HKDCurrencyMember 2019-07-01 2019-12-31 0001713210 AATP:AUDCurrencyMember 2019-07-01 2019-12-31 0001713210 AATP:GreenproCapitalCorpMember 2019-12-31 0001713210 AATP:GreenproCapitalCorpMember 2019-07-01 2019-12-31 0001713210 srt:DirectorMember 2020-03-31 0001713210 srt:DirectorMember AATP:MYRCurrencyMember 2020-03-31 0001713210 srt:MaximumMember 2019-03-10 0001713210 srt:MinimumMember 2019-03-10 0001713210 AATP:MrHowKokChoongMember 2019-12-31 0001713210 AATP:DirectorsOfUnreservedInvestmentMember 2019-12-31 0001713210 AATP:PhoenixPlusCorpMember 2019-12-31 0001713210 AATP:AgapeSEASdnBhdMember 2020-01-01 2020-03-31 0001713210 AATP:AgapeSuperiorLivingPtyLtdMember 2020-01-01 2020-03-31 0001713210 AATP:AgapeATPAsiaLimitedMember 2020-01-01 2020-03-31 0001713210 AATP:AgapeSuperiorLivingSdnBhdMember 2020-01-01 2020-03-31 0001713210 AATP:AgapeSEASdnBhdMember 2019-12-31 0001713210 AATP:AgapeSEASdnBhdMember 2020-03-31 0001713210 AATP:AgapeATPAsiaLimitedMember 2019-01-01 2019-03-31 0001713210 AATP:AgapeATPAsiaLimitedMember 2019-12-31 0001713210 AATP:AgapeATPAsiaLimitedMember 2020-03-31 0001713210 country:US 2020-03-31 0001713210 country:US 2020-01-01 2020-03-31 0001713210 country:US AATP:IfUnutilizedMember 2020-01-01 2020-03-31 0001713210 AATP:LabuanMember 2020-01-01 2020-03-31 0001713210 country:HK 2020-01-01 2020-03-31 0001713210 AATP:OneCustomersMember us-gaap:AccountsReceivableMember 2019-07-01 2019-12-31 0001713210 AATP:OneVendorMember us-gaap:AccountsPayableMember 2019-07-01 2019-12-31 0001713210 2020-05-11 0001713210 2020-03-31 0001713210 2019-01-01 2019-03-31 0001713210 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001713210 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001713210 us-gaap:CommonStockMember 2020-03-31 0001713210 us-gaap:CommonStockMember 2019-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001713210 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001713210 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001713210 us-gaap:RetainedEarningsMember 2020-03-31 0001713210 us-gaap:RetainedEarningsMember 2019-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001713210 2019-03-31 0001713210 AATP:AgapeATPInternationalHoldingLimitedMember 2020-03-31 0001713210 AATP:IonizedCalMagMember 2019-01-01 2019-03-31 0001713210 AATP:OmegaBlendMember 2019-01-01 2019-03-31 0001713210 AATP:YoungFormulaMember 2019-01-01 2019-03-31 0001713210 AATP:OrganicYouthCareCleansingBarMember 2019-01-01 2019-03-31 0001713210 AATP:TrimPlusMember 2019-01-01 2019-03-31 0001713210 AATP:LipomaskMember 2019-01-01 2019-03-31 0001713210 AATP:PeriodEndMYRMember 2020-03-31 0001713210 AATP:PeriodEndMYRMember 2019-03-31 0001713210 AATP:PeriodAverageMYRMember 2020-03-31 0001713210 AATP:PeriodAverageMYRMember 2019-03-31 0001713210 AATP:PeriodEndHKDMember 2020-03-31 0001713210 AATP:PeriodEndHKDMember 2019-03-31 0001713210 AATP:PeriodAverageHKDMember 2020-03-31 0001713210 AATP:PeriodAverageHKDMember 2019-03-31 0001713210 AATP:PeriodendAUDMember 2020-03-31 0001713210 AATP:PeriodendAUDMember 2019-03-31 0001713210 AATP:PeriodAverageAUDMember 2020-03-31 0001713210 AATP:PeriodAverageAUDMember 2019-03-31 0001713210 AATP:MYRCurrencyMember 2020-01-01 2020-03-31 0001713210 AATP:MYRCurrencyMember 2019-01-01 2019-03-31 0001713210 AATP:HKDCurrencyMember 2020-01-01 2020-03-31 0001713210 AATP:HKDCurrencyMember 2019-01-01 2019-03-31 0001713210 AATP:AUDCurrencyMember 2020-01-01 2020-03-31 0001713210 AATP:AUDCurrencyMember 2019-01-01 2019-03-31 0001713210 AATP:GreenproCapitalCorpMember 2020-03-31 0001713210 AATP:GreenproCapitalCorpMember 2020-01-01 2020-03-31 0001713210 AATP:MrHowKokChoongMember 2020-03-31 0001713210 AATP:DirectorsOfUnreservedInvestmentMember 2020-03-31 0001713210 AATP:PhoenixPlusCorpMember 2020-03-31 0001713210 2020-03-02 0001713210 AATP:AgapeSEASdnBhdMember 2019-01-01 2019-03-31 0001713210 AATP:AgapeSuperiorLivingPtyLtdMember 2019-01-01 2019-03-31 0001713210 AATP:AgapeSuperiorLivingPtyLtdMember 2020-03-31 0001713210 AATP:AgapeSuperiorLivingPtyLtdMember 2019-12-31 0001713210 2019-07-01 2019-12-31 0001713210 country:US AATP:IfUnutilizedMember 2020-03-31 0001713210 country:US 2019-12-31 0001713210 AATP:LabuanMember 2019-01-01 2019-03-31 0001713210 country:HK 2019-01-01 2019-03-31 0001713210 AATP:OneCustomersMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0001713210 AATP:OneCustomersMember us-gaap:AccountsReceivableMember 2020-01-01 2020-03-31 0001713210 AATP:VendorOneMember 2019-01-01 2019-03-31 0001713210 AATP:VendorTwoMember 2019-01-01 2019-03-31 0001713210 AATP:OneVendorMember us-gaap:AccountsPayableMember 2020-01-01 2020-03-31 0001713210 us-gaap:SubsequentEventMember 2020-05-30 2020-05-31 0001713210 us-gaap:SubsequentEventMember AATP:ShareExchangeAgreementMember AATP:MrHowKokChoongMember AATP:AgapeSuperiorLivingSdnBhdMember 2020-05-07 2020-05-08 0001713210 us-gaap:SubsequentEventMember AATP:ShareExchangeAgreementMember AATP:MrHowKokChoongMember AATP:AgapeSuperiorLivingSdnBhdMember 2020-05-08 0001713210 us-gaap:SubsequentEventMember AATP:ShareExchangeAgreementMember AATP:MrHowKokChoongMember 2020-05-07 2020-05-08 0001713210 us-gaap:SubsequentEventMember AATP:ShareExchangeAgreementMember AATP:MrHowKokChoongMember 2020-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:MYR Agape ATP Corp 0001713210 10-Q 2020-03-31 false --12-31 Accelerated Filer Q1 2020 376275500 0.0001 0.0001 0.0001 0.0001 200000000 200000000 1000000000 1000000000 2500000 376275500 376275500 2500000 376275500 376275500 2500000 376438194 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>11. OTHER PAYABLES AND ACCRUED LIABILITIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued professional fees</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">68,474</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">58,594</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Others</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">28,985</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">18,652</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total payables and accrued liabilities</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">97,459</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">77,246</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>9. RELATED PARTY TRANSACTIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s related party list and relationship are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; width: 34%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Related parties</b></font></td> <td style="width: 2%; text-align: justify">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 64%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Relationships</b></font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Agape S.E.A. Sdn Bhd</u></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape S.E.A. Sdn Bhd</u></font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Agape Superior Living Pty Ltd</u></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Mr. How Kok Choong, the CEO and director of the Company is a 51% shareholder and a director of Agape Superior Living Pty Ltd</u></font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Agape Superior Living Sdn Bhd</u></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape Superior Living Sdn Bhd</u></font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Agape ATP (Asia) Limited</u></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape ATP (Asia) Limited.</u></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Related party transactions for the three months ended March 31, 2020 and 2019; and as of March 31, 2020, and December 31, 2019 are as per table below:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the three months ended</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Revenue</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Accounts Receivable, Trade</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%"><font style="font: 10pt Times New Roman, Times, Serif">Agape S.E.A. Sdn Bhd</font></td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">464,297</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">523,141</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">520,786</font></td> <td style="width: 1%">&#160;</td></tr> <tr> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Expenses paid on behalf</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Amount due from a related party</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%"><font style="font: 10pt Times New Roman, Times, Serif">Agape ATP (Asia) Limited</font></td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,200</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,227</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,217</font></td> <td style="width: 1%">&#160;</td></tr> <tr> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Sundry Purchases</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Prepayments and Deposits</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%"><font style="font: 10pt Times New Roman, Times, Serif">Agape Superior Living Pty Ltd</font></td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,783</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>15. SUBSEQUENT EVENT</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, a novel strain of coronavirus (COVID-19) surfaced. The spread of COVID-19 around the world in the first quarter of 2020 has caused significant volatility in Malaysia. There is significant uncertainty around the duration of business disruptions related to COVID-19, as well as its impact on the Malaysia economies and, as such, the Company is unable to determine if it will have a material impact to its operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn Bhd, an entity incorporated in Malaysia for $1,714,003. The purchase consideration represented the net asset carrying value of the acquiree as of March 31, 2020. The payment, net of the amount due from Mr. How Kok Choong of $656,495 as of March 31, 2020 arising from the purchase of the Company&#8217;s non-marketable security, will be satisfied together with the issuance of 162,694 shares of the Company&#8217;s common stock. Upon completion, the number of shares of common stock of the Company will be increased from 376,275,500 to 376,438,194, equivalent to approximately 0.0432% increase of the total issued and outstanding common stock of the Company after the issuance of the additional shares, which was valued at $1,057,508 based on the closing price of $6.50 of the Company at March 31, 2020.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Basis of presentation</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for information pursuant to the rules and regulations of the Securities Exchange Commission (&#8220;SEC&#8221;).</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Basis of consolidation</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the financial statements of the Company and its subsidiaries. All transactions and balances among the Company and its subsidiaries have been eliminated upon consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Use of estimates</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company&#8217;s consolidated financial statements include allowance for doubtful accounts, allowance for deferred tax assets and uncertain tax position, and impairment of investment in non-marketable securities. Actual results could differ from these estimates.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Revenue recognition</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 1, 2019, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (ASC Topic 606) using the modified retrospective method for contracts that were not completed as of June 30, 2019. This did not result in an adjustment to retained earnings upon adoption of this new guidance as the Company&#8217;s revenue was recognized based on the amount of consideration expected to receive in exchange for satisfying the performance obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company&#8217;s revenue streams are recognized at a point in time for the Company&#8217;s sale of health and wellness products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to July 1, 2019, the Company recognizes revenue from sales of goods when the following four revenue criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) selling price is fixed or determinable; and (4) collectability is reasonably assured. Revenue from supplies of health and wellness products is recognized when title and risk of loss are transferred and there are no continuing obligations to the customer. Title and the risks and rewards of ownership transfer to and accepted by the customer when the products are collected by the customer at the Company&#8217;s office. Revenue is recorded net of sales discounts, returns, allowances, and other adjustments that are based upon management&#8217;s best estimates and historical experience and are provided for in the same period as the related revenues are recorded.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The application of the five-step model to the revenue streams compared to the prior guidance did not result in significant changes in the way the Company records its revenue. Upon adoption on July 1, 2019, the Company evaluated its revenue recognition policy for all revenue streams within the scope of the ASU under previous standards and using the five-step model under the new guidance and confirmed that there were no differences in the pattern of revenue recognition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Sales of Health and Wellness products</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">-&#160;<i>Performance obligations satisfied at a point in time</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 1, 2019, the Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company&#8217;s office or shipment of the goods, which is generally similar to when its delivery has occurred prior to July 1, 2019. Such revenues are recognized at a point in time after all performance obligations are satisfied. The revenue is recorded net of estimated discounts and return allowances. Historically, there were no sales return as the Company&#8217;s products sold are not refundable, returnable or exchangeable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Disaggregated information of revenues by products are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the three months ended</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Ionized Cal-Mag</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">55,493</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Omega Blend</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">68,689</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Young Formula</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">116,979</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Organic Youth Care Cleansing Bar</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">17,675</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Trim+</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">65,295</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Lipomask</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">140,166</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total revenues</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">464,297</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Cost of revenue</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of revenue includes freight-in and the purchase cost of manufactured goods for sale to customers</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Cash and cash equivalents</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents are carried at cost and represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Income taxes</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An uncertain tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. No penalties and interest incurred related to underpayment of income tax.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company conducts much of its businesses activities in Hong Kong and is subject to tax in this jurisdiction. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Earnings (loss) per share</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes earnings (loss) per share (&#8220;EPS&#8221;) in accordance with ASC 260, &#8220;Earnings per Share&#8221;. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common share outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Related parties</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Fair value of financial instruments</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The United States and foreign components of income (loss) before income taxes were comprised of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the three months ended</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Tax jurisdictions from:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 61%; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">- Local</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(142,419</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(14,724</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">- Foreign - Labuan</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(55,587</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">59,674</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">- Foreign - Hong Kong</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(33,744</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">19,300</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Income (Loss) before income tax</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(231,750</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">64,250</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The benefit for income taxes consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the three months ended</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Current:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">- Local</font></td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 61%; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">- Foreign</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6,965</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Deferred:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">- Local</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">- Foreign</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Benefit for income taxes</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6,965</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the significant components of the aggregate deferred tax assets of the Company as of:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> March 31, 2020</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>As of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31, 2019</b></p></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Deferred tax assets:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Net operating loss carry forwards in U.S.</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">73,318</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">43,410</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Less: valuation allowance</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(73,318</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(43,410</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Deferred tax assets</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued professional fees</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">68,474</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">58,594</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Others</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">28,985</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">18,652</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total payables and accrued liabilities</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">97,459</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">77,246</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of and for the three months ended</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%"><font style="font: 10pt Times New Roman, Times, Serif">Period-end MYR : US$1 exchange rate</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.34</font></td> <td style="width: 1%">&#160;</td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.10</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.09</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-average MYR : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.21</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.08</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.16</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-end HKD : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.75</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.85</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.79</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-average HKD : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.77</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.85</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.83</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-end AUD : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.63</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.41</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.43</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-average AUD : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.55</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.40</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.46</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> 44119 -6965 -231750 71215 -231750 71215 0 0 376275500 376275500 4956334 4251286 37628 37628 5293082 5293082 -373082 -1089209 -1294 9785 4027306 37628 37628 5293082 5293082 -1320959 -301867 17555 -4491 5024352 3952 420178 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>3. CASH AND CASH EQUIVALENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.2pt 0 0; text-align: justify; background-color: white"><font style="background-color: white">As of March 31, 2020 and December 31, 2019 the Company recorded $2,588,207 and $2,744,457, respectively, of cash and cash equivalents, which consists $135,436 and $238,937, respectively, of cash in bank and $2,452,771 and $2,505,520, respectively, of time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less. The effective interest rate for the time deposits ranges between 2.95% to 3.25% per annum.</font></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="background-color: white"><b>7. PREPAYMENTS AND DEPOSITS</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,458</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,641</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Deposits to supplier</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">299,310</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">266,552</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total prepaid expenses and deposits</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">304,768</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">269,193</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Cost of investment</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">66,484</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">134,166</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Less: Unrealized holding loss</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(18,538</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(68,391</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Exchange rate effect</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">256</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">709</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Investment in marketable securities</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">48,202</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">66,484</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Investment in marketable equity securities</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to July 1, 2019, marketable securities included in investment in marketable equity securities (non-current) are stated at the lower of cost or market in the aggregate. Other marketable securities (non-current) are stated at the lower of cost or market in the aggregate and investments other than marketable equity securities in other investments (non-current) are stated at cost less any significant decline in fair value assessed to be other than temporary. Realized gains and losses on the sale of securities are based on the average cost of all the units of a particular security held at the time of sale.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 1, 2019, the Company adopted ASU 2016-01, <i>Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>. Investments in marketable equity securities (non-current) are reported at fair value with changes in fair value recognized in the Company&#8217;s consolidated statements of operations and comprehensive loss in the caption of &#8220;unrealized holding losses on marketable securities&#8221; in each reporting period.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="background-color: white"><u>Selling, general and administrative expenses</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Selling, general and administrative expenses are primarily comprised of rental of office premises, travelling, licensing and professional fees.</p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,458</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,641</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Deposits to supplier</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">299,310</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">266,552</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total prepaid expenses and deposits</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">304,768</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">269,193</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Details of the Company&#8217;s subsidiaries:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Subsidiary company</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>name</b></p></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Place and</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>date of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>incorporation</b></p></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Particulars of issued capital</b></font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Principal activities</b></font></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Proportional of ownership</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>interest and</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>voting power</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>held</b></p></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 5%"><font style="font: 10pt Times New Roman, Times, Serif">1.</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: top; width: 32%"><font style="font: 10pt Times New Roman, Times, Serif">Agape ATP Corporation</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: top; width: 14%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Labuan,<br /> March 6, 2017</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: top; width: 16%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">100 shares of ordinary share of US$1 each</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: top; width: 13%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Investment holding</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: top; width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td> <td style="vertical-align: top; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">2.</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">Agape ATP International Holding Limited</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Hong Kong,<br /> June 1, 2017</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000 shares of ordinary share of HK$1 each</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Health and wellness products and health solution advisory services</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td> <td style="vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="margin: 0pt"></p> 6 0.03 0.0001 6.50 2790 159516 28226 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Foreign currencies translation and transaction</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the Condensed Consolidated Statements of Operations and Comprehensive Income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The reporting currency of the Company is United States Dollars (&#8220;US$&#8221;) and the accompanying financial statements have been expressed in US$. The Company&#8217;s subsidiary in Labuan maintains its books and record in United States Dollars (&#8220;US$&#8221;) albeit its functional currency being the primary currency of the economic environment in which the entity operates is the Malaysian Ringgit (&#8220;MYR&#8221;). The Company&#8217;s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars (&#8220;HK$&#8221;), similar to its functional currency.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, &#8220;<i>Translation of Financial Statement&#8221;</i>, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders&#8217; equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of and for the three months ended</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%"><font style="font: 10pt Times New Roman, Times, Serif">Period-end MYR : US$1 exchange rate</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.34</font></td> <td style="width: 1%">&#160;</td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.10</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.09</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-average MYR : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.21</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.08</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.16</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-end HKD : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.75</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.85</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.79</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-average HKD : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.77</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.85</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.83</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-end AUD : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.63</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.41</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.43</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-average AUD : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.55</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.40</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.46</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> 66484 66484 48202 48202 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Accounts receivable &#8211; related party</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable &#8211; related party are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due on demand. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer&#8217;s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company&#8217;s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of March 31, 2020, and December 31, 2019, no valuation allowance was recorded.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>5. INVESTMENT IN MARKETABLE SECURITIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 14px">&#160;</td> <td style="width: 34px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(i)</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On May 17, 2018, the Company purchased 83,333 shares of common stock in Greenpro Capital Corp. for $500,000 at a purchase price of $6 per share.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(ii)</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On October 16, 2018, the Company purchased 33,333 shares of common stock in Greenpro Capital Corp. for $1,000 at a purchase price of $0.03 per share.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Cost of investment</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">66,484</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">134,166</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Less: Unrealized holding loss</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(18,538</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(68,391</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Exchange rate effect</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">256</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">709</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Investment in marketable securities</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">48,202</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">66,484</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> true true false -231750 64250 7770 -3197 3452917 2744457 2588207 3091400 376275500 376275500 376275500 376275500 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>1. ORGANIZATION AND BUSINESS BACKGROUND</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Agape ATP Corporation, a Nevada corporation (&#8220;the Company&#8221;) was incorporated under the laws of the State of Nevada on June 1, 2016.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Agape ATP Corporation operates through its wholly owned subsidiary, Agape ATP Corporation, a Company organized in Labuan, Malaysia.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Agape ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International Holding Limited, a company incorporated in Hong Kong.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company and its subsidiaries provide health and wellness products and advisory services to the public. The principal activity of the Company and its subsidiaries is to supply high-quality health and wellness products, including supplement to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system in our body.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Details of the Company&#8217;s subsidiaries:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Subsidiary company</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>name</b></p></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Place and</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>date of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>incorporation</b></p></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Particulars of issued capital</b></font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Principal activities</b></font></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Proportional of ownership</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>interest and</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>voting power</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>held</b></p></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 5%"><font style="font: 10pt Times New Roman, Times, Serif">1.</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: top; width: 32%"><font style="font: 10pt Times New Roman, Times, Serif">Agape ATP Corporation</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: top; width: 14%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Labuan,<br /> March 6, 2017</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: top; width: 16%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">100 shares of ordinary share of US$1 each</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: top; width: 13%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Investment holding</font></td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: bottom; width: 1%">&#160;</td> <td style="vertical-align: top; width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td> <td style="vertical-align: top; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">2.</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">Agape ATP International Holding Limited</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Hong Kong,<br /> June 1, 2017</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000 shares of ordinary share of HK$1 each</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Health and wellness products and health solution advisory services</font></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: top; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td> <td style="vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Business Overview</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Agape ATP Corporation is a company that provides health solution advisory services to our clients. We primarily focus our efforts on attracting customers in Malaysia. Our advisory services center on the &#8220;ATP Zeta Health Program&#8221;, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At its core, the ATP Zeta Super Health Program is focused upon biological energy, Adenosine Triphosphate (ATP), at the cellular level. The stimulation of ATP production at the cellular level can increase the metabolism and service to promote and maintain normal and healthy functioning of the body&#8217;s systems. As a strong advocator of &#8220;beauty from within&#8221;, our program shall emphasize nutrient absorption through the membrane ion channel to provide complete and balanced nutrients to improve cell health. Thus, ATP Zeta Super Health Program provides ionized and high zeta potential (high bioavailability) nutrients to enhance the absorption at the cellular level.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ATP Zeta Super Health Program consists of eight products. None of these products are owned or produced by Agape ATP Corporation. In the event that any of these products are no longer produced, or are otherwise unavailable, we may have to devote significant effort to identifying and obtaining comparable replacement products. The eight products that comprise the ATP Zeta Super Health Program are ATP1s Survivor Select, ATP2 Energized Mineral Concentrate, ATP3 Ionized Cal-Mag, ATP4 Omega Blend, ATP5 BetaMaxx, AGN-Vege Fruit Fiber, AGP1-Iron and YFA-Young Formula.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At present, our products are mainly sold in Malaysia, and due to the contents and combination of the main ingredients in the products they are categorized as health food rather than medicines or drugs. As such, all products require authorization from the Food and Quality Division of Ministry of Health according to the Food Act of 1983 and Food Regulation 1985 in order to be sold in the country. All of the products in the ATP Zeta Super Health Program have obtained the appropriate authorizations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of a continuous effort to increase market share of the health and wellness industry that is growing at an exponential rate, we will also evaluate adding additional products to the ATP Zeta Super Health Program; and considering the potential of the synergies between the health and beauty sectors, we will further involve ourselves in the topical approach of skin and hair regime. Other than organic growth, the Company will also consider mergers and acquisitions where synergistic. As detailed in Note 15, Subsequent Events, to improve its sales channel, the Company is in the process of acquiring a Malaysia incorporated entity whose principal activity is in the trading of health and wellness products.</p> -223980 68018 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Basis of presentation</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for information pursuant to the rules and regulations of the Securities Exchange Commission (&#8220;SEC&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Basis of consolidation</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the financial statements of the Company and its subsidiaries. All transactions and balances among the Company and its subsidiaries have been eliminated upon consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Use of estimates</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company&#8217;s consolidated financial statements include allowance for doubtful accounts, allowance for deferred tax assets and uncertain tax position, and impairment of investment in non-marketable securities. Actual results could differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Cash and cash equivalents</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents are carried at cost and represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Accounts receivable &#8211; related party</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable &#8211; related party are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due on demand. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer&#8217;s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company&#8217;s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of March 31, 2020, and December 31, 2019, no valuation allowance was recorded.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Prepayments and deposits</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepayments and deposits are cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after management has determined that the likelihood of collection is not probable. The Company&#8217;s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Investment in marketable equity securities</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to July 1, 2019, marketable securities included in investment in marketable equity securities (non-current) are stated at the lower of cost or market in the aggregate. Other marketable securities (non-current) are stated at the lower of cost or market in the aggregate and investments other than marketable equity securities in other investments (non-current) are stated at cost less any significant decline in fair value assessed to be other than temporary. Realized gains and losses on the sale of securities are based on the average cost of all the units of a particular security held at the time of sale.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 1, 2019, the Company adopted ASU 2016-01,&#160;<i>Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>. Investments in marketable equity securities (non-current) are reported at fair value with changes in fair value recognized in the Company&#8217;s consolidated statements of operations and comprehensive loss in the caption of &#8220;unrealized holding losses on marketable securities&#8221; in each reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Investment in non-marketable equity securities</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to July 1, 2019, investments in non-marketable equity securities (non-current) are stated at cost less any significant decline in fair value assessed to be other than temporary. Realized gains and losses on the sale of securities are based on the average cost of all the units of a particular security held at the time of sale.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 1, 2019, the Company adopted ASU 2016-01,&#160;<i>Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>. Due to the Company&#8217;s non-marketable equity securities (non-current) does not qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that raise significant concerns about the investee&#8217;s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment loss equal to the difference between the fair value of the investment and its carrying amount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Revenue recognition</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 1, 2019, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (ASC Topic 606) using the modified retrospective method for contracts that were not completed as of June 30, 2019. This did not result in an adjustment to retained earnings upon adoption of this new guidance as the Company&#8217;s revenue was recognized based on the amount of consideration expected to receive in exchange for satisfying the performance obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company&#8217;s revenue streams are recognized at a point in time for the Company&#8217;s sale of health and wellness products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to July 1, 2019, the Company recognizes revenue from sales of goods when the following four revenue criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) selling price is fixed or determinable; and (4) collectability is reasonably assured. Revenue from supplies of health and wellness products is recognized when title and risk of loss are transferred and there are no continuing obligations to the customer. Title and the risks and rewards of ownership transfer to and accepted by the customer when the products are collected by the customer at the Company&#8217;s office. Revenue is recorded net of sales discounts, returns, allowances, and other adjustments that are based upon management&#8217;s best estimates and historical experience and are provided for in the same period as the related revenues are recorded.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The application of the five-step model to the revenue streams compared to the prior guidance did not result in significant changes in the way the Company records its revenue. Upon adoption on July 1, 2019, the Company evaluated its revenue recognition policy for all revenue streams within the scope of the ASU under previous standards and using the five-step model under the new guidance and confirmed that there were no differences in the pattern of revenue recognition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Sales of Health and Wellness products</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">-&#160;<i>Performance obligations satisfied at a point in time</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 1, 2019, the Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company&#8217;s office or shipment of the goods, which is generally similar to when its delivery has occurred prior to July 1, 2019. Such revenues are recognized at a point in time after all performance obligations are satisfied. The revenue is recorded net of estimated discounts and return allowances. Historically, there were no sales return as the Company&#8217;s products sold are not refundable, returnable or exchangeable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Disaggregated information of revenues by products are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the three months ended</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Ionized Cal-Mag</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">55,493</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Omega Blend</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">68,689</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Young Formula</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">116,979</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Organic Youth Care Cleansing Bar</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">17,675</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Trim+</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">65,295</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Lipomask</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">140,166</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total revenues</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">464,297</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Cost of revenue</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of revenue includes freight-in and the purchase cost of manufactured goods for sale to customers</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="background-color: white"><u>Selling, general and administrative expenses</u></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Selling, general and administrative expenses are primarily comprised of rental of office premises, travelling, licensing and professional fees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Income taxes</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An uncertain tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test, no tax benefit is recorded. No penalties and interest incurred related to underpayment of income tax.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company conducts much of its businesses activities in Hong Kong and is subject to tax in this jurisdiction. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Comprehensive income (loss)</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Comprehensive income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net income. Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Earnings (loss) per share</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes earnings (loss) per share (&#8220;EPS&#8221;) in accordance with ASC 260, &#8220;Earnings per Share&#8221;. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common share outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Foreign currencies translation and transaction</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the Condensed Consolidated Statements of Operations and Comprehensive Income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The reporting currency of the Company is United States Dollars (&#8220;US$&#8221;) and the accompanying financial statements have been expressed in US$. The Company&#8217;s subsidiary in Labuan maintains its books and record in United States Dollars (&#8220;US$&#8221;) albeit its functional currency being the primary currency of the economic environment in which the entity operates is the Malaysian Ringgit (&#8220;MYR&#8221;). The Company&#8217;s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars (&#8220;HK$&#8221;), similar to its functional currency.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, &#8220;<i>Translation of Financial Statement&#8221;</i>, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders&#8217; equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of and for the three months ended</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 42%"><font style="font: 10pt Times New Roman, Times, Serif">Period-end MYR : US$1 exchange rate</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.34</font></td> <td style="width: 1%">&#160;</td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.10</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.09</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-average MYR : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.21</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.08</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">4.16</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-end HKD : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.75</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.85</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.79</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-average HKD : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.77</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.85</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">7.83</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-end AUD : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.63</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.41</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.43</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Period-average AUD : US$1 exchange rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.55</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.40</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1.46</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Related parties</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Fair value of financial instruments</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Operating leases</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A lease for which substantially all the benefits and risks incidental to ownership remain with the lessor is classified by the lessee as an operating lease. All leases of the Company are currently classified as operating leases. The Company records the total expenses on a straight-line basis over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company had on July 1, 2019, adopted ASU 2016-02, &#8220;Leases&#8221; (Topic 842), and elected the practical expedients that do not require us to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. The Company adopted the practical expedient that allows lessees to treat the lease and non-lease components of a lease as a single lease component. There is no impact from the adoption of ASC 842 as of January 1, 2020, as the Company did not have any existing leases with a lease term in excess of twelve months on January 1, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Recent accounting pronouncements</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of such any pronouncements may be expected to cause a material impact on its financial condition or the results of its operations, as follow:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, the FASB Issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815). The amendments in Part I of the Update change the reclassification analysis of certain equity-lined financial instruments (or embedded features) with down round features. The amendments in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part II of this Update do not require any transition guidance because those amendments do not have an accounting effect. The adoption of this ASU did not have a material effect on the Company&#8217;s consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The amendments in this Update affect any entity that is required to apply the provisions of Topic 220, Income Statement &#8211; Reporting Comprehensive Income, and has items of other comprehensive income for which the related tax effects are presented in other comprehensive income as required by GAAP. The amendments in this Update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this Update should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. The adoption of this ASU did not have a material effect on the Company&#8217;s consolidated financial statements<font style="background-color: white">.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">In August 2018, the FASB has issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements of Fair Value Measurement. This amendment modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits, with the primary purpose to improve the effectiveness of disclosures in the notes to financial statements by facilitating clear communication of the information required by US GAAP. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company is currently evaluating the impact of ASU 2018-13 will have on its consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In May 2019, the FASB issued ASU 2019-05, which is an update to ASU Update No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments&#8212;Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments&#8212; Credit Losses&#8212;Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders&#8217; concerns by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful information. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 due the Company is qualified as an emerging growth company. The Company is currently evaluating the impact of ASU 2019-05 will have on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In January 2020, the FASB issued ASU 2020-01 to clarify the interaction of the accounting for equity securities under ASC 321 and investments accounted for under the equity method of accounting in ASC 323 and the accounting for certain forward contracts and purchased options accounted for under ASC 815. With respect to the interactions between ASC 321 and ASC 323, the amendments clarify that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting when applying the measurement alternative in ASC 321, immediately before applying or upon discontinuing the equity method of accounting. With respect to forward contracts or purchased options to purchase securities, the amendments clarify that when applying the guidance in ASC 815-10-15-141(a), an entity should not consider whether upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in ASC 323 or the fair value option in accordance with ASC 825. The ASU is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Reclassification</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior period amounts have been reclassified to conform to the current period presentation for the three months ended March 31, 2019. These reclassifications have no effect on the condensed consolidated statements of operations and comprehensive income.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Recent accounting pronouncements</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of such any pronouncements may be expected to cause a material impact on its financial condition or the results of its operations, as follow:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, the FASB Issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815). The amendments in Part I of the Update change the reclassification analysis of certain equity-lined financial instruments (or embedded features) with down round features. The amendments in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part II of this Update do not require any transition guidance because those amendments do not have an accounting effect. The adoption of this ASU did not have a material effect on the Company&#8217;s consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The amendments in this Update affect any entity that is required to apply the provisions of Topic 220, Income Statement &#8211; Reporting Comprehensive Income, and has items of other comprehensive income for which the related tax effects are presented in other comprehensive income as required by GAAP. The amendments in this Update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this Update should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. The adoption of this ASU did not have a material effect on the Company&#8217;s consolidated financial statements<font style="background-color: white">.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">In August 2018, the FASB has issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements of Fair Value Measurement. This amendment modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits, with the primary purpose to improve the effectiveness of disclosures in the notes to financial statements by facilitating clear communication of the information required by US GAAP. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company is currently evaluating the impact of ASU 2018-13 will have on its consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In May 2019, the FASB issued ASU 2019-05, which is an update to ASU Update No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments&#8212;Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments&#8212; Credit Losses&#8212;Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders&#8217; concerns by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful information. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 due the Company is qualified as an emerging growth company. The Company is currently evaluating the impact of ASU 2019-05 will have on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In January 2020, the FASB issued ASU 2020-01 to clarify the interaction of the accounting for equity securities under ASC 321 and investments accounted for under the equity method of accounting in ASC 323 and the accounting for certain forward contracts and purchased options accounted for under ASC 815. With respect to the interactions between ASC 321 and ASC 323, the amendments clarify that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting when applying the measurement alternative in ASC 321, immediately before applying or upon discontinuing the equity method of accounting. With respect to forward contracts or purchased options to purchase securities, the amendments clarify that when applying the guidance in ASC 815-10-15-141(a), an entity should not consider whether upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in ASC 323 or the fair value option in accordance with ASC 825. The ASU is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Related party transactions for the three months ended March 31, 2020 and 2019; and as of March 31, 2020, and December 31, 2019 are as per table below:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the three months ended</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Revenue</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Accounts Receivable, Trade</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%"><font style="font: 10pt Times New Roman, Times, Serif">Agape S.E.A. Sdn Bhd</font></td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">464,297</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">523,141</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">520,786</font></td> <td style="width: 1%">&#160;</td></tr> <tr> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Expenses paid on behalf</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Amount due from a related party</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%"><font style="font: 10pt Times New Roman, Times, Serif">Agape ATP (Asia) Limited</font></td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,200</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,227</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,217</font></td> <td style="width: 1%">&#160;</td></tr> <tr> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Sundry Purchases</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Prepayments and Deposits</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%"><font style="font: 10pt Times New Roman, Times, Serif">Agape Superior Living Pty Ltd</font></td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 13%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 12%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,783</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 2.25pt double; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>12. INCOME TAXES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The United States and foreign components of income (loss) before income taxes were comprised of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the three months ended</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Tax jurisdictions from:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 61%; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">- Local</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(142,419</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(14,724</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">- Foreign - Labuan</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(55,587</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">59,674</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">- Foreign - Hong Kong</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(33,744</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">19,300</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Income (Loss) before income tax</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(231,750</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">64,250</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The benefit for income taxes consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the three months ended</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Current:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">- Local</font></td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 61%; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">- Foreign</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6,965</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Deferred:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">- Local</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">- Foreign</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>-</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Benefit for income taxes</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6,965</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rates. The Company and its subsidiary that operate in various countries: United States, Labuan and Hong Kong that are subject to taxes in the jurisdictions in which they operate, as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>United States of America</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Agape ATP Corporation was incorporated in the State of Nevada and is subject to the tax laws of the United States of America. As of March 31, 2020, the operations in the United States of America incurred approximately $349,000 of cumulative net operating losses which can be carried forward to offset future taxable income. Approximately $10,000 and $24,000 of the net operating loss carry forwards will expire in 2027and 2028, respectively, if unutilized. The remaining balance can be carried forward indefinitely. The deferred tax valuation allowance as of March 31, 2020 and December 31, 2019 were approximately $73,000 and $43,000, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Labuan</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the current laws of the Labuan, Agape ATP Corporation is governed under the Labuan Business Activity Act, 1990. The tax charge for such company is based on 3% of net audited profit. Due to Agape ATP Corporation is a holding company, it did not generate any income nor incurred any income tax. In addition, its related expenses incurred cannot be carried forward to offset any future operation income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Hong Kong</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Agape ATP International Holding (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income rate of 16.5% on its assessable income derived from Hong Kong. Business income derived or business expenses incurred outside the Special Administrative Region is not subject to Hong Kong Profits Tax or deduction.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table reconciles the local (United States) statutory rates to the Company&#8217;s effective tax rate for the periods indicated below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the three months ended</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 63%"><font style="font: 10pt Times New Roman, Times, Serif">U.S. statutory rate</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21.0</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21.0</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(21.0</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(21.0</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Permanent difference&#160;<sup>(1)</sup></font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(10.8</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Effective tax rate</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(10.8</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><sup>(1)&#160;</sup>This was related to disallowed expenditure incurred in the ordinary course of business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the significant components of the aggregate deferred tax assets of the Company as of:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> March 31, 2020</b></font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>As of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>December 31, 2019</b></p></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Deferred tax assets:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Net operating loss carry forwards in U.S.</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">73,318</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">43,410</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Less: valuation allowance</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(73,318</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(43,410</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Deferred tax assets</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>13. CONCENTRATIONS OF RISKS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) Major customers</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no sales for the three months ended March 31, 2020. For the three months ended March 31, 2019, one related party customer accounted for 100% of the Company&#8217;s total revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, and December 31, 2019, one related party customer accounted for 100% of the total balance of accounts receivable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) Major vendors</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no purchases for the three months ended March 31, 2020. For the three months ended March 31, 2019, two vendors accounted for approximately 54% and 46% of the Company&#8217;s total purchases, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts payable as of March 31, 2020 was nil. As of December 31, 2019, one vendor accounted for 100% of the total balance of accounts payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) Credit risk</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its account receivable is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Historically, the Company did not have any bad debt on its account receivable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(d) Exchange rate risk</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="background-color: white">The Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower profit depending on exchange rate of RM$ and HK$ converted to US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.</font></p> 7770 -3197 7770 -3197 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Investment in non-marketable equity securities</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to July 1, 2019, investments in non-marketable equity securities (non-current) are stated at cost less any significant decline in fair value assessed to be other than temporary. Realized gains and losses on the sale of securities are based on the average cost of all the units of a particular security held at the time of sale.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 1, 2019, the Company adopted ASU 2016-01,&#160;<i>Financial Instruments &#8211; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>. Due to the Company&#8217;s non-marketable equity securities (non-current) does not qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that raise significant concerns about the investee&#8217;s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment loss equal to the difference between the fair value of the investment and its carrying amount.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>6. INVESTMENT IN NON-MARKETABLE SECURITIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company invested in Unreserved Sdn Bhd with the investment amount of $863,592 (MYR3,500,000), which approximated 20% of the equity interest of Unreserved Sdn Bhd and is accounted for under the equity method of accounting. On March 10, 2019 Unreserved Sdn Bhd issued additional common stock for working capital. As the Company did not subscribe for the additional common stock, the Company&#8217;s equity interest in investee company was diluted from approximately 20.0% to approximately 17.86%. Effective from March 10, 2019, the Company discontinued equity accounting on the investee company. The Company also ceased control over the operations of the investee company on the same date. Accordingly, the investment in investee company was reclassified to investment in non-marketable securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unreserved Sdn Bhd was incorporated in Malaysia with 2,500,000 ordinary shares authorized, issued and outstanding. Mr. Lim Hun Soon @ David Lim and Ms. Aniza Helina Akmi Karim are the directors of Unreserved Sdn Bhd. Mr. How Kok Choong was a director of the company from April 30, 2018 to March 27, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 2, 2020, the Company agreed to sell the 17.86% ownership interest in Unreserved Sdn Bhd at the December 31, 2019 carrying value of $730,637 to Mr. How Kok Choong, the CEO and director of the Company. The Company received proceeds of $70,173, and had an amount due from director balance of $660,464 as at March 31, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2020, the entire outstanding balance was settled as part of the consideration in a transaction which the Company had acquired the CEO&#8217;s ownership interest of Agape Superior Living Sdn. Bhd.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 3, 2019, the Company purchased a 5% of stock or 15,000,000 shares of common stock in Phoenix Plus Corp. for $1,500 at purchase price of $0.0001 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Unreserved Sdn Bhd</font></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Investment in non-marketable securities</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">730,637</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">730,637</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif"><i>Less: Sale of investment in non-marketable securities</i></font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(730,637</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Investment in non-marketable securities</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">730,637</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Phoenix Plus Corporation</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Cost of investment</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total investment in non-marketable securities</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">732,137</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> Yes Yes false 732137 732137 1500 1500 2744457 2588207 269193 304993 2783 2217 2227 3536653 4075063 4335274 4124765 77246 97459 83988 97459 83988 97459 37628 37628 5293082 5293082 9785 17555 -1089209 -1320959 4335274 4124765 34593 100029 2200 -2803 1323 19892 952 -230431 -358320 4008 -3197 -156250 -361517 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="background-color: white"><b>4. ACCOUNTS RECEIVABLE &#8211; RELATED PARTY</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable &#8211; related party</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">523,141</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">520,786</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Allowance for doubtful accounts</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total accounts receivable &#8211; related party</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">523,141</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">520,786</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>10. STOCKHOLDERS&#8217; EQUITY</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Preferred stock</u></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, and December 31, 2019, there were 200,000,000 preferred stocks authorized but none were issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Common stock</u></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, and December 31, 2019, there were 1,000,000,000 common stocks authorized, 376,275,500 were issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no stock options, warrants or other potentially dilutive securities outstanding as of March 31, 2020 and December 31, 2019.</p> 0.05 1.00 1.00 0.20 0.200 0.1786 1.00 0.1786 0.9999 Agape ATP Corporation Agape ATP International Holding Limited Labuan, March 6, 2017 Hong Kong, June 1, 2017 100 shares of ordinary share of US$1 each 1,000,000 shares of ordinary share of HK$1 each Investment holding Health and wellness products and health solution advisory services Greater than 50% 4.09 4.16 7.79 7.83 1.43 1.46 4.34 4.10 4.21 4.08 7.75 7.85 7.77 7.85 1.63 1.41 1.55 1.40 1 1 1 1 1 1 1 1 1 500000 1000 1500 134166 863592 3500000 730637 1500 66484 1500 83333 33333 15000000 238937 135436 2505520 2452771 0.0325 0.0295 2641 5458 266552 299310 Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape S.E.A. Sdn Bhd Mr. How Kok Choong, the CEO and director of the Company is a 51% shareholder and a director of Agape Superior Living Pty Ltd Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape ATP (Asia) Limited. Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape Superior Living Sdn Bhd 58594 68474 18652 28985 349000 10000 24000 2027 2028 0.000 0.03 -0.108 0.210 0.165 0.210 -142419 -14724 -55587 -33744 59674 19300 -6965 43410 73318 43410 73000 73318 43000 1.00 1.00 1.00 1.00 0.54 0.46 520786 523141 464297 55493 68689 116979 17675 65295 140166 464297 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s related party list and relationship are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; width: 34%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Related parties</b></font></td> <td style="width: 2%; text-align: justify">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 64%; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Relationships</b></font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Agape S.E.A. Sdn Bhd</u></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape S.E.A. Sdn Bhd</u></font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Agape Superior Living Pty Ltd</u></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Mr. How Kok Choong, the CEO and director of the Company is a 51% shareholder and a director of Agape Superior Living Pty Ltd</u></font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Agape Superior Living Sdn Bhd</u></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape Superior Living Sdn Bhd</u></font></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Agape ATP (Asia) Limited</u></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape ATP (Asia) Limited.</u></font></td></tr> </table> <p style="margin: 0pt"></p> 2200 520786 520786 523141 523141 798621 49702 -159516 15893 -18538 68391 18538 16509 1057508 162694 -12299 70173 724619 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>14. COMMITMENTS AND CONTINGENCIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Lease commitments</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In view of the recent economic development in Hong Kong, the Company has decided not to extend the tenancy for the office in Hong Kong when the tenancy expires on April 30, 2020. Accordingly, the Company had on April 23, 2020 served a termination notice to the landlord, The Company&#8217;s commitment for minimum lease payments under the operating lease as of March 31, 2020 for the remaining lease period ending May 31, 2020 is $7,862.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rent expense for the three months ended March 31, 2020 and 2019 was $13,508 and $13,375, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><u>Purchase commitments</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total future minimum purchase commitment under a non-cancellable purchase contract as of March 31, 2020 for the next five years and thereafter is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>Twelve months ending March 31,</b></font></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Minimum purchase</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">693,900</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">693,900</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">693,900</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">2024</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">693,900</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">2025</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">693,900</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,908,225</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Total minimum purchase commitments required</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,377,725</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the date of this report, the Company&#8217;s vendor is not able to meet the Company&#8217;s minimum purchase commitment of the health and wellness products due to the manufacturing process was being delayed by its vendor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Contingencies</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, the Company is party to certain legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued, as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the consolidated financial statements.</p> 709 256 520786 523141 2217 2227 -0.210 -0.210 13508 13375 7862 693900 693900 693900 693900 693900 1908225 5377725 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Prepayments and deposits</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepayments and deposits are cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after management has determined that the likelihood of collection is not probable. The Company&#8217;s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Comprehensive income (loss)</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Comprehensive income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net income. Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Operating leases</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A lease for which substantially all the benefits and risks incidental to ownership remain with the lessor is classified by the lessee as an operating lease. All leases of the Company are currently classified as operating leases. The Company records the total expenses on a straight-line basis over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company had on July 1, 2019, adopted ASU 2016-02, &#8220;Leases&#8221; (Topic 842), and elected the practical expedients that do not require us to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. The Company adopted the practical expedient that allows lessees to treat the lease and non-lease components of a lease as a single lease component. There is no impact from the adoption of ASC 842 as of January 1, 2020, as the Company did not have any existing leases with a lease term in excess of twelve months on January 1, 2020.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Reclassification</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior period amounts have been reclassified to conform to the current period presentation for the three months ended March 31, 2019. These reclassifications have no effect on the condensed consolidated statements of operations and comprehensive income.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Disaggregated information of revenues by products are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the three months ended</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Ionized Cal-Mag</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">55,493</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Omega Blend</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">68,689</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Young Formula</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">116,979</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Organic Youth Care Cleansing Bar</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">17,675</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Trim+</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">65,295</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Lipomask</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">140,166</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total revenues</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">464,297</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table reconciles the local (United States) statutory rates to the Company&#8217;s effective tax rate for the periods indicated below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the three months ended</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>March 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 63%"><font style="font: 10pt Times New Roman, Times, Serif">U.S. statutory rate</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21.0</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">21.0</font></td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(21.0</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(21.0</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Permanent difference&#160;<sup>(1)</sup></font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(10.8</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Effective tax rate</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.0</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">%</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(10.8</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><sup>(1)&#160;</sup>This was related to disallowed expenditure incurred in the ordinary course of business.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total future minimum purchase commitment under a non-cancellable purchase contract as of March 31, 2020 for the next five years and thereafter is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><b>Twelve months ending March 31,</b></font></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Minimum purchase</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%"><font style="font: 10pt Times New Roman, Times, Serif">2021</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 17%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">693,900</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">2022</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">693,900</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">2023</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">693,900</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">2024</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">693,900</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">2025</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">693,900</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,908,225</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Total minimum purchase commitments required</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5,377,725</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> -285 186536 730637 656495 -26085 70173 730637 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="background-color: white"><b>8. AMOUNT DUE FROM A DIRECTOR</b></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 2, 2020, the Company agreed to sell the 17.86% ownership interest in Unreserved Sdn Bhd at December 31, 2019 carrying value of $730,637 to Mr. How Kok Choong, the CEO and director of the Company. On March 19, 2020, Mr. How made a payment of 10% of the amount due from him arising from the sale of the non-marketable securities. As of March 31, 2020, balance due from Mr. How was $656,495.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2020, the entire outstanding balance was settled as part of the consideration in a merger transaction in which the Company had acquired the CEO&#8217;s ownership interest of Agape Superior Living Sdn. Bhd.</p> 730637 730637 730637 -730637 0.10 0.000 -0.108 2020-04-30 2020-04-23 9590596 1714003 0.000432 -72234 48357 -53696 57933 -140322 <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable &#8211; related party</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">523,141</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">520,786</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Allowance for doubtful accounts</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total accounts receivable &#8211; related party</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">523,141</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">520,786</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Unreserved Sdn Bhd</font></td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> March 31, 2020</b></font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of<br /> December 31, 2019</b></font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font: 10pt Times New Roman, Times, Serif">Investment in non-marketable securities</font></td> <td style="width: 2%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 16%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">730,637</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">730,637</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif"><i>Less: Sale of investment in non-marketable securities</i></font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(730,637</font></td> <td><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font: 10pt Times New Roman, Times, Serif">Investment in non-marketable securities</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">730,637</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Phoenix Plus Corporation</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Cost of investment</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font: 10pt Times New Roman, Times, Serif">Total investment in non-marketable securities</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,500</font></td> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">732,137</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> This was related to disallowed expenditure incurred in the ordinary course of business. EX-101.SCH 5 aatp-20200331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Business Background link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Cash and Cash Equivalents link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Accounts Receivables - Related Party link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Investment in Marketable Securities link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Investment In Non-Marketable Securities link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Prepayments and Deposits link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Amount Due From a Director link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Other Payables and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Concentrations of Risks link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Organization and Business Background (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Accounts Receivables - Related Party (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Investment in Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Investment in Non-Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Prepayments and Deposits (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Other Payables and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Organization and Business Background (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Organization and Business Background - Schedule of Subsidiaries and Associates (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dis-aggregated Information of Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Foreign Currencies Translation Exchange Rates (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Summary of Significant Accounting Policies - Schedule of Foreign Currencies Translation Exchange Rates (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Cash and Cash Equivalents (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Accounts Receivables - Related Party - Schedule of Accounts Receivables - Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Investment in Marketable Securities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Investment in Marketable Securities - Schedule of Investment in Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Investment in Non-Marketable Securities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Investment in Non-Marketable Securities - Schedule of Investment in Non Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Prepayments and Deposits - Schedule of Prepaid Expenses and Deposits (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Amount Due From a Director (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Related Party Transactions - Schedule of Related Parties Relationships (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Related Party Transactions - Schedule of Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Other Payables and Accrued Liabilities - Schedule of Other Payables and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Income Taxes - Schedule of Components of Income/(Loss) Before Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Income Taxes - Schedule of Provision for Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Concentrations of Risks (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Purchase Commitment (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Subsequent Event (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 aatp-20200331_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 aatp-20200331_def.xml XBRL DEFINITION FILE EX-101.LAB 8 aatp-20200331_lab.xml XBRL LABEL FILE Legal Entity [Axis] Greenpro Capital Corp. [Member] Phoenix Plus Corporation [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Income (Loss) [Member] Consolidated Entities [Axis] Subsidiary Company [Member] Subsidiary Company One [Member] Product and Service [Axis] Ionized Cal-Mag [Member] Omega Blend [Member] Young Formula [Member] Organic Youth Care Cleansing Bar [Member] Trim+ [Member] Lipomask [Member] Variable Rate [Axis] Period-end MYR [Member] Period-average MYR [Member] Period-end HKD [Member] Period-average HKD [Member] Period-end AUD [Member] Period-average AUD [Member] Award Type [Axis] MYR Currency [Member] HKD Currency [Member] AUD Currency [Member] Title of Individual [Axis] Director [Member] Statistical Measurement [Axis] Maximum [Member] Minimum [Member] Mr. How Kok Choong [Member] Directors of Unreserved Investments [Member] Related Party [Axis] Agape S.E.A. Sdn Bhd [Member] Agape Superior Living Pty Ltd [Member] Agape ATP (Asia) Limited [Member] Agape Superior Living Sdn Bhd [Member] Geographical [Axis] United States of America [Member] Scenario [Axis] If Unutilized [Member] Labuan [Member] Hong Kong [Member] Customer [Axis] One Customer [Member] Concentration Risk Benchmark [Axis] Accounts Receivable [Member] One Vendor [Member] Extinguishment of Debt [Axis] Accounts Payable [Member] Agape ATP International Holding Limited [Member] Revenues [Member] Vendor One [Member] Vendor Two [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Share Exchange Agreement [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash and cash equivalents Accounts receivable - related party Amount due from a related party Prepayments and deposits Amount due from a director Total Current Assets OTHER ASSETS Investment in marketable securities Investment in non-marketable securities Total other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable Other payables and accrued liabilities Amount due to a director Total Current Liabilities TOTAL LIABILITIES STOCKHOLDERS' EQUITY Preferred stock, $0.0001 par value; 200,000,000 shares authorized; None issued and outstanding Common stock, par value $0.0001; 1,000,000,000 shares authorized, 376,275,500 issued and outstanding as of March 31, 2020 and December 31, 2019 Additional paid in capital Accumulated deficit Accumulated other comprehensive income TOTAL STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] REVENUE - RELATED PARTY COST OF REVENUE GROSS PROFIT SELLING, GENERAL AND ADMINISTRATIVE EXPENSES INCOME (LOSS) FROM OPERATIONS OTHER INCOME (EXPENSES) Other Income (Expenses), Net Loss from equity investment Unrealized holding loss on marketable securities Gain on deemed disposal of shares in Investee Company TOTAL OTHER INCOME (EXPENSES), NET INCOME (LOSS) BEFORE INCOME TAXES BENEFIT FOR INCOME TAXES NET INCOME (LOSS) OTHER COMPREHENSIVE INCOME (LOSS) Foreign currency translation adjustment COMPREHENSIVE INCOME (LOSS) EARNINGS (LOSS) PER SHARE Basic and diluted WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Basic and diluted Statement [Table] Statement [Line Items] Balance Balance, shares Net income (loss) Foreign currency translation adjustment Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net income (loss) to net cash used in operating activities: Unrealized holding loss on marketable securities Loss from equity investment Gain on deemed disposal of shares in Investee Company Changes in operating assets and liabilities: Accounts receivable - related party Amount due from a related party Prepayments and deposits Accounts payable Customer deposits Income taxes payable Other payables and accrued liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from sale of non-marketable securities to a related party Net cash provided by investing activities EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS DECREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL CASH FLOWS INFORMATION Income taxes paid Interest paid SUPPLEMENTAL NON-CASH FLOWS INFORMATION Amount transferred from investment in investee company to investment in non-marketable securities Sale of the non-marketable securities to a director in exchange for a loan receivable Accounting Policies [Abstract] Organization and Business Background Summary of Significant Accounting Policies Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents Receivables [Abstract] Accounts Receivables - Related Party Investments, Debt and Equity Securities [Abstract] Investment in Marketable Securities Investment In Non-marketable Securities Investment In Non-Marketable Securities Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Prepayments and Deposits Related Party Transactions [Abstract] Amount Due From a Director Related Party Transactions Equity [Abstract] Stockholders' Equity Other Liabilities Disclosure [Abstract] Other Payables and Accrued Liabilities Income Tax Disclosure [Abstract] Income Taxes Risks and Uncertainties [Abstract] Concentrations of Risks Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Event Basis of Presentation Basis of Consolidation Use of Estimates Cash and Cash Equivalents Accounts Receivable - Related party Prepayments and Deposits Investment in Marketable Equity Securities Investment in Non-marketable Securities Revenue Recognition Cost of Revenue Selling, General, and Administrative Expenses Income Taxes Comprehensive Income (Loss) Earnings (Loss) Per Share Foreign Currencies Translation and Transaction Related Parties Fair Value of Financial Instruments Operating Leases Recent Accounting Pronouncements Reclassification Schedule of Subsidiaries and Associates Schedule of Dis-aggregated Information of Revenues Schedule of Foreign Currencies Translation Exchange Rates Schedule of Accounts Receivables - Related Party Schedule of Investment in Marketable Securities Schedule of Investment in Non Marketable Securities Schedule of Prepaid Expenses and Deposits Schedule of Related Parties Relationships Schedule of Related Party Transactions Schedule of Other Payables and Accrued Liabilities Schedule of Components of Income/(Loss) Before Income Tax Schedule of Provision for Income Tax Schedule of Effective Income Tax Rate Schedule of Deferred Tax Assets Schedule of Future Minimum Purchase Commitment Ownership interest percentage Subsidiary company name Place and date of incorporation Particulars of issued capital Principal activities Proportional of ownership interest and voting power held Accounts receivable - related party valuation allowance Income tax examination, likelihood of unfavorable settlement Total revenues Foreign Currency Exchange Rate, Translation Exchange rate Cash on hand Time deposits Percentage of Interest rate for time deposits Accounts receivable - related party Allowance for doubtful accounts Total accounts receivables - related Party Investment in securities, shares Investment amount Purchased price per shares Cost of investment Less: Unrealized holding loss Exchange rate effect Equity interest percentage Ordinary shares authorized Ordinary shares issued Ordinary shares outstanding Proceeds from investments Amount due from director Shares purchased during period Share purchased price per share Investment in non-marketable securities Less: Sale of investment in non-marketable securities Investment in non-marketable securities Total investment in non-marketable securities Prepaid expenses Deposits to supplier Total prepaid expenses and deposits Sale of non-marketable securities percentage Related parties relationship, description Revenue Accounts Receivable, Trade Expenses paid on behalf Amount due from a related party Sundry Purchases Prepayments and Deposits Potentially dilutive securities outstanding Accrued professional fees Others Total payables and accrued liabilities Cumulative net operating loss Operating loss carryforwards expire year Valuation allowance Tax percentage Statutory income tax rate Local Foreign Loss before income tax Current, Local Current, Foreign Deferred, Local Deferred, Foreign Income tax expense U.S. statutory rate Valuation allowance Permanent difference Effective tax rate Net operating loss carry forwards in U.S. Less: valuation allowance Deferred tax asset Concentrations of risk percentage Operating lease, expiration date Remaining operating lease termination date Operating lease, rent expenses 2021 2022 2023 2024 2025 Thereafter Total minimum purchase commitments required Payments to acquire ordinary shares Ordinary shares no par value Purchase consideration value Issuance of common stock shares Common stock shares outstanding Percentage of common stock shares issued and outstanding Value of addtional shares issued Shares issued price per share AUD Currency [Member] Adam Network Oneand Damon Member. Agape ATP (Asia) Limited [Member] Agape ATP International Holding Limited [Member] Agape S.E.A. Sdn Bhd [Member] Agape Superior Living Pty Ltd [Member] Agape Superior Living Sdn Bhd [Member] Amount Due From a Director [Text Block] Amount transferred from investment in investee company to investment in non-marketable securities. BetaMaxx [Member] Customer A [Member] Customer [Member] Customer [Member] Deposits to supplier. Directors of Unreserved Investments [Member] Energetique Hyaluronic Acid Serum [Member] Energized Mineral Concentrate [Member] Exchange rate effect on investment securities. Greenpro Capital Corp. [Member] Greenpro Capital Corporation [Member] HKD Currency [Member] If Unutilized [Member] Invetsee Company [Member] Investment in Marketable Securities [Text Block] Investment in non-marketable securities. Investment in non-marketable securities. Investment In Non- Marketable Securities [Text Block] Investment in non-marketable securities, net. Ionized Cal-Mag [Member] Iron [Member] Labuan [Member] Lipomask [Member] MYR Currency [Member] Mr. How Kok Choong [Member] Name of the company name. Investment in non-marketable securities [Policy Text Block] Omega Blend [Member] One Customer [Member] One Vendor [Member] Operating leases [Policy Text Block] Operating loss carryforwards expire year. Organic Youth Care Cleansing Bar [Member] Other [Member] Other Payables and Accrued Liabilities [Member] Particulars of issued capital. Percentage of common stock shares issued and outstanding. Period-average AUD [Member] Period-average HKD [Member] Period-average MYR [Member] Period-end HKD [Member] Period-end MYR [Member] Period-end AUD [Member] Phoenix Plus Corporation [Member] Place and date of incorporation. Prepayments and deposits [Policy text block] Prepayments and Deposits [Text Block] Principal activities. Proceeds from sale of non-marketable securities to a related party. Related Parties [Policy Text Block] Related parties, relationships, description. Related party A [Member] Related party B [Member] Related Party C [Member] Remaining operating lease termination date. Sale of investment in non-marketable securities. Sale of non-marketable securities percentage. Sale of the non-marketable securities to a director in exchange for a loan receivable. Schedule of dis-aggregated information of revenues [Table Text Block] Schedule of purchase commitments [Table Text Block] Schedule of Other Payables and Accrued Liabilities [Table Text Block] Schedule of Prepaid Expenses and Deposits [Table Text Block] Schedule of Related Parties Relationships [Table Text Block] Share Exchange Agreement [Member] Subsidiary Company [Member] Subsidiary Company One [Member] Survivor Select [Member] Trim+ [Member] Two Vendor [Member] Vendor A [Member] Vendor B [Member] Vendor [Member] Vendor One [Member] Vendor Two [Member] Young Formula [Member] Tabular disclosure of Non-marketable securities. Assets, Current Other Assets Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Cost of Goods and Services Sold Gross Profit Selling, General and Administrative Expense Nonoperating Income (Expense) Income Tax Expense (Benefit) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Shares, Outstanding Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Increase (Decrease) in Accounts Receivable, Related Parties Increase (Decrease) in Due from Related Parties, Current Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Investing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash and Cash Equivalents, Policy [Policy Text Block] PrepaymentsAndDepositsPolicyTextBlock Income Tax, Policy [Policy Text Block] Accounts Receivable, before Allowance for Credit Loss, Current InvestmentInNonMarketableSecuritiesGross InvestmentInNonmarketableSecuritiesNet Due from Related Parties Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Purchase Obligation EX-101.PRE 9 aatp-20200331_pre.xml XBRL PRESENTATION FILE XML 10 R48.htm IDEA: XBRL DOCUMENT v3.20.1
Related Party Transactions - Schedule of Related Party Transactions (Details) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Revenue $ 464,297  
Accounts Receivable, Trade 523,141   $ 520,786
Prepayments and Deposits 304,993   269,193
Agape S.E.A. Sdn Bhd [Member]      
Revenue 464,297  
Accounts Receivable, Trade 523,141   520,786
Agape ATP (Asia) Limited [Member]      
Expenses paid on behalf 2,200  
Amount due from a related party 2,227   2,217
Agape Superior Living Pty Ltd [Member]      
Sundry Purchases  
Prepayments and Deposits $ 2,783  
XML 11 R44.htm IDEA: XBRL DOCUMENT v3.20.1
Investment in Non-Marketable Securities - Schedule of Investment in Non Marketable Securities (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Apr. 03, 2019
Total investment in non-marketable securities $ 1,500 $ 732,137  
Phoenix Plus Corporation [Member]      
Cost of investment 1,500 1,500 $ 1,500
Total investment in non-marketable securities 1,500 732,137  
Directors of Unreserved Investments [Member]      
Investment in non-marketable securities 730,637 730,637  
Less: Sale of investment in non-marketable securities (730,637)  
Investment in non-marketable securities $ 730,637  
XML 12 R40.htm IDEA: XBRL DOCUMENT v3.20.1
Accounts Receivables - Related Party - Schedule of Accounts Receivables - Related Party (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Receivables [Abstract]    
Accounts receivable - related party $ 523,141 $ 520,786
Allowance for doubtful accounts
Total accounts receivables - related Party $ 523,141 $ 520,786
XML 13 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Cash and Cash Equivalents
3 Months Ended
Mar. 31, 2020
Cash and Cash Equivalents [Abstract]  
Cash and Cash Equivalents

3. CASH AND CASH EQUIVALENTS

 

As of March 31, 2020 and December 31, 2019 the Company recorded $2,588,207 and $2,744,457, respectively, of cash and cash equivalents, which consists $135,436 and $238,937, respectively, of cash in bank and $2,452,771 and $2,505,520, respectively, of time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less. The effective interest rate for the time deposits ranges between 2.95% to 3.25% per annum.

XML 14 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Subsequent Event
3 Months Ended
Mar. 31, 2020
Subsequent Events [Abstract]  
Subsequent Event

15. SUBSEQUENT EVENT

 

In December 2019, a novel strain of coronavirus (COVID-19) surfaced. The spread of COVID-19 around the world in the first quarter of 2020 has caused significant volatility in Malaysia. There is significant uncertainty around the duration of business disruptions related to COVID-19, as well as its impact on the Malaysia economies and, as such, the Company is unable to determine if it will have a material impact to its operations.

 

On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn Bhd, an entity incorporated in Malaysia for $1,714,003. The purchase consideration represented the net asset carrying value of the acquiree as of March 31, 2020. The payment, net of the amount due from Mr. How Kok Choong of $656,495 as of March 31, 2020 arising from the purchase of the Company’s non-marketable security, will be satisfied together with the issuance of 162,694 shares of the Company’s common stock. Upon completion, the number of shares of common stock of the Company will be increased from 376,275,500 to 376,438,194, equivalent to approximately 0.0432% increase of the total issued and outstanding common stock of the Company after the issuance of the additional shares, which was valued at $1,057,508 based on the closing price of $6.50 of the Company at March 31, 2020.

XML 15 R25.htm IDEA: XBRL DOCUMENT v3.20.1
Accounts Receivables - Related Party (Tables)
3 Months Ended
Mar. 31, 2020
Receivables [Abstract]  
Schedule of Accounts Receivables - Related Party

    As of
March 31, 2020
    As of
December 31, 2019
 
Accounts receivable – related party   $ 523,141     $ 520,786  
Allowance for doubtful accounts     -       -  
Total accounts receivable – related party   $ 523,141     $ 520,786  

XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Total
Balance at Dec. 31, 2018 $ 37,628 $ 5,293,082 $ (373,082) $ (1,294) $ 4,956,334
Balance, shares at Dec. 31, 2018 376,275,500        
Net income (loss) 71,215 71,215
Foreign currency translation adjustment (3,197) (3,197)
Balance at Mar. 31, 2019 $ 37,628 5,293,082 (301,867) (4,491) 5,024,352
Balance, shares at Mar. 31, 2019 376,275,500        
Balance at Dec. 31, 2019 $ 37,628 5,293,082 (1,089,209) 9,785 4,251,286
Balance, shares at Dec. 31, 2019 376,275,500        
Net income (loss) (231,750) (231,750)
Foreign currency translation adjustment 7,770 7,770
Balance at Mar. 31, 2020 $ 37,628 $ 5,293,082 $ (1,320,959) $ 17,555 $ 4,027,306
Balance, shares at Mar. 31, 2020 376,275,500        
XML 17 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2020
May 11, 2020
Document And Entity Information    
Entity Registrant Name Agape ATP Corp  
Entity Central Index Key 0001713210  
Document Type 10-Q  
Document Period End Date Mar. 31, 2020  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business Flag true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   376,275,500
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2020  
XML 18 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Related Party Transactions (Tables)
3 Months Ended
Mar. 31, 2020
Related Party Transactions [Abstract]  
Schedule of Related Parties Relationships

The Company’s related party list and relationship are as follows:

 

Related parties   Relationships
     
Agape S.E.A. Sdn Bhd   Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape S.E.A. Sdn Bhd
     
Agape Superior Living Pty Ltd   Mr. How Kok Choong, the CEO and director of the Company is a 51% shareholder and a director of Agape Superior Living Pty Ltd
     
Agape Superior Living Sdn Bhd   Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape Superior Living Sdn Bhd
     
Agape ATP (Asia) Limited   Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape ATP (Asia) Limited.

Schedule of Related Party Transactions

Related party transactions for the three months ended March 31, 2020 and 2019; and as of March 31, 2020, and December 31, 2019 are as per table below:

 

    For the three months ended     As of  
    March 31, 2020     March 31, 2019     March 31, 2020     December 31, 2019  
    (Unaudited)     (Unaudited)     (Unaudited)        
    Revenue     Accounts Receivable, Trade  
                         
Agape S.E.A. Sdn Bhd   $               -     $ 464,297     $ 523,141     $ 520,786  
                                 

 

 

    Expenses paid on behalf     Amount due from a related party  
                         
Agape ATP (Asia) Limited   $ -     $ 2,200     $ 2,227     $ 2,217  
                                 

 

 

    Sundry Purchases     Prepayments and Deposits  
                         
Agape Superior Living Pty Ltd   $ -     $ -     $ 2,783     $ -  

ZIP 19 0001493152-20-008620-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-20-008620-xbrl.zip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end XML 20 R38.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies - Schedule of Foreign Currencies Translation Exchange Rates (Details) (Parenthetical) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
MYR Currency [Member]      
Exchange rate $ 1 $ 1 $ 1
HKD Currency [Member]      
Exchange rate 1 1 1
AUD Currency [Member]      
Exchange rate $ 1 $ 1 $ 1
XML 21 R34.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Business Background - Schedule of Subsidiaries and Associates (Details)
3 Months Ended
Mar. 31, 2020
Mar. 02, 2020
Proportional of ownership interest and voting power held   17.86%
Subsidiary Company [Member]    
Subsidiary company name Agape ATP Corporation  
Place and date of incorporation Labuan, March 6, 2017  
Particulars of issued capital 100 shares of ordinary share of US$1 each  
Principal activities Investment holding  
Proportional of ownership interest and voting power held 100.00%  
Subsidiary Company One [Member]    
Subsidiary company name Agape ATP International Holding Limited  
Place and date of incorporation Hong Kong, June 1, 2017  
Particulars of issued capital 1,000,000 shares of ordinary share of HK$1 each  
Principal activities Health and wellness products and health solution advisory services  
Proportional of ownership interest and voting power held 100.00%  
XML 22 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Other Payables and Accrued Liabilities (Tables)
3 Months Ended
Mar. 31, 2020
Other Liabilities Disclosure [Abstract]  
Schedule of Other Payables and Accrued Liabilities

    As of
March 31, 2020
    As of
December 31, 2019
 
Accrued professional fees   $ 68,474     $ 58,594  
Others     28,985       18,652  
Total payables and accrued liabilities   $ 97,459     $ 77,246  

XML 23 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 129 278 1 true 46 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://agapeatp.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://agapeatp.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://agapeatp.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) Sheet http://agapeatp.com/role/StatementsOfOperationsAndComprehensiveIncomeLoss Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://agapeatp.com/role/StatementsOfChangesInStockholdersEquity Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://agapeatp.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Business Background Sheet http://agapeatp.com/role/OrganizationAndBusinessBackground Organization and Business Background Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Cash and Cash Equivalents Sheet http://agapeatp.com/role/CashAndCashEquivalents Cash and Cash Equivalents Notes 9 false false R10.htm 00000010 - Disclosure - Accounts Receivables - Related Party Sheet http://agapeatp.com/role/AccountsReceivables-RelatedParty Accounts Receivables - Related Party Notes 10 false false R11.htm 00000011 - Disclosure - Investment in Marketable Securities Sheet http://agapeatp.com/role/InvestmentInMarketableSecurities Investment in Marketable Securities Notes 11 false false R12.htm 00000012 - Disclosure - Investment In Non-Marketable Securities Sheet http://agapeatp.com/role/InvestmentInNon-marketableSecurities Investment In Non-Marketable Securities Notes 12 false false R13.htm 00000013 - Disclosure - Prepayments and Deposits Sheet http://agapeatp.com/role/PrepaymentsAndDeposits Prepayments and Deposits Notes 13 false false R14.htm 00000014 - Disclosure - Amount Due From a Director Sheet http://agapeatp.com/role/AmountDueFromDirector Amount Due From a Director Notes 14 false false R15.htm 00000015 - Disclosure - Related Party Transactions Sheet http://agapeatp.com/role/RelatedPartyTransactions Related Party Transactions Notes 15 false false R16.htm 00000016 - Disclosure - Stockholders' Equity Sheet http://agapeatp.com/role/StockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 00000017 - Disclosure - Other Payables and Accrued Liabilities Sheet http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities Other Payables and Accrued Liabilities Notes 17 false false R18.htm 00000018 - Disclosure - Income Taxes Sheet http://agapeatp.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 00000019 - Disclosure - Concentrations of Risks Sheet http://agapeatp.com/role/ConcentrationsOfRisks Concentrations of Risks Notes 19 false false R20.htm 00000020 - Disclosure - Commitments and Contingencies Sheet http://agapeatp.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 00000021 - Disclosure - Subsequent Event Sheet http://agapeatp.com/role/SubsequentEvent Subsequent Event Notes 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - Organization and Business Background (Tables) Sheet http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables Organization and Business Background (Tables) Tables http://agapeatp.com/role/OrganizationAndBusinessBackground 23 false false R24.htm 00000024 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 00000025 - Disclosure - Accounts Receivables - Related Party (Tables) Sheet http://agapeatp.com/role/AccountsReceivables-RelatedPartyTables Accounts Receivables - Related Party (Tables) Tables http://agapeatp.com/role/AccountsReceivables-RelatedParty 25 false false R26.htm 00000026 - Disclosure - Investment in Marketable Securities (Tables) Sheet http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables Investment in Marketable Securities (Tables) Tables http://agapeatp.com/role/InvestmentInMarketableSecurities 26 false false R27.htm 00000027 - Disclosure - Investment in Non-Marketable Securities (Tables) Sheet http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables Investment in Non-Marketable Securities (Tables) Tables 27 false false R28.htm 00000028 - Disclosure - Prepayments and Deposits (Tables) Sheet http://agapeatp.com/role/PrepaymentsAndDepositsTables Prepayments and Deposits (Tables) Tables http://agapeatp.com/role/PrepaymentsAndDeposits 28 false false R29.htm 00000029 - Disclosure - Related Party Transactions (Tables) Sheet http://agapeatp.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://agapeatp.com/role/RelatedPartyTransactions 29 false false R30.htm 00000030 - Disclosure - Other Payables and Accrued Liabilities (Tables) Sheet http://agapeatp.com/role/OtherPayablesAndAccruedLiabilitiesTables Other Payables and Accrued Liabilities (Tables) Tables http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities 30 false false R31.htm 00000031 - Disclosure - Income Taxes (Tables) Sheet http://agapeatp.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://agapeatp.com/role/IncomeTaxes 31 false false R32.htm 00000032 - Disclosure - Commitments and Contingencies (Tables) Sheet http://agapeatp.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://agapeatp.com/role/CommitmentsAndContingencies 32 false false R33.htm 00000033 - Disclosure - Organization and Business Background (Details Narrative) Sheet http://agapeatp.com/role/OrganizationAndBusinessBackgroundDetailsNarrative Organization and Business Background (Details Narrative) Details http://agapeatp.com/role/OrganizationAndBusinessBackgroundTables 33 false false R34.htm 00000034 - Disclosure - Organization and Business Background - Schedule of Subsidiaries and Associates (Details) Sheet http://agapeatp.com/role/OrganizationAndBusinessBackground-ScheduleOfSubsidiariesAndAssociatesDetails Organization and Business Background - Schedule of Subsidiaries and Associates (Details) Details 34 false false R35.htm 00000035 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://agapeatp.com/role/SummaryOfSignificantAccountingPoliciesTables 35 false false R36.htm 00000036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dis-aggregated Information of Revenues (Details) Sheet http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfDis-aggregatedInformationOfRevenuesDetails Summary of Significant Accounting Policies - Schedule of Dis-aggregated Information of Revenues (Details) Details 36 false false R37.htm 00000037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Foreign Currencies Translation Exchange Rates (Details) Sheet http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfForeignCurrenciesTranslationExchangeRatesDetails Summary of Significant Accounting Policies - Schedule of Foreign Currencies Translation Exchange Rates (Details) Details 37 false false R38.htm 00000038 - Disclosure - Summary of Significant Accounting Policies - Schedule of Foreign Currencies Translation Exchange Rates (Details) (Parenthetical) Sheet http://agapeatp.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfForeignCurrenciesTranslationExchangeRatesDetailsParenthetical Summary of Significant Accounting Policies - Schedule of Foreign Currencies Translation Exchange Rates (Details) (Parenthetical) Details 38 false false R39.htm 00000039 - Disclosure - Cash and Cash Equivalents (Details Narrative) Sheet http://agapeatp.com/role/CashAndCashEquivalentsDetailsNarrative Cash and Cash Equivalents (Details Narrative) Details http://agapeatp.com/role/CashAndCashEquivalents 39 false false R40.htm 00000040 - Disclosure - Accounts Receivables - Related Party - Schedule of Accounts Receivables - Related Party (Details) Sheet http://agapeatp.com/role/AccountsReceivables-RelatedParty-ScheduleOfAccountsReceivables-RelatedPartyDetails Accounts Receivables - Related Party - Schedule of Accounts Receivables - Related Party (Details) Details 40 false false R41.htm 00000041 - Disclosure - Investment in Marketable Securities (Details Narrative) Sheet http://agapeatp.com/role/InvestmentInMarketableSecuritiesDetailsNarrative Investment in Marketable Securities (Details Narrative) Details http://agapeatp.com/role/InvestmentInMarketableSecuritiesTables 41 false false R42.htm 00000042 - Disclosure - Investment in Marketable Securities - Schedule of Investment in Marketable Securities (Details) Sheet http://agapeatp.com/role/InvestmentInMarketableSecurities-ScheduleOfInvestmentInMarketableSecuritiesDetails Investment in Marketable Securities - Schedule of Investment in Marketable Securities (Details) Details 42 false false R43.htm 00000043 - Disclosure - Investment in Non-Marketable Securities (Details Narrative) Sheet http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesDetailsNarrative Investment in Non-Marketable Securities (Details Narrative) Details http://agapeatp.com/role/InvestmentInNon-marketableSecuritiesTables 43 false false R44.htm 00000044 - Disclosure - Investment in Non-Marketable Securities - Schedule of Investment in Non Marketable Securities (Details) Sheet http://agapeatp.com/role/InvestmentInNon-marketableSecurities-ScheduleOfInvestmentInNonMarketableSecuritiesDetails Investment in Non-Marketable Securities - Schedule of Investment in Non Marketable Securities (Details) Details 44 false false R45.htm 00000045 - Disclosure - Prepayments and Deposits - Schedule of Prepaid Expenses and Deposits (Details) Sheet http://agapeatp.com/role/PrepaymentsAndDeposits-ScheduleOfPrepaidExpensesAndDepositsDetails Prepayments and Deposits - Schedule of Prepaid Expenses and Deposits (Details) Details 45 false false R46.htm 00000046 - Disclosure - Amount Due From a Director (Details Narrative) Sheet http://agapeatp.com/role/AmountDueFromDirectorDetailsNarrative Amount Due From a Director (Details Narrative) Details http://agapeatp.com/role/AmountDueFromDirector 46 false false R47.htm 00000047 - Disclosure - Related Party Transactions - Schedule of Related Parties Relationships (Details) Sheet http://agapeatp.com/role/RelatedPartyTransactions-ScheduleOfRelatedPartiesRelationshipsDetails Related Party Transactions - Schedule of Related Parties Relationships (Details) Details 47 false false R48.htm 00000048 - Disclosure - Related Party Transactions - Schedule of Related Party Transactions (Details) Sheet http://agapeatp.com/role/RelatedPartyTransactions-ScheduleOfRelatedPartyTransactionsDetails Related Party Transactions - Schedule of Related Party Transactions (Details) Details 48 false false R49.htm 00000049 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://agapeatp.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://agapeatp.com/role/StockholdersEquity 49 false false R50.htm 00000050 - Disclosure - Other Payables and Accrued Liabilities - Schedule of Other Payables and Accrued Liabilities (Details) Sheet http://agapeatp.com/role/OtherPayablesAndAccruedLiabilities-ScheduleOfOtherPayablesAndAccruedLiabilitiesDetails Other Payables and Accrued Liabilities - Schedule of Other Payables and Accrued Liabilities (Details) Details 50 false false R51.htm 00000051 - Disclosure - Income Taxes (Details Narrative) Sheet http://agapeatp.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://agapeatp.com/role/IncomeTaxesTables 51 false false R52.htm 00000052 - Disclosure - Income Taxes - Schedule of Components of Income/(Loss) Before Income Tax (Details) Sheet http://agapeatp.com/role/IncomeTaxes-ScheduleOfComponentsOfIncomelossBeforeIncomeTaxDetails Income Taxes - Schedule of Components of Income/(Loss) Before Income Tax (Details) Details 52 false false R53.htm 00000053 - Disclosure - Income Taxes - Schedule of Provision for Income Tax (Details) Sheet http://agapeatp.com/role/IncomeTaxes-ScheduleOfProvisionForIncomeTaxDetails Income Taxes - Schedule of Provision for Income Tax (Details) Details 53 false false R54.htm 00000054 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate (Details) Sheet http://agapeatp.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateDetails Income Taxes - Schedule of Effective Income Tax Rate (Details) Details 54 false false R55.htm 00000055 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details) Sheet http://agapeatp.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsDetails Income Taxes - Schedule of Deferred Tax Assets (Details) Details 55 false false R56.htm 00000056 - Disclosure - Concentrations of Risks (Details Narrative) Sheet http://agapeatp.com/role/ConcentrationsOfRisksDetailsNarrative Concentrations of Risks (Details Narrative) Details http://agapeatp.com/role/ConcentrationsOfRisks 56 false false R57.htm 00000057 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://agapeatp.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://agapeatp.com/role/CommitmentsAndContingenciesTables 57 false false R58.htm 00000058 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Purchase Commitment (Details) Sheet http://agapeatp.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumPurchaseCommitmentDetails Commitments and Contingencies - Schedule of Future Minimum Purchase Commitment (Details) Details 58 false false R59.htm 00000059 - Disclosure - Subsequent Event (Details Narrative) Sheet http://agapeatp.com/role/SubsequentEventDetailsNarrative Subsequent Event (Details Narrative) Details http://agapeatp.com/role/SubsequentEvent 59 false false All Reports Book All Reports aatp-20200331.xml aatp-20200331.xsd aatp-20200331_cal.xml aatp-20200331_def.xml aatp-20200331_lab.xml aatp-20200331_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true XML 24 R13.htm IDEA: XBRL DOCUMENT v3.20.1
Prepayments and Deposits
3 Months Ended
Mar. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepayments and Deposits

7. PREPAYMENTS AND DEPOSITS

 

    As of
March 31, 2020
    As of
December 31, 2019
 
Prepaid expenses   $ 5,458     $ 2,641  
Deposits to supplier     299,310       266,552  
Total prepaid expenses and deposits   $ 304,768     $ 269,193  

XML 25 R17.htm IDEA: XBRL DOCUMENT v3.20.1
Other Payables and Accrued Liabilities
3 Months Ended
Mar. 31, 2020
Other Liabilities Disclosure [Abstract]  
Other Payables and Accrued Liabilities

11. OTHER PAYABLES AND ACCRUED LIABILITIES

 

    As of
March 31, 2020
    As of
December 31, 2019
 
Accrued professional fees   $ 68,474     $ 58,594  
Others     28,985       18,652  
Total payables and accrued liabilities   $ 97,459     $ 77,246  

XML 26 R51.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Cumulative net operating loss $ 10,000    
Valuation allowance $ 73,318   $ 43,410
Tax percentage 0.00% (10.80%)  
Statutory income tax rate 21.00% 21.00%  
United States of America [Member]      
Cumulative net operating loss $ 349,000    
Operating loss carryforwards expire year 2027    
Valuation allowance $ 73,000   $ 43,000
United States of America [Member] | If Unutilized [Member]      
Cumulative net operating loss $ 24,000    
Operating loss carryforwards expire year 2028    
Labuan [Member]      
Tax percentage 3.00%    
Hong Kong [Member]      
Statutory income tax rate 16.50%    
XML 27 R55.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]    
Net operating loss carry forwards in U.S. $ 73,318 $ 43,410
Less: valuation allowance (73,318) (43,410)
Deferred tax asset
XML 28 R59.htm IDEA: XBRL DOCUMENT v3.20.1
Subsequent Event (Details Narrative) - USD ($)
May 08, 2020
Mar. 31, 2020
Mar. 02, 2020
Dec. 31, 2019
Ownership interest percentage     17.86%  
Common stock shares outstanding   376,275,500   376,275,500
Mr. How Kok Choong [Member]        
Common stock shares outstanding   2,500,000    
Subsequent Event [Member] | Share Exchange Agreement [Member] | Mr. How Kok Choong [Member]        
Issuance of common stock shares 162,694      
Common stock shares outstanding 376,438,194      
Percentage of common stock shares issued and outstanding 0.0432%      
Value of addtional shares issued $ 1,057,508      
Shares issued price per share $ 6.50      
Subsequent Event [Member] | Share Exchange Agreement [Member] | Mr. How Kok Choong [Member] | Agape Superior Living Sdn Bhd [Member]        
Payments to acquire ordinary shares $ 9,590,596      
Ordinary shares no par value      
Ownership interest percentage 99.99%      
Purchase consideration value $ 1,714,003      
XML 29 R35.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Accounting Policies [Abstract]    
Accounts receivable - related party valuation allowance
Income tax examination, likelihood of unfavorable settlement Greater than 50%  
XML 30 R31.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes (Tables)
3 Months Ended
Mar. 31, 2020
Income Tax Disclosure [Abstract]  
Schedule of Components of Income/(Loss) Before Income Tax

The United States and foreign components of income (loss) before income taxes were comprised of the following:

 

    For the three months ended  
    March 31, 2020     March 31, 2019  
    (Unaudited)     (Unaudited)  
Tax jurisdictions from:                
- Local   $ (142,419 )   $ (14,724 )
- Foreign - Labuan     (55,587 )     59,674  
- Foreign - Hong Kong     (33,744 )     19,300  
Income (Loss) before income tax   $ (231,750 )   $ 64,250  

Schedule of Provision for Income Tax

The benefit for income taxes consisted of the following:

 

    For the three months ended  
    March 31, 2020     March 31, 2019  
    (Unaudited)     (Unaudited)  
Current:                
- Local   $ -     $ -  
- Foreign     -       (6,965 )
                 
Deferred:                
- Local     -       -  
- Foreign     -       -  
                 
Benefit for income taxes   $ -     $ (6,965 )

Schedule of Effective Income Tax Rate

The following table reconciles the local (United States) statutory rates to the Company’s effective tax rate for the periods indicated below:

 

    For the three months ended  
    March 31, 2020     March 31, 2019  
    (Unaudited)     (Unaudited)  
U.S. statutory rate     21.0 %     21.0 %
Valuation allowance     (21.0 )%     (21.0 )%
Permanent difference (1)     0.0 %     (10.8 )%
Effective tax rate     0.0 %     (10.8 )%

 

(1) This was related to disallowed expenditure incurred in the ordinary course of business.

Schedule of Deferred Tax Assets

The following table sets forth the significant components of the aggregate deferred tax assets of the Company as of:

 

    As of
March 31, 2020
   

As of

December 31, 2019

 
    (Unaudited)        
Deferred tax assets:                
Net operating loss carry forwards in U.S.   $ 73,318     $ 43,410  
Less: valuation allowance     (73,318 )     (43,410 )
Deferred tax assets   $ -     $ -  

XML 31 R39.htm IDEA: XBRL DOCUMENT v3.20.1
Cash and Cash Equivalents (Details Narrative) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Mar. 10, 2019
Cash and cash equivalents $ 2,588,207 $ 2,744,457  
Cash on hand 135,436 238,937  
Time deposits $ 2,452,771 $ 2,505,520  
Minimum [Member]      
Percentage of Interest rate for time deposits     2.95%
Maximum [Member]      
Percentage of Interest rate for time deposits     3.25%
EXCEL 32 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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end XML 33 R12.htm IDEA: XBRL DOCUMENT v3.20.1
Investment In Non-Marketable Securities
3 Months Ended
Mar. 31, 2020
Investment In Non-marketable Securities  
Investment In Non-Marketable Securities

6. INVESTMENT IN NON-MARKETABLE SECURITIES

 

The Company invested in Unreserved Sdn Bhd with the investment amount of $863,592 (MYR3,500,000), which approximated 20% of the equity interest of Unreserved Sdn Bhd and is accounted for under the equity method of accounting. On March 10, 2019 Unreserved Sdn Bhd issued additional common stock for working capital. As the Company did not subscribe for the additional common stock, the Company’s equity interest in investee company was diluted from approximately 20.0% to approximately 17.86%. Effective from March 10, 2019, the Company discontinued equity accounting on the investee company. The Company also ceased control over the operations of the investee company on the same date. Accordingly, the investment in investee company was reclassified to investment in non-marketable securities.

 

Unreserved Sdn Bhd was incorporated in Malaysia with 2,500,000 ordinary shares authorized, issued and outstanding. Mr. Lim Hun Soon @ David Lim and Ms. Aniza Helina Akmi Karim are the directors of Unreserved Sdn Bhd. Mr. How Kok Choong was a director of the company from April 30, 2018 to March 27, 2019.

 

On March 2, 2020, the Company agreed to sell the 17.86% ownership interest in Unreserved Sdn Bhd at the December 31, 2019 carrying value of $730,637 to Mr. How Kok Choong, the CEO and director of the Company. The Company received proceeds of $70,173, and had an amount due from director balance of $660,464 as at March 31, 2020.

 

In May 2020, the entire outstanding balance was settled as part of the consideration in a transaction which the Company had acquired the CEO’s ownership interest of Agape Superior Living Sdn. Bhd.

 

On April 3, 2019, the Company purchased a 5% of stock or 15,000,000 shares of common stock in Phoenix Plus Corp. for $1,500 at purchase price of $0.0001 per share.

 

Unreserved Sdn Bhd   As of
March 31, 2020
    As of
December 31, 2019
 
Investment in non-marketable securities   $ 730,637     $ 730,637  
Less: Sale of investment in non-marketable securities     (730,637 )     -  
Investment in non-marketable securities   $ -     $ 730,637  
                 
Phoenix Plus Corporation                
Cost of investment   $ 1,500     $ 1,500  
                 
Total investment in non-marketable securities   $ 1,500     $ 732,137  

XML 34 R16.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Stockholders' Equity

10. STOCKHOLDERS’ EQUITY

 

Preferred stock

 

As of March 31, 2020, and December 31, 2019, there were 200,000,000 preferred stocks authorized but none were issued and outstanding.

 

Common stock

 

As of March 31, 2020, and December 31, 2019, there were 1,000,000,000 common stocks authorized, 376,275,500 were issued and outstanding.

 

There were no stock options, warrants or other potentially dilutive securities outstanding as of March 31, 2020 and December 31, 2019.

XML 35 R58.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies - Schedule of Future Minimum Purchase Commitment (Details)
Mar. 31, 2020
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2021 $ 693,900
2022 693,900
2023 693,900
2024 693,900
2025 693,900
Thereafter 1,908,225
Total minimum purchase commitments required $ 5,377,725
XML 36 R50.htm IDEA: XBRL DOCUMENT v3.20.1
Other Payables and Accrued Liabilities - Schedule of Other Payables and Accrued Liabilities (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Other Liabilities Disclosure [Abstract]    
Accrued professional fees $ 68,474 $ 58,594
Others 28,985 18,652
Total payables and accrued liabilities $ 97,459 $ 77,246
XML 37 R54.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes - Schedule of Effective Income Tax Rate (Details)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Tax Disclosure [Abstract]    
U.S. statutory rate 21.00% 21.00%
Valuation allowance (21.00%) (21.00%)
Permanent difference [1] 0.00% (10.80%)
Effective tax rate 0.00% (10.80%)
[1] This was related to disallowed expenditure incurred in the ordinary course of business.
XML 38 R45.htm IDEA: XBRL DOCUMENT v3.20.1
Prepayments and Deposits - Schedule of Prepaid Expenses and Deposits (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid expenses $ 5,458 $ 2,641
Deposits to supplier 299,310 266,552
Total prepaid expenses and deposits $ 304,993 $ 269,193
XML 39 R41.htm IDEA: XBRL DOCUMENT v3.20.1
Investment in Marketable Securities (Details Narrative) - Greenpro Capital Corp. [Member] - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Oct. 16, 2018
May 17, 2018
Investment in securities, shares     33,333 83,333
Investment amount $ 66,484 $ 134,166 $ 1,000 $ 500,000
Purchased price per shares     $ 0.03 $ 6
XML 40 R49.htm IDEA: XBRL DOCUMENT v3.20.1
Stockholders' Equity (Details Narrative) - shares
3 Months Ended 6 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Equity [Abstract]    
Preferred stock, shares authorized 200,000,000 200,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares issued 376,275,500 376,275,500
Common stock, shares outstanding 376,275,500 376,275,500
Potentially dilutive securities outstanding
XML 41 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Statement [Abstract]    
REVENUE - RELATED PARTY $ 464,297
COST OF REVENUE (420,178)
GROSS PROFIT 44,119
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (159,516) (28,226)
INCOME (LOSS) FROM OPERATIONS (159,516) 15,893
OTHER INCOME (EXPENSES)    
Other Income (Expenses), Net (53,696) 57,933
Loss from equity investment (26,085)
Unrealized holding loss on marketable securities (18,538)
Gain on deemed disposal of shares in Investee Company 16,509
TOTAL OTHER INCOME (EXPENSES), NET (72,234) 48,357
INCOME (LOSS) BEFORE INCOME TAXES (231,750) 64,250
BENEFIT FOR INCOME TAXES 6,965
NET INCOME (LOSS) (231,750) 71,215
OTHER COMPREHENSIVE INCOME (LOSS)    
Foreign currency translation adjustment 7,770 (3,197)
COMPREHENSIVE INCOME (LOSS) $ (223,980) $ 68,018
EARNINGS (LOSS) PER SHARE    
Basic and diluted $ 0 $ 0
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Basic and diluted 376,275,500 376,275,500
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.20.1
Prepayments and Deposits (Tables)
3 Months Ended
Mar. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Prepaid Expenses and Deposits

    As of
March 31, 2020
    As of
December 31, 2019
 
Prepaid expenses   $ 5,458     $ 2,641  
Deposits to supplier     299,310       266,552  
Total prepaid expenses and deposits   $ 304,768     $ 269,193  

XML 43 R8.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.

 

Basis of presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for information pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”).

 

Basis of consolidation

 

The consolidated financial statements include the financial statements of the Company and its subsidiaries. All transactions and balances among the Company and its subsidiaries have been eliminated upon consolidation.

 

Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.

 

Use of estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s consolidated financial statements include allowance for doubtful accounts, allowance for deferred tax assets and uncertain tax position, and impairment of investment in non-marketable securities. Actual results could differ from these estimates.

 

Cash and cash equivalents

 

Cash and cash equivalents are carried at cost and represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less.

 

Accounts receivable – related party

 

Accounts receivable – related party are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due on demand. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of March 31, 2020, and December 31, 2019, no valuation allowance was recorded.

 

Prepayments and deposits

 

Prepayments and deposits are cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after management has determined that the likelihood of collection is not probable. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary.

 

Investment in marketable equity securities

 

Prior to July 1, 2019, marketable securities included in investment in marketable equity securities (non-current) are stated at the lower of cost or market in the aggregate. Other marketable securities (non-current) are stated at the lower of cost or market in the aggregate and investments other than marketable equity securities in other investments (non-current) are stated at cost less any significant decline in fair value assessed to be other than temporary. Realized gains and losses on the sale of securities are based on the average cost of all the units of a particular security held at the time of sale.

 

On July 1, 2019, the Company adopted ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Investments in marketable equity securities (non-current) are reported at fair value with changes in fair value recognized in the Company’s consolidated statements of operations and comprehensive loss in the caption of “unrealized holding losses on marketable securities” in each reporting period.

 

Investment in non-marketable equity securities

 

Prior to July 1, 2019, investments in non-marketable equity securities (non-current) are stated at cost less any significant decline in fair value assessed to be other than temporary. Realized gains and losses on the sale of securities are based on the average cost of all the units of a particular security held at the time of sale.

 

On July 1, 2019, the Company adopted ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Due to the Company’s non-marketable equity securities (non-current) does not qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issue.

 

At each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment loss equal to the difference between the fair value of the investment and its carrying amount.

 

Revenue recognition

 

On July 1, 2019, the Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606) using the modified retrospective method for contracts that were not completed as of June 30, 2019. This did not result in an adjustment to retained earnings upon adoption of this new guidance as the Company’s revenue was recognized based on the amount of consideration expected to receive in exchange for satisfying the performance obligations.

 

The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

 

The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

 

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

 

Prior to July 1, 2019, the Company recognizes revenue from sales of goods when the following four revenue criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) selling price is fixed or determinable; and (4) collectability is reasonably assured. Revenue from supplies of health and wellness products is recognized when title and risk of loss are transferred and there are no continuing obligations to the customer. Title and the risks and rewards of ownership transfer to and accepted by the customer when the products are collected by the customer at the Company’s office. Revenue is recorded net of sales discounts, returns, allowances, and other adjustments that are based upon management’s best estimates and historical experience and are provided for in the same period as the related revenues are recorded.

 

The application of the five-step model to the revenue streams compared to the prior guidance did not result in significant changes in the way the Company records its revenue. Upon adoption on July 1, 2019, the Company evaluated its revenue recognition policy for all revenue streams within the scope of the ASU under previous standards and using the five-step model under the new guidance and confirmed that there were no differences in the pattern of revenue recognition.

 

Sales of Health and Wellness products

 

Performance obligations satisfied at a point in time

 

On July 1, 2019, the Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods, which is generally similar to when its delivery has occurred prior to July 1, 2019. Such revenues are recognized at a point in time after all performance obligations are satisfied. The revenue is recorded net of estimated discounts and return allowances. Historically, there were no sales return as the Company’s products sold are not refundable, returnable or exchangeable.

 

Disaggregated information of revenues by products are as follows:

 

    For the three months ended  
    March 31, 2020     March 31, 2019  
    (Unaudited)     (Unaudited)  
             
Ionized Cal-Mag   $ -     $ 55,493  
Omega Blend     -       68,689  
Young Formula     -       116,979  
Organic Youth Care Cleansing Bar     -       17,675  
Trim+     -       65,295  
Lipomask     -       140,166  
Total revenues   $ -     $ 464,297  

 

Cost of revenue

 

Cost of revenue includes freight-in and the purchase cost of manufactured goods for sale to customers

 

Selling, general and administrative expenses

 

Selling, general and administrative expenses are primarily comprised of rental of office premises, travelling, licensing and professional fees.

 

Income taxes

 

The Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

 

Deferred taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.

 

An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. No penalties and interest incurred related to underpayment of income tax.

 

The Company conducts much of its businesses activities in Hong Kong and is subject to tax in this jurisdiction. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

 

Comprehensive income (loss)

 

Comprehensive income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders’ equity but are excluded from net income. Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.

 

Earnings (loss) per share

 

The Company computes earnings (loss) per share (“EPS”) in accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common share outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

 

Foreign currencies translation and transaction

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the Condensed Consolidated Statements of Operations and Comprehensive Income.

 

The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. The Company’s subsidiary in Labuan maintains its books and record in United States Dollars (“US$”) albeit its functional currency being the primary currency of the economic environment in which the entity operates is the Malaysian Ringgit (“MYR”). The Company’s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars (“HK$”), similar to its functional currency.

 

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.

 

Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:

 

    As of and for the three months ended     As of  
    March 31, 2020     March 31, 2019     December 31, 2019  
    (Unaudited)     (Unaudited)        
                   
Period-end MYR : US$1 exchange rate     4.34       4.10       4.09  
Period-average MYR : US$1 exchange rate     4.21       4.08       4.16  
Period-end HKD : US$1 exchange rate     7.75       7.85       7.79  
Period-average HKD : US$1 exchange rate     7.77       7.85       7.83  
Period-end AUD : US$1 exchange rate     1.63       1.41       1.43  
Period-average AUD : US$1 exchange rate     1.55       1.40       1.46  

 

Related parties

 

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

 

Fair value of financial instruments

 

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

 

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

 

Operating leases

 

A lease for which substantially all the benefits and risks incidental to ownership remain with the lessor is classified by the lessee as an operating lease. All leases of the Company are currently classified as operating leases. The Company records the total expenses on a straight-line basis over the lease term.

 

The Company had on July 1, 2019, adopted ASU 2016-02, “Leases” (Topic 842), and elected the practical expedients that do not require us to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. The Company adopted the practical expedient that allows lessees to treat the lease and non-lease components of a lease as a single lease component. There is no impact from the adoption of ASC 842 as of January 1, 2020, as the Company did not have any existing leases with a lease term in excess of twelve months on January 1, 2020.

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of such any pronouncements may be expected to cause a material impact on its financial condition or the results of its operations, as follow:

 

In July 2017, the FASB Issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815). The amendments in Part I of the Update change the reclassification analysis of certain equity-lined financial instruments (or embedded features) with down round features. The amendments in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020.

 

Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part II of this Update do not require any transition guidance because those amendments do not have an accounting effect. The adoption of this ASU did not have a material effect on the Company’s consolidated financial statements.

 

In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The amendments in this Update affect any entity that is required to apply the provisions of Topic 220, Income Statement – Reporting Comprehensive Income, and has items of other comprehensive income for which the related tax effects are presented in other comprehensive income as required by GAAP. The amendments in this Update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this Update should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. The adoption of this ASU did not have a material effect on the Company’s consolidated financial statements.

 

In August 2018, the FASB has issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements of Fair Value Measurement. This amendment modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits, with the primary purpose to improve the effectiveness of disclosures in the notes to financial statements by facilitating clear communication of the information required by US GAAP. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company is currently evaluating the impact of ASU 2018-13 will have on its consolidated financial statements.

 

In May 2019, the FASB issued ASU 2019-05, which is an update to ASU Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments— Credit Losses—Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders’ concerns by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful information. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 due the Company is qualified as an emerging growth company. The Company is currently evaluating the impact of ASU 2019-05 will have on its consolidated financial statements.

 

In January 2020, the FASB issued ASU 2020-01 to clarify the interaction of the accounting for equity securities under ASC 321 and investments accounted for under the equity method of accounting in ASC 323 and the accounting for certain forward contracts and purchased options accounted for under ASC 815. With respect to the interactions between ASC 321 and ASC 323, the amendments clarify that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting when applying the measurement alternative in ASC 321, immediately before applying or upon discontinuing the equity method of accounting. With respect to forward contracts or purchased options to purchase securities, the amendments clarify that when applying the guidance in ASC 815-10-15-141(a), an entity should not consider whether upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in ASC 323 or the fair value option in accordance with ASC 825. The ASU is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.

 

Reclassification

 

Certain prior period amounts have been reclassified to conform to the current period presentation for the three months ended March 31, 2019. These reclassifications have no effect on the condensed consolidated statements of operations and comprehensive income.

XML 44 R20.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

14. COMMITMENTS AND CONTINGENCIES

 

Lease commitments

 

In view of the recent economic development in Hong Kong, the Company has decided not to extend the tenancy for the office in Hong Kong when the tenancy expires on April 30, 2020. Accordingly, the Company had on April 23, 2020 served a termination notice to the landlord, The Company’s commitment for minimum lease payments under the operating lease as of March 31, 2020 for the remaining lease period ending May 31, 2020 is $7,862.

 

Rent expense for the three months ended March 31, 2020 and 2019 was $13,508 and $13,375, respectively.

 

Purchase commitments

 

The total future minimum purchase commitment under a non-cancellable purchase contract as of March 31, 2020 for the next five years and thereafter is as follows:

 

Twelve months ending March 31,   Minimum purchase  
2021   $ 693,900  
2022     693,900  
2023     693,900  
2024     693,900  
2025     693,900  
Thereafter     1,908,225  
Total minimum purchase commitments required   $ 5,377,725  

 

As of the date of this report, the Company’s vendor is not able to meet the Company’s minimum purchase commitment of the health and wellness products due to the manufacturing process was being delayed by its vendor.

 

Contingencies

 

From time to time, the Company is party to certain legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued, as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the consolidated financial statements.

XML 45 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Schedule of Dis-aggregated Information of Revenues

Disaggregated information of revenues by products are as follows:

 

    For the three months ended  
    March 31, 2020     March 31, 2019  
    (Unaudited)     (Unaudited)  
             
Ionized Cal-Mag   $ -     $ 55,493  
Omega Blend     -       68,689  
Young Formula     -       116,979  
Organic Youth Care Cleansing Bar     -       17,675  
Trim+     -       65,295  
Lipomask     -       140,166  
Total revenues   $ -     $ 464,297  

Schedule of Foreign Currencies Translation Exchange Rates

Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:

 

    As of and for the three months ended     As of  
    March 31, 2020     March 31, 2019     December 31, 2019  
    (Unaudited)     (Unaudited)        
                   
Period-end MYR : US$1 exchange rate     4.34       4.10       4.09  
Period-average MYR : US$1 exchange rate     4.21       4.08       4.16  
Period-end HKD : US$1 exchange rate     7.75       7.85       7.79  
Period-average HKD : US$1 exchange rate     7.77       7.85       7.83  
Period-end AUD : US$1 exchange rate     1.63       1.41       1.43  
Period-average AUD : US$1 exchange rate     1.55       1.40       1.46  

XML 46 R10.htm IDEA: XBRL DOCUMENT v3.20.1
Accounts Receivables - Related Party
3 Months Ended
Mar. 31, 2020
Receivables [Abstract]  
Accounts Receivables - Related Party

4. ACCOUNTS RECEIVABLE – RELATED PARTY

 

    As of
March 31, 2020
    As of
December 31, 2019
 
Accounts receivable – related party   $ 523,141     $ 520,786  
Allowance for doubtful accounts     -       -  
Total accounts receivable – related party   $ 523,141     $ 520,786  

XML 47 R14.htm IDEA: XBRL DOCUMENT v3.20.1
Amount Due From a Director
3 Months Ended
Mar. 31, 2020
Related Party Transactions [Abstract]  
Amount Due From a Director

8. AMOUNT DUE FROM A DIRECTOR

 

On March 2, 2020, the Company agreed to sell the 17.86% ownership interest in Unreserved Sdn Bhd at December 31, 2019 carrying value of $730,637 to Mr. How Kok Choong, the CEO and director of the Company. On March 19, 2020, Mr. How made a payment of 10% of the amount due from him arising from the sale of the non-marketable securities. As of March 31, 2020, balance due from Mr. How was $656,495.

 

In May 2020, the entire outstanding balance was settled as part of the consideration in a merger transaction in which the Company had acquired the CEO’s ownership interest of Agape Superior Living Sdn. Bhd.

XML 48 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes
3 Months Ended
Mar. 31, 2020
Income Tax Disclosure [Abstract]  
Income Taxes

12. INCOME TAXES

 

The United States and foreign components of income (loss) before income taxes were comprised of the following:

 

    For the three months ended  
    March 31, 2020     March 31, 2019  
    (Unaudited)     (Unaudited)  
Tax jurisdictions from:                
- Local   $ (142,419 )   $ (14,724 )
- Foreign - Labuan     (55,587 )     59,674  
- Foreign - Hong Kong     (33,744 )     19,300  
Income (Loss) before income tax   $ (231,750 )   $ 64,250  

 

The benefit for income taxes consisted of the following:

 

    For the three months ended  
    March 31, 2020     March 31, 2019  
    (Unaudited)     (Unaudited)  
Current:                
- Local   $ -     $ -  
- Foreign     -       (6,965 )
                 
Deferred:                
- Local     -       -  
- Foreign     -       -  
                 
Benefit for income taxes   $ -     $ (6,965 )

 

The effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rates. The Company and its subsidiary that operate in various countries: United States, Labuan and Hong Kong that are subject to taxes in the jurisdictions in which they operate, as follows:

 

United States of America

 

Agape ATP Corporation was incorporated in the State of Nevada and is subject to the tax laws of the United States of America. As of March 31, 2020, the operations in the United States of America incurred approximately $349,000 of cumulative net operating losses which can be carried forward to offset future taxable income. Approximately $10,000 and $24,000 of the net operating loss carry forwards will expire in 2027and 2028, respectively, if unutilized. The remaining balance can be carried forward indefinitely. The deferred tax valuation allowance as of March 31, 2020 and December 31, 2019 were approximately $73,000 and $43,000, respectively.

 

Labuan

 

Under the current laws of the Labuan, Agape ATP Corporation is governed under the Labuan Business Activity Act, 1990. The tax charge for such company is based on 3% of net audited profit. Due to Agape ATP Corporation is a holding company, it did not generate any income nor incurred any income tax. In addition, its related expenses incurred cannot be carried forward to offset any future operation income.

 

Hong Kong

 

Agape ATP International Holding (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income rate of 16.5% on its assessable income derived from Hong Kong. Business income derived or business expenses incurred outside the Special Administrative Region is not subject to Hong Kong Profits Tax or deduction.

 

The following table reconciles the local (United States) statutory rates to the Company’s effective tax rate for the periods indicated below:

 

    For the three months ended  
    March 31, 2020     March 31, 2019  
    (Unaudited)     (Unaudited)  
U.S. statutory rate     21.0 %     21.0 %
Valuation allowance     (21.0 )%     (21.0 )%
Permanent difference (1)     0.0 %     (10.8 )%
Effective tax rate     0.0 %     (10.8 )%

 

(1) This was related to disallowed expenditure incurred in the ordinary course of business.

 

The following table sets forth the significant components of the aggregate deferred tax assets of the Company as of:

 

    As of
March 31, 2020
   

As of

December 31, 2019

 
    (Unaudited)        
Deferred tax assets:                
Net operating loss carry forwards in U.S.   $ 73,318     $ 43,410  
Less: valuation allowance     (73,318 )     (43,410 )
Deferred tax assets   $ -     $ -  

XML 49 R37.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies - Schedule of Foreign Currencies Translation Exchange Rates (Details)
Mar. 31, 2020
Dec. 31, 2019
Mar. 31, 2019
Period-end MYR [Member]      
Foreign Currency Exchange Rate, Translation 4.34 4.09 4.10
Period-average MYR [Member]      
Foreign Currency Exchange Rate, Translation 4.21 4.16 4.08
Period-end HKD [Member]      
Foreign Currency Exchange Rate, Translation 7.75 7.79 7.85
Period-average HKD [Member]      
Foreign Currency Exchange Rate, Translation 7.77 7.83 7.85
Period-end AUD [Member]      
Foreign Currency Exchange Rate, Translation 1.63 1.43 1.41
Period-average AUD [Member]      
Foreign Currency Exchange Rate, Translation 1.55 1.46 1.40
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Business Background (Details Narrative)
Mar. 31, 2020
Mar. 02, 2020
Ownership interest percentage   17.86%
Agape ATP International Holding Limited [Member]    
Ownership interest percentage 100.00%  
XML 51 R52.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes - Schedule of Components of Income/(Loss) Before Income Tax (Details) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Local $ (142,419) $ (14,724)
Loss before income tax (231,750) 64,250
Labuan [Member]    
Foreign (55,587) 59,674
Hong Kong [Member]    
Foreign $ (33,744) $ 19,300
XML 52 R56.htm IDEA: XBRL DOCUMENT v3.20.1
Concentrations of Risks (Details Narrative)
3 Months Ended 6 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
One Customer [Member] | Revenues [Member]      
Concentrations of risk percentage 100.00%    
One Customer [Member] | Accounts Receivable [Member]      
Concentrations of risk percentage 100.00%   100.00%
Vendor One [Member]      
Concentrations of risk percentage   54.00%  
Vendor Two [Member]      
Concentrations of risk percentage   46.00%  
One Vendor [Member] | Accounts Payable [Member]      
Concentrations of risk percentage   100.00%
XML 53 R47.htm IDEA: XBRL DOCUMENT v3.20.1
Related Party Transactions - Schedule of Related Parties Relationships (Details)
3 Months Ended
Mar. 31, 2020
Agape S.E.A. Sdn Bhd [Member]  
Related parties relationship, description Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape S.E.A. Sdn Bhd
Agape Superior Living Pty Ltd [Member]  
Related parties relationship, description Mr. How Kok Choong, the CEO and director of the Company is a 51% shareholder and a director of Agape Superior Living Pty Ltd
Agape Superior Living Sdn Bhd [Member]  
Related parties relationship, description Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape Superior Living Sdn Bhd
Agape ATP (Asia) Limited [Member]  
Related parties relationship, description Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape ATP (Asia) Limited.
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.20.1
Investment in Non-Marketable Securities (Details Narrative)
3 Months Ended
Mar. 31, 2020
USD ($)
shares
Mar. 31, 2019
USD ($)
Mar. 31, 2020
MYR (RM)
shares
Mar. 02, 2020
Dec. 31, 2019
USD ($)
shares
Apr. 03, 2019
USD ($)
$ / shares
shares
Mar. 10, 2019
Equity interest percentage       17.86%      
Ordinary shares authorized 1,000,000,000   1,000,000,000   1,000,000,000    
Ordinary shares issued 376,275,500   376,275,500   376,275,500    
Ordinary shares outstanding 376,275,500   376,275,500   376,275,500    
Proceeds from investments | $ $ 70,173          
Amount due from director | $ 656,495          
Phoenix Plus Corporation [Member]              
Investment amount | $ 1,500       1,500 $ 1,500  
Equity interest percentage           5.00%  
Share purchased price per share | $ / shares           $ 0.0001  
Phoenix Plus Corporation [Member] | Common Stock [Member]              
Shares purchased during period           15,000,000  
Maximum [Member]              
Equity interest percentage             20.00%
Minimum [Member]              
Equity interest percentage             17.86%
Director [Member]              
Investment amount | $ $ 863,592            
Equity interest percentage 20.00%   20.00%        
Director [Member] | MYR Currency [Member]              
Investment amount | RM     RM 3,500,000        
Mr. How Kok Choong [Member]              
Investment amount | $         730,637    
Ordinary shares authorized 2,500,000   2,500,000        
Ordinary shares issued 2,500,000   2,500,000        
Ordinary shares outstanding 2,500,000   2,500,000        
Amount due from director | $         $ 730,637    
XML 55 R6.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) $ (231,750) $ 71,215
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Unrealized holding loss on marketable securities 18,538
Loss from equity investment 26,085
Gain on deemed disposal of shares in Investee Company (16,509)
Changes in operating assets and liabilities:    
Accounts receivable - related party 285 (186,536)
Amount due from a related party (2,200)
Prepayments and deposits (34,593) (100,029)
Accounts payable (2,803) 1,323
Customer deposits   (140,322)
Income taxes payable (12,299)
Other payables and accrued liabilities 19,892 952
Net cash used in operating activities (230,431) (358,320)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Proceeds from sale of non-marketable securities to a related party 70,173
Net cash provided by investing activities 70,173
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS 4,008 (3,197)
DECREASE IN CASH AND CASH EQUIVALENTS (156,250) (361,517)
CASH AND CASH EQUIVALENTS, beginning of period 2,744,457 3,452,917
CASH AND CASH EQUIVALENTS, end of period 2,588,207 3,091,400
SUPPLEMENTAL CASH FLOWS INFORMATION    
Income taxes paid
Interest paid
SUPPLEMENTAL NON-CASH FLOWS INFORMATION    
Amount transferred from investment in investee company to investment in non-marketable securities 724,619
Sale of the non-marketable securities to a director in exchange for a loan receivable $ 730,637
XML 56 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
CURRENT ASSETS    
Cash and cash equivalents $ 2,588,207 $ 2,744,457
Accounts receivable - related party 523,141 520,786
Amount due from a related party 2,227 2,217
Prepayments and deposits 304,993 269,193
Amount due from a director 656,495
Total Current Assets 4,075,063 3,536,653
OTHER ASSETS    
Investment in marketable securities 48,202 66,484
Investment in non-marketable securities 1,500 732,137
Total other assets 49,702 798,621
TOTAL ASSETS 4,124,765 4,335,274
CURRENT LIABILITIES    
Accounts payable 2,790
Other payables and accrued liabilities 97,459 77,246
Amount due to a director 3,952
Total Current Liabilities 97,459 83,988
TOTAL LIABILITIES 97,459 83,988
STOCKHOLDERS' EQUITY    
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; None issued and outstanding
Common stock, par value $0.0001; 1,000,000,000 shares authorized, 376,275,500 issued and outstanding as of March 31, 2020 and December 31, 2019 37,628 37,628
Additional paid in capital 5,293,082 5,293,082
Accumulated deficit (1,320,959) (1,089,209)
Accumulated other comprehensive income 17,555 9,785
TOTAL STOCKHOLDERS' EQUITY 4,027,306 4,251,286
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 4,124,765 $ 4,335,274
XML 57 R22.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Basis of Presentation

Basis of presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for information pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”).

Basis of Consolidation

Basis of consolidation

 

The consolidated financial statements include the financial statements of the Company and its subsidiaries. All transactions and balances among the Company and its subsidiaries have been eliminated upon consolidation.

 

Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.

Use of Estimates

Use of estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s consolidated financial statements include allowance for doubtful accounts, allowance for deferred tax assets and uncertain tax position, and impairment of investment in non-marketable securities. Actual results could differ from these estimates.

Cash and Cash Equivalents

Cash and cash equivalents

 

Cash and cash equivalents are carried at cost and represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less.

Accounts Receivable - Related party

Accounts receivable – related party

 

Accounts receivable – related party are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due on demand. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of March 31, 2020, and December 31, 2019, no valuation allowance was recorded.

Prepayments and Deposits

Prepayments and deposits

 

Prepayments and deposits are cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after management has determined that the likelihood of collection is not probable. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary.

Investment in Marketable Equity Securities

Investment in marketable equity securities

 

Prior to July 1, 2019, marketable securities included in investment in marketable equity securities (non-current) are stated at the lower of cost or market in the aggregate. Other marketable securities (non-current) are stated at the lower of cost or market in the aggregate and investments other than marketable equity securities in other investments (non-current) are stated at cost less any significant decline in fair value assessed to be other than temporary. Realized gains and losses on the sale of securities are based on the average cost of all the units of a particular security held at the time of sale.

 

On July 1, 2019, the Company adopted ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Investments in marketable equity securities (non-current) are reported at fair value with changes in fair value recognized in the Company’s consolidated statements of operations and comprehensive loss in the caption of “unrealized holding losses on marketable securities” in each reporting period.

Investment in Non-marketable Securities

Investment in non-marketable equity securities

 

Prior to July 1, 2019, investments in non-marketable equity securities (non-current) are stated at cost less any significant decline in fair value assessed to be other than temporary. Realized gains and losses on the sale of securities are based on the average cost of all the units of a particular security held at the time of sale.

 

On July 1, 2019, the Company adopted ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Due to the Company’s non-marketable equity securities (non-current) does not qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issue.

 

At each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment loss equal to the difference between the fair value of the investment and its carrying amount.

Revenue Recognition

Revenue recognition

 

On July 1, 2019, the Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606) using the modified retrospective method for contracts that were not completed as of June 30, 2019. This did not result in an adjustment to retained earnings upon adoption of this new guidance as the Company’s revenue was recognized based on the amount of consideration expected to receive in exchange for satisfying the performance obligations.

 

The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

 

The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

 

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

 

Prior to July 1, 2019, the Company recognizes revenue from sales of goods when the following four revenue criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) selling price is fixed or determinable; and (4) collectability is reasonably assured. Revenue from supplies of health and wellness products is recognized when title and risk of loss are transferred and there are no continuing obligations to the customer. Title and the risks and rewards of ownership transfer to and accepted by the customer when the products are collected by the customer at the Company’s office. Revenue is recorded net of sales discounts, returns, allowances, and other adjustments that are based upon management’s best estimates and historical experience and are provided for in the same period as the related revenues are recorded.

 

The application of the five-step model to the revenue streams compared to the prior guidance did not result in significant changes in the way the Company records its revenue. Upon adoption on July 1, 2019, the Company evaluated its revenue recognition policy for all revenue streams within the scope of the ASU under previous standards and using the five-step model under the new guidance and confirmed that there were no differences in the pattern of revenue recognition.

 

Sales of Health and Wellness products

 

Performance obligations satisfied at a point in time

 

On July 1, 2019, the Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods, which is generally similar to when its delivery has occurred prior to July 1, 2019. Such revenues are recognized at a point in time after all performance obligations are satisfied. The revenue is recorded net of estimated discounts and return allowances. Historically, there were no sales return as the Company’s products sold are not refundable, returnable or exchangeable.

 

Disaggregated information of revenues by products are as follows:

 

    For the three months ended  
    March 31, 2020     March 31, 2019  
    (Unaudited)     (Unaudited)  
             
Ionized Cal-Mag   $ -     $ 55,493  
Omega Blend     -       68,689  
Young Formula     -       116,979  
Organic Youth Care Cleansing Bar     -       17,675  
Trim+     -       65,295  
Lipomask     -       140,166  
Total revenues   $ -     $ 464,297  

Cost of Revenue

Cost of revenue

 

Cost of revenue includes freight-in and the purchase cost of manufactured goods for sale to customers

Selling, General, and Administrative Expenses

Selling, general and administrative expenses

 

Selling, general and administrative expenses are primarily comprised of rental of office premises, travelling, licensing and professional fees.

Income Taxes

Income taxes

 

The Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

 

Deferred taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.

 

An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. No penalties and interest incurred related to underpayment of income tax.

 

The Company conducts much of its businesses activities in Hong Kong and is subject to tax in this jurisdiction. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

Comprehensive Income (Loss)

Comprehensive income (loss)

 

Comprehensive income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders’ equity but are excluded from net income. Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.

Earnings (Loss) Per Share

Earnings (loss) per share

 

The Company computes earnings (loss) per share (“EPS”) in accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common share outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential common shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

Foreign Currencies Translation and Transaction

Foreign currencies translation and transaction

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the Condensed Consolidated Statements of Operations and Comprehensive Income.

 

The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. The Company’s subsidiary in Labuan maintains its books and record in United States Dollars (“US$”) albeit its functional currency being the primary currency of the economic environment in which the entity operates is the Malaysian Ringgit (“MYR”). The Company’s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars (“HK$”), similar to its functional currency.

 

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.

 

Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:

 

    As of and for the three months ended     As of  
    March 31, 2020     March 31, 2019     December 31, 2019  
    (Unaudited)     (Unaudited)        
                   
Period-end MYR : US$1 exchange rate     4.34       4.10       4.09  
Period-average MYR : US$1 exchange rate     4.21       4.08       4.16  
Period-end HKD : US$1 exchange rate     7.75       7.85       7.79  
Period-average HKD : US$1 exchange rate     7.77       7.85       7.83  
Period-end AUD : US$1 exchange rate     1.63       1.41       1.43  
Period-average AUD : US$1 exchange rate     1.55       1.40       1.46  

Related Parties

Related parties

 

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

Fair Value of Financial Instruments

Fair value of financial instruments

 

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

 

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

Operating Leases

Operating leases

 

A lease for which substantially all the benefits and risks incidental to ownership remain with the lessor is classified by the lessee as an operating lease. All leases of the Company are currently classified as operating leases. The Company records the total expenses on a straight-line basis over the lease term.

 

The Company had on July 1, 2019, adopted ASU 2016-02, “Leases” (Topic 842), and elected the practical expedients that do not require us to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. The Company adopted the practical expedient that allows lessees to treat the lease and non-lease components of a lease as a single lease component. There is no impact from the adoption of ASC 842 as of January 1, 2020, as the Company did not have any existing leases with a lease term in excess of twelve months on January 1, 2020.

Recent Accounting Pronouncements

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of such any pronouncements may be expected to cause a material impact on its financial condition or the results of its operations, as follow:

 

In July 2017, the FASB Issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815). The amendments in Part I of the Update change the reclassification analysis of certain equity-lined financial instruments (or embedded features) with down round features. The amendments in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020.

 

Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part II of this Update do not require any transition guidance because those amendments do not have an accounting effect. The adoption of this ASU did not have a material effect on the Company’s consolidated financial statements.

 

In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The amendments in this Update affect any entity that is required to apply the provisions of Topic 220, Income Statement – Reporting Comprehensive Income, and has items of other comprehensive income for which the related tax effects are presented in other comprehensive income as required by GAAP. The amendments in this Update are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this Update should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. The adoption of this ASU did not have a material effect on the Company’s consolidated financial statements.

 

In August 2018, the FASB has issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements of Fair Value Measurement. This amendment modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits, with the primary purpose to improve the effectiveness of disclosures in the notes to financial statements by facilitating clear communication of the information required by US GAAP. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company is currently evaluating the impact of ASU 2018-13 will have on its consolidated financial statements.

 

In May 2019, the FASB issued ASU 2019-05, which is an update to ASU Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments— Credit Losses—Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders’ concerns by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful information. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 due the Company is qualified as an emerging growth company. The Company is currently evaluating the impact of ASU 2019-05 will have on its consolidated financial statements.

 

In January 2020, the FASB issued ASU 2020-01 to clarify the interaction of the accounting for equity securities under ASC 321 and investments accounted for under the equity method of accounting in ASC 323 and the accounting for certain forward contracts and purchased options accounted for under ASC 815. With respect to the interactions between ASC 321 and ASC 323, the amendments clarify that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting when applying the measurement alternative in ASC 321, immediately before applying or upon discontinuing the equity method of accounting. With respect to forward contracts or purchased options to purchase securities, the amendments clarify that when applying the guidance in ASC 815-10-15-141(a), an entity should not consider whether upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in ASC 323 or the fair value option in accordance with ASC 825. The ASU is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.

Reclassification

Reclassification

 

Certain prior period amounts have been reclassified to conform to the current period presentation for the three months ended March 31, 2019. These reclassifications have no effect on the condensed consolidated statements of operations and comprehensive income.

XML 58 R26.htm IDEA: XBRL DOCUMENT v3.20.1
Investment in Marketable Securities (Tables)
3 Months Ended
Mar. 31, 2020
Investments, Debt and Equity Securities [Abstract]  
Schedule of Investment in Marketable Securities

    As of
March 31, 2020
    As of
December 31, 2019
 
Cost of investment   $ 66,484     $ 134,166  
Less: Unrealized holding loss     (18,538 )     (68,391 )
Exchange rate effect     256       709  
Investment in marketable securities   $ 48,202     $ 66,484  

XML 59 R46.htm IDEA: XBRL DOCUMENT v3.20.1
Amount Due From a Director (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 02, 2020
Dec. 31, 2019
Ownership interest percentage   17.86%  
Amount due from a director $ 656,495  
Sale of non-marketable securities percentage 10.00%    
Mr. How Kok Choong [Member]      
Amount due from a director     $ 730,637
XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Investment in Marketable Securities - Schedule of Investment in Marketable Securities (Details) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Oct. 16, 2018
May 17, 2018
Less: Unrealized holding loss $ 18,538      
Investment in marketable securities 48,202   $ 66,484    
Greenpro Capital Corp. [Member]          
Cost of investment 66,484   134,166 $ 1,000 $ 500,000
Less: Unrealized holding loss (18,538)   (68,391)    
Exchange rate effect 256   709    
Investment in marketable securities $ 48,202   $ 66,484    
XML 62 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Business Background (Tables)
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Schedule of Subsidiaries and Associates

Details of the Company’s subsidiaries:

 

   

Subsidiary company

name

 

Place and

date of

incorporation

  Particulars of issued capital   Principal activities  

Proportional of ownership

interest and

voting power

held

 
                       
1.   Agape ATP Corporation   Labuan,
March 6, 2017
  100 shares of ordinary share of US$1 each   Investment holding     100 %
                         
2.   Agape ATP International Holding Limited   Hong Kong,
June 1, 2017
  1,000,000 shares of ordinary share of HK$1 each   Health and wellness products and health solution advisory services     100 %

XML 63 R27.htm IDEA: XBRL DOCUMENT v3.20.1
Investment in Non-Marketable Securities (Tables)
3 Months Ended
Mar. 31, 2020
Investment In Non-marketable Securities  
Schedule of Investment in Non Marketable Securities

Unreserved Sdn Bhd   As of
March 31, 2020
    As of
December 31, 2019
 
Investment in non-marketable securities   $ 730,637     $ 730,637  
Less: Sale of investment in non-marketable securities     (730,637 )     -  
Investment in non-marketable securities   $ -     $ 730,637  
                 
Phoenix Plus Corporation                
Cost of investment   $ 1,500     $ 1,500  
                 
Total investment in non-marketable securities   $ 1,500     $ 732,137  

XML 64 R7.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Business Background
3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Organization and Business Background

1. ORGANIZATION AND BUSINESS BACKGROUND

 

Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.

 

Agape ATP Corporation operates through its wholly owned subsidiary, Agape ATP Corporation, a Company organized in Labuan, Malaysia.

 

Agape ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International Holding Limited, a company incorporated in Hong Kong.

 

The Company and its subsidiaries provide health and wellness products and advisory services to the public. The principal activity of the Company and its subsidiaries is to supply high-quality health and wellness products, including supplement to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system in our body.

 

Details of the Company’s subsidiaries:

 

   

Subsidiary company

name

 

Place and

date of

incorporation

  Particulars of issued capital   Principal activities  

Proportional of ownership

interest and

voting power

held

 
                       
1.   Agape ATP Corporation   Labuan,
March 6, 2017
  100 shares of ordinary share of US$1 each   Investment holding     100 %
                         
2.   Agape ATP International Holding Limited   Hong Kong,
June 1, 2017
  1,000,000 shares of ordinary share of HK$1 each   Health and wellness products and health solution advisory services     100 %

 

Business Overview

 

Agape ATP Corporation is a company that provides health solution advisory services to our clients. We primarily focus our efforts on attracting customers in Malaysia. Our advisory services center on the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.

 

At its core, the ATP Zeta Super Health Program is focused upon biological energy, Adenosine Triphosphate (ATP), at the cellular level. The stimulation of ATP production at the cellular level can increase the metabolism and service to promote and maintain normal and healthy functioning of the body’s systems. As a strong advocator of “beauty from within”, our program shall emphasize nutrient absorption through the membrane ion channel to provide complete and balanced nutrients to improve cell health. Thus, ATP Zeta Super Health Program provides ionized and high zeta potential (high bioavailability) nutrients to enhance the absorption at the cellular level.

 

The ATP Zeta Super Health Program consists of eight products. None of these products are owned or produced by Agape ATP Corporation. In the event that any of these products are no longer produced, or are otherwise unavailable, we may have to devote significant effort to identifying and obtaining comparable replacement products. The eight products that comprise the ATP Zeta Super Health Program are ATP1s Survivor Select, ATP2 Energized Mineral Concentrate, ATP3 Ionized Cal-Mag, ATP4 Omega Blend, ATP5 BetaMaxx, AGN-Vege Fruit Fiber, AGP1-Iron and YFA-Young Formula.

 

At present, our products are mainly sold in Malaysia, and due to the contents and combination of the main ingredients in the products they are categorized as health food rather than medicines or drugs. As such, all products require authorization from the Food and Quality Division of Ministry of Health according to the Food Act of 1983 and Food Regulation 1985 in order to be sold in the country. All of the products in the ATP Zeta Super Health Program have obtained the appropriate authorizations.

 

As part of a continuous effort to increase market share of the health and wellness industry that is growing at an exponential rate, we will also evaluate adding additional products to the ATP Zeta Super Health Program; and considering the potential of the synergies between the health and beauty sectors, we will further involve ourselves in the topical approach of skin and hair regime. Other than organic growth, the Company will also consider mergers and acquisitions where synergistic. As detailed in Note 15, Subsequent Events, to improve its sales channel, the Company is in the process of acquiring a Malaysia incorporated entity whose principal activity is in the trading of health and wellness products.

XML 65 R3.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 200,000,000 200,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares issued 376,275,500 376,275,500
Common stock, shares outstanding 376,275,500 376,275,500
XML 66 R19.htm IDEA: XBRL DOCUMENT v3.20.1
Concentrations of Risks
3 Months Ended
Mar. 31, 2020
Risks and Uncertainties [Abstract]  
Concentrations of Risks

13. CONCENTRATIONS OF RISKS

 

(a) Major customers

 

There were no sales for the three months ended March 31, 2020. For the three months ended March 31, 2019, one related party customer accounted for 100% of the Company’s total revenues.

 

As of March 31, 2020, and December 31, 2019, one related party customer accounted for 100% of the total balance of accounts receivable.

 

(b) Major vendors

 

There were no purchases for the three months ended March 31, 2020. For the three months ended March 31, 2019, two vendors accounted for approximately 54% and 46% of the Company’s total purchases, respectively.

 

Accounts payable as of March 31, 2020 was nil. As of December 31, 2019, one vendor accounted for 100% of the total balance of accounts payable.

 

(c) Credit risk

 

Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its account receivable is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Historically, the Company did not have any bad debt on its account receivable.

 

(d) Exchange rate risk

 

The Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower profit depending on exchange rate of RM$ and HK$ converted to US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.

XML 67 R11.htm IDEA: XBRL DOCUMENT v3.20.1
Investment in Marketable Securities
3 Months Ended
Mar. 31, 2020
Investments, Debt and Equity Securities [Abstract]  
Investment in Marketable Securities

5. INVESTMENT IN MARKETABLE SECURITIES

 

  (i) On May 17, 2018, the Company purchased 83,333 shares of common stock in Greenpro Capital Corp. for $500,000 at a purchase price of $6 per share.
     
  (ii) On October 16, 2018, the Company purchased 33,333 shares of common stock in Greenpro Capital Corp. for $1,000 at a purchase price of $0.03 per share.

 

    As of
March 31, 2020
    As of
December 31, 2019
 
Cost of investment   $ 66,484     $ 134,166  
Less: Unrealized holding loss     (18,538 )     (68,391 )
Exchange rate effect     256       709  
Investment in marketable securities   $ 48,202     $ 66,484  

XML 68 R15.htm IDEA: XBRL DOCUMENT v3.20.1
Related Party Transactions
3 Months Ended
Mar. 31, 2020
Related Party Transactions [Abstract]  
Related Party Transactions

9. RELATED PARTY TRANSACTIONS

 

The Company’s related party list and relationship are as follows:

 

Related parties   Relationships
     
Agape S.E.A. Sdn Bhd   Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape S.E.A. Sdn Bhd
     
Agape Superior Living Pty Ltd   Mr. How Kok Choong, the CEO and director of the Company is a 51% shareholder and a director of Agape Superior Living Pty Ltd
     
Agape Superior Living Sdn Bhd   Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape Superior Living Sdn Bhd
     
Agape ATP (Asia) Limited   Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of Agape ATP (Asia) Limited.

 

Related party transactions for the three months ended March 31, 2020 and 2019; and as of March 31, 2020, and December 31, 2019 are as per table below:

 

    For the three months ended     As of  
    March 31, 2020     March 31, 2019     March 31, 2020     December 31, 2019  
    (Unaudited)     (Unaudited)     (Unaudited)        
    Revenue     Accounts Receivable, Trade  
                         
Agape S.E.A. Sdn Bhd   $               -     $ 464,297     $ 523,141     $ 520,786  
                                 

 

 

    Expenses paid on behalf     Amount due from a related party  
                         
Agape ATP (Asia) Limited   $ -     $ 2,200     $ 2,227     $ 2,217  
                                 

 

 

    Sundry Purchases     Prepayments and Deposits  
                         
Agape Superior Living Pty Ltd   $ -     $ -     $ 2,783     $ -  

XML 69 R36.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies - Schedule of Dis-aggregated Information of Revenues (Details) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Total revenues $ 464,297
Ionized Cal-Mag [Member]    
Total revenues 55,493
Omega Blend [Member]    
Total revenues 68,689
Young Formula [Member]    
Total revenues 116,979
Organic Youth Care Cleansing Bar [Member]    
Total revenues 17,675
Trim+ [Member]    
Total revenues 65,295
Lipomask [Member]    
Total revenues $ 140,166
XML 70 R32.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies (Tables)
3 Months Ended
Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Purchase Commitment

The total future minimum purchase commitment under a non-cancellable purchase contract as of March 31, 2020 for the next five years and thereafter is as follows:

 

Twelve months ending March 31,   Minimum purchase  
2021   $ 693,900  
2022     693,900  
2023     693,900  
2024     693,900  
2025     693,900  
Thereafter     1,908,225  
Total minimum purchase commitments required   $ 5,377,725  

XML 71 R53.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes - Schedule of Provision for Income Tax (Details) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Tax Disclosure [Abstract]    
Current, Local
Current, Foreign (6,965)
Deferred, Local
Deferred, Foreign
Income tax expense $ (6,965)
XML 73 R57.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies (Details Narrative) - USD ($)
3 Months Ended
May 31, 2020
Mar. 31, 2020
Mar. 31, 2019
Operating lease, expiration date   Apr. 30, 2020  
Remaining operating lease termination date   Apr. 23, 2020  
Operating lease, rent expenses   $ 13,508 $ 13,375
Subsequent Event [Member]      
Operating lease, rent expenses $ 7,862    
XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; }